

(12) NACH DEM VERTRAG ÜBER DIE INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES
PATENTWESENS (PCT) VERÖFFENTLICHTE INTERNATIONALE ANMELDUNG

(19) Weltorganisation für geistiges Eigentum
Internationales Büro



(43) Internationales Veröffentlichungsdatum
18. Juli 2002 (18.07.2002)

PCT

(10) Internationale Veröffentlichungsnummer
WO 02/055693 A2

(51) Internationale Patentklassifikation⁷: C12N 15/11

(21) Internationales Aktenzeichen: PCT/EP02/00152

(22) Internationales Anmeldedatum:
9. Januar 2002 (09.01.2002)

(25) Einreichungssprache: Deutsch

(26) Veröffentlichungssprache: Deutsch

(30) Angaben zur Priorität:
101 00 586.5 9. Januar 2001 (09.01.2001) DE
101 55 280.7 26. Oktober 2001 (26.10.2001) DE
101 58 411.3 29. November 2001 (29.11.2001) DE
101 60 151.4 7. Dezember 2001 (07.12.2001) DE

LIMMER, Stephan [DE/DE]; Universitätsstrasse 30,
95447 Bayreuth (DE). ROST, Sylvia [DE/DE]; Univer-
sitätsstrasse 30, 95447 Bayreuth (DE). HADWIGER,
Philipp [DE/DE]; Universitätsstrasse 30, 95447 Bayreuth
(DE).

(74) Anwalt: GASSNER, Wolfgang; Nägelsbachstrasse 49a,
91052 Erlangen (DE).

(81) Bestimmungsstaaten (*national*): AE, AG, AL, AM, AT,
AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR,
CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,
MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,
US, UZ, VN, YU, ZA, ZM, ZW.

(71) Anmelder (für alle Bestimmungsstaaten mit Ausnahme von
US): RIBOPHARMA AG [DE/DE]; Universitätsstrasse
30, 95447 Bayreuth (DE).

(72) Erfinder; und


(75) Erfinder/Anmelder (nur für US): KREUTZER, Roland
[DE/DE]; Universitätsstrasse 30, 95447 Bayreuth (DE).

(84) Bestimmungsstaaten (*regional*): ARIPO-Patent (GH,
GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW),
eurasisches Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ,
TM), europäisches Patent (AT, BE, CH, CY, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR),
OAPI-Patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

[Fortsetzung auf der nächsten Seite]

(54) Title: METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

(54) Bezeichnung: VERFAHREN ZUR HEMMUNG DER EXPRESSION EINE ZIELGENS



(57) Abstract: The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 - 4 nucleotides.

(57) Zusammenfassung: Die Erfindung betrifft ein Verfahren zur Hemmung der Expression eines Zielgens in einer Zelle umfassend die folgenden Schritte: Einführen mindestens einer doppelsträngigen Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinanderfolgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinn-Strang des Zielgens ist, und wobei die dsRNA am einen Ende (E1) der dsRNA I einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

WO 02/055693 A2

The PTO did not receive the following listed items: 94 pages found empty



Veröffentlicht:

— ohne internationalen Recherchenbericht und erneut zu veröffentlichen nach Erhalt des Berichts

Zur Erklärung der Zweibuchstaben-Codes und der anderen Abkürzungen wird auf die Erklärungen ("Guidance Notes on Codes and Abbreviations") am Anfang jeder regulären Ausgabe der PCT-Gazette verwiesen.

Verfahren zur Hemmung der Expression eines Zielgens

Die Erfindung betrifft ein Verfahren, eine Verwendung und ein Medikament zur Hemmung der Expression eines Zielgens.

5

Aus der WQ 99/32619 sowie der WO 00/44895 sind Verfahren zur Hemmung der Expression von medizinisch oder biotechnologisch interessanten Genen mit Hilfe einer doppelsträngigen Ribonukleinsäure (dsRNA) bekannt. Die bekannten Verfahren sind zwar
10 hoch effektiv. Es besteht gleichwohl das Bedürfnis, deren Effizienz weiter zu steigern.

Aufgabe der vorliegenden Erfindung ist es, die Nachteile nach dem Stand der Technik zu beseitigen. Es sollen insbesondere
15 ein Verfahren, eine Verwendung und ein Medikament angegeben werden, mit denen eine noch effizientere Hemmung der Expression eines Zielgens erreichbar ist.

Diese Aufgabe wird durch die Merkmale der Ansprüche 1, 41 und
20 81 gelöst. Vorteilhafte Ausgestaltungen ergeben sich aus den Merkmalen der Ansprüche 2 bis 40, 42 bis 80 und 82 bis 120.

Mit den erfindungsgemäß beanspruchten Merkmalen wird überraschenderweise eine drastische Erhöhung der Effektivität der
25 Hemmung der Expression eines Zielgens in vitro und in vivo erreicht. Durch die besondere Ausbildung der Enden der dsRNA kann sowohl deren Effizienz bei der Vermittlung der hemmenden Wirkung auf die Expression eines Zielgens als auch deren Stabilität gezielt beeinflusst werden. Durch die Vergrößerung der
30 Stabilität wird die wirksame Konzentration in der Zelle erhöht.

Unter einem "Zielgen" im Sinne der Erfindung wird der DNA-Strang der doppelsträngigen DNA in der Zelle verstanden, welcher komplementär zu einem bei der Transkription als Matritze
35 dienenden DNA-Strang einschließlich aller transkribierten Be-

reiche ist. Bei dem "Zielgen" handelt es sich also im allgemeinen um den Sinnstrang. Der eine Strang bzw. Antisinnstrang (as1) kann komplementär zu einem bei der Expression des Zielgens gebildeten RNA-Transkript oder deren Prozessierungsprodukt, z.B. eine mRNA, sein. Unter "Einführen" wird die Aufnahme in die Zelle verstanden. Die Aufnahme kann durch die Zelle selbst erfolgen; sie kann auch durch Hilfsstoffe oder Hilfsmittel vermittelt werden. Unter einem "Überhang" wird ein endständiger einzelsträngiger Überstand verstanden, welcher nicht nach Watson & Crick gepaarte Nukleotide aufweist. Unter einer "doppelsträngigen Struktur" wird eine Struktur verstanden, bei der die Nukleotide der Einzelstränge im Wesentlichen nach Watson & Crick gepaart sind. Im Rahmen der vorliegenden Erfindung kann eine doppelsträngige Struktur auch einzelne Fehlpaarungen ("Mismatches") aufweisen.

Nach einer besonders vorteilhaften Ausgestaltung weist die dsRNA I den Überhang am 3'-Ende des einen Strangs bzw. Antisinnstrangs as1 und/oder am 3'-Ende des anderen Strangs bzw. Sinnstrang ss1 auf. Die dsRNA I kann auch an einem Ende glatt ausgebildet sein. In diesem Fall befindet sich das glatte Ende vorteilhafterweise auf der Seite der dsRNA I, die das 5'-Ende des einen Strangs (Antisinnstrang; as1). In dieser Ausbildung zeigt die dsRNA I einerseits eine sehr gute Effektivität und andererseits eine hohe Stabilität im lebenden Organismus. Die Effektivität insgesamt in vivo ist hervorragend. Der Überhang ist zweckmäßigerweise aus 1 bis 4 Nukleotiden, vorzugsweise aus 1 oder 2 Nukleotiden, gebildet.

Nach einem weiteren Ausgestaltungsmerkmal kann die Effektivität des Verfahrens weiter erhöht werden, wenn zumindest eine entsprechend der erfindungsgemäßen dsRNA I ausgebildete weitere dsRNA II in die Zelle eingeführt wird, wobei der eine Strang oder zumindest ein Abschnitt des einen Strangs der doppelsträngigen Struktur der dsRNA I komplementär zu einem ersten Bereich des Sinnstrangs des Zielgens ist, und wobei

ein weiterer Strang oder zumindest ein Abschnitt des weiteren Strangs der doppelsträngigen Struktur der weiteren dsRNA II komplementär zu einem zweiten Bereich des Sinnstrangs des Zielgens ist. Die Hemmung der Expression des Zielgens ist in diesem Fall deutlich gesteigert. Der erste und der zweite Bereich können abschnittsweise überlappen, aneinander grenzen oder auch voneinander beabstandet sein.

Es hat sich weiter als vorteilhaft erwiesen, wenn die dsRNA I und/oder die weitere dsRNA II eine Länge von weniger als 25 aufeinander folgenden Nukleotidpaaren aufweisen. Als besonders effektiv hat sich eine Länge im Bereich zwischen 19 und 23 Nukleotidpaaren erwiesen. Die Effizienz kann weiter gesteigert werden, wenn an den vorzugsweise aus 19 bis 23 Nukleotidpaaren gebildeten Doppelsträngen einzelsträngige Überhänge von 1 bis 4 Nukleotiden vorhanden sind.

Das Zielgen kann nach einem weiteren Ausgestaltungsmerkmal eine der in dem anhängenden Sequenzprotokoll wiedergegebenen Sequenzen SQ001 bis SQ140 aufweisen. Es kann auch aus der folgenden Gruppe ausgewählt sein: Onkogen, Cytokin-Gen, Id-Protein-Gen, Prionen, Gene zur Expression von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie Apoptose- und Zellzyklus-regulierende Molekülen sowie Gene zur Expression des EGF-Rezeptors. Beim Zielgen kann es sich insbesondere um das MDR1-Gen handeln. Es kann in diesem Zusammenhang eine der Sequenzen SQ141 - 173 bestehende bzw. ein aus jeweils zusammengehörenden Antisinn (as)- und Sinnsequenzen (ss) kombinierte dsRNA I/II verwendet werden.

Nach einem weiteren vorteilhaften Ausgestaltungsmerkmal wird die Expression nach dem Prinzip der RNA-Interferenz gehemmt.

Das Zielgen wird zweckmäßigerweise in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert. Es kann Bestandteil eines Virus oder Viroids, insbesondere eines humanpathogenen Virus oder Viroids, sein. Das Virus oder Viroid kann auch ein
5 tier- oder pflanzenpathogenes Virus oder Viroid sein.

Nach einem weiteren Ausgestaltungsmerkmal ist vorgesehen, dass die ungepaarten Nukleotide durch Nukleosidthiophosphate substituiert sind.

10

Zumindest ein Ende der dsRNA I/II kann modifiziert werden, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken. Vorteilhafterweise wird dazu der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt
15 der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht. Die chemische Verknüpfung kann durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-
20 Ionenkoordination gebildet werden. Es hat sich weiter als zweckmäßig und die Stabilität erhöhend erwiesen, wenn die chemische Verknüpfung in der Nähe des einen Endes gebildet ist. Weitere vorteilhafte Ausgestaltungen hinsichtlich der chemischen Verknüpfung können den Merkmalen der Ansprüche 24
25 bis 30 entnommen werden, ohne dass es dafür einer näheren Erläuterung bedarf.

Die dsRNA I/II kann dann besonders einfach in die Zelle eingeschleust werden, wenn sie in micellare Strukturen, vorteil-
30 hafterweise in Liposomen, eingeschlossen wird. Zum Transport der dsRNA I/II in die Zelle hat es sich auch als vorteilhaft erwiesen, dass diese an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon um-
35 geben werden. Das Hüllprotein kann vom Polyomavirus abgeleitet sein. Das Hüllprotein kann insbesondere das Virus-Protein

1 und/oder das Virus-Protein 2 des Polyomavirus enthalten. Nach einer weiteren Ausgestaltung ist vorgesehen, dass bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist. Ferner ist es von Vorteil, dass der eine Strang der dsRNA I/II (as1/2) zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist. Die Zelle kann eine Vertebratenzelle oder eine menschliche Zelle sein.

Weiterhin hat es sich gezeigt, dass die dsRNA I/II vorteilhafterweise bereits in einer Menge von höchstens 5 mg/kg Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht werden kann. Bereits in dieser geringen Dosis wird eine ausgezeichnete Effektivität erzielt.

Überraschenderweise hat sich gezeigt, dass die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen und dann oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht werden kann.

Erfindungsgemäß ist weiterhin die Verwendung einer doppelsträngigen Ribonukleinsäure (dsRNA I) zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist, und wobei ein Strang (Antisinnstrang; as1) oder zumindest ein Abschnitt des einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Sinnstrang des Zielgens ist, und wobei die dsRNA I zumindest an einem Ende einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

Nach weiterer Maßgabe der Erfindung ist ein Medikament zur Hemmung der Expression eines Zielgens in einer Zelle vorgesehen, enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausrei-

tung unter dem Fluoreszenzmikroskop erfolgte frühestens 3 Stunden nach Injektion anhand der grünen Fluoreszenz.

Vorbereitung der Zellkulturen:

5 Die Kultivierung der Zellen erfolgte in DMEM mit 4,5 g/l Glucose, 10 % fötalem Kälberserum (FCS), 2 mM L-Glutamin, Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom) im Brutschrank unter 5 % CO₂-Atmosphäre bei 37°C. Die Zellen wurden alle 3 Tage passagiert, um sie in der exponentiellen Wachstumsphase zu halten. Einen Tag vor der Durchführung der Transfektion wurden die Zellen trypsinisiert (10x Trypsin/TEDTA, Biochrom) und mit einer Zelldichte von 0,3 x 10⁵ Zellen in beschichteten Petrischalen (CORNING® Cell Culture Dish, 35 mm, Corning Inc., Corning, USA) ausgesät. Die Petrischalen wurden mit 0,2 % Gelatine (Biochrom) für mindestens 30 Minuten bei 37°C inkubiert, einmal mit PBS gewaschen und sofort für die Aussaat der Zellen verwendet. Um ein Wiederfinden individueller Zellen zu ermöglichen, wurden CELLocate Coverslips der Fa. Eppendorf (Square size 55 µm) verwendet.

20

Mikroinjektion:

Zur Durchführung der Mikroinjektion wurden die Petrischalen ca. 10 Minuten aus dem Brutschrank genommen. Pro Schale und Ansatz wurden ca. 50 Zellen mikroinjiziert (FemtoJet; Mikromanipulator 5171, Eppendorf). Für die Mikroinjektion wurden Glaskapillaren (FemtoTip) der Firma Eppendorf mit einem Spitzeninnendurchmesser von 0,5 µm verwendet. Die Injektionsdauer betrug 0,8 Sekunden und der Druck 30 hPa. Durchgeführt wurden die Mikroinjektionen an einem Olympus IX50 Mikroskop mit Fluoreszenzeinrichtung. Als Injektionspuffer wurde 14 mM NaCl, 3 mM KCl, 10 mM KH₂PO₄, pH 7,0 verwendet, der 0,01 µg/µl pcDNA-YFP enthielt. Zur Überprüfung einer erfolgreichen Mikroinjektion wurde der Injektionslösung jeweils 0,08% (w/v) an Dextran-70000 gekoppeltes Texas-Rot (Molecular Probes, Leiden, Niederlande) zugesetzt. Um die Inhibition der YFP-Expression mit spezifischer dsRNA zu untersuchen, wurden der

Injektionslösung dsRNAs zugegeben: Ansatz 1: 0,1 μ M dsRNA (Sequenzprotokoll SQ148/149); Ansatz 2: 0,1 μ M dsRNA (Sequenzprotokoll SQ148/159); Ansatz 3: ohne RNA. Nach der Mikroinjektion wurden die Zellen für mindestens drei weitere
5 Stunden im Brutschrank inkubiert. Danach wurden die intrazelluläre YFP-Fluoreszenz am Mikroskop ausgewertet:
gleichzeitig rot und grün-fluoreszierende Zellen: Mikroinjektion war erfolgreich, es wird keine Inhibition der YFP-Expression durch dsRNA beobachtet; bzw. es handelt sich um
10 Kontrollzellen, in die keine dsRNA injiziert wurde;
nur rot-fluoreszierende Zellen: Mikroinjektion war erfolgreich, die dsRNA inhibiert YFP-Expression.

Ergebnisse:

15 Bei einer dsRNA-Konzentration von 0,1 μ M konnte beim Einsatz der dsRNA mit den an beiden 3'-Enden um je zwei Nukleotide überstehenden Einzelstrangbereichen (Sequenzprotokoll SQ148/159) eine merklich erhöhte Hemmung der Expression des YFP-Gens in Fibroblasten beobachtet werden im Vergleich zur
20 dsRNA ohne überstehende Einzelstrangenden (Tabelle 1).

Die Verwendung von kurzen, 19-25 Basenpaare enthaltenden, dsRNA-Molekülen mit Überhängen aus wenigen, vorzugsweise 1 bis 3 nicht-basengepaarten, einzelsträngigen Nukleotiden er-
25 möglicht somit eine vergleichsweise stärkere Hemmung der Genexpression in Säugerzellen als die Verwendung von dsRNAs mit derselben Anzahl von Basenpaaren ohne die entsprechenden Einzelstrangüberhänge bei jeweils gleichen RNA-Konzentrationen.

Ansatz	Name	Sequenzprotokoll-Nr.	0.1 μ M
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (überstehende Enden) SQ159	+++
3		ohne RNA	-

Tabelle 1: Die Symbole geben den relativen Anteil an nicht oder schwach grün-fluoreszierenden Zellen an (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

5

II. Hemmung der Genexpression eines Zielgens in kultivierten HELA-S3-Zellen und Mausfibroblasten durch dsRNA:

- 10 Die Effektivität der Inhibition der YFP-Expression nach transienter Transfektion eines YFP-codierenden Plasmids auf der Basis der RNA-Interferenz mit dsRNAs läßt sich durch Gestaltung der 3'-Enden und der Länge des basengepaarten Bereichs modulieren.

15

Ausführungsbeispiel:

- Zum Wirksamkeitsnachweis der dsRNA bei der spezifischen Inhibition der Genexpression wurden transient transfizierte
- 20 NIH/3T3-Zellen (Fibroblasten aus NIH Swiss Mausembryo, ECCAC (European collection of animal cell culture) Nr. 93061524) und HELA-S3 (humane cervikale Karzinomzellen, DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) Nr. ACC 161) verwendet. Für die Transfektion wurde das Plasmid pcDNA-YFP
- 25 verwendet, das ein 800 bp großes Bam HI /Eco RI-YFP-Fragment in den entsprechenden Schnittstellen des Vektors pcDNA3 enthält. Aus der Sequenz des gelb-fluoreszierenden Proteins (YFP) abgeleitete doppelsträngige RNAs (dsRNAs) wurden herge-

stellt und zusammen mit dem Plasmid pcDNA-YFP transient in die Fibroblasten transfiziert (Die verwendeten spezifischen dsRNAs sind in ihren Antisinn-Strängen komplementär zu entsprechenden Abschnitten der Gensequenzen von sowohl YFP als auch GFP). Nach 48 Stunden wurde die Fluoreszenzabnahme quantifiziert. Als Kontrollen fungierten Zellen, die entweder nur mit pcDNA-YFP oder mit pcDNA-YFP und einer Kontroll-dsRNA (nicht aus der YFP-Sequenz abgeleitet) transfiziert wurden.

10 Versuchsprotokoll:

dsRNA-Synthese:

Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO₄, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO₄, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute. Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

Aussaat der Zellen:

30 Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der NIH/3T3-Zellen und der HELA-S3 erfolgte im Brutschrank (CO₂-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO₂ und gesättigter

Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom), für die Mausfibroblasten, und Ham's F12 für die HELA-Zellen mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom) und Penicillin/Streptomycin (100 IE/100 $\mu\text{g/ml}$, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Durchführung der Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA, Biochrom, Deutschland) und mit einer Zelldichte von $1,0 \times 10^4$ Zellen/Vertiefung in einer 96-Loch-Platte (Multiwell Schalen 96-Well Flachboden, Labor Schubert & Weiss GmbH) in 150 μl Wachstumsmedium ausgesät.

15

Durchführung der transienten Transfektion:

Die Transfektion wurde mit Lipofectamine Plus™ Reagent (Life Technologies) gemäß den Angaben des Herstellers durchgeführt. Pro Well wurden 0,15 μg pcDNA-YFP-Plasmid eingesetzt. Das Gesamt-Transfektionsvolumen betrug 60 μl . Es wurden jeweils 3-fach-Proben angesetzt. Die Plasmid-DNA wurde zuerst zusammen mit der dsRNA komplexiert. Dazu wurde die Plasmid-DNA und die dsRNA in serumfreiem Medium verdünnt und pro 0,1 μg Plasmid-DNA 1 μl PLUS Reagent eingesetzt (in einem Volumen von 10 μl) und nach dem Mischen für 15 Minuten bei Raumtemperatur inkubiert. Während der Inkubation wurde pro 0,1 μg Plasmid-DNA 0,5 μl Lipofectamine in insgesamt 10 μl serumfreiem Medium verdünnt, gut gemischt, zu dem Plasmid/dsRNA/PLUS-Gemisch zugegeben und nochmals 15 Minuten inkubiert. Während der Inkubation wurde ein Mediumwechsel durchgeführt. Die Zellen wurden dazu 1 x mit 200 μl serumfreiem Medium gewaschen und danach mit 40 μl serumfreiem Medium bis zur Zugabe von DNA/dsRNA/PLUS/Lipofectamine weiter im Brutschrank inkubiert. Nach der Zugabe von 20 μl DNA/dsRNA/PLUS/Lipofectamine pro

Well wurden die Zellen für 2,5 Stunden im Brutschrank inkubiert. Anschließend wurden die Zellen nach der Inkubation 1 x mit 200 µl Wachstumsmedium gewaschen und für 24 Stunden bis zur Detektion der Fluoreszenz in 200 µl Wachstumsmedium im Brutschrank inkubiert.

Detektion der Fluoreszenz:

24 Stunden nach dem letzten Mediumwechsel wurde die Fluoreszenz der Zellen am Fluoreszenz-Mikroskop (IX50-S8F2, Fluoreszenz-Einheit U-ULS100Hg, Brenner U-RFL-T200, Olympus) mit einer USH-I02D-Quecksilber-Lampe (USHIO Inc., Tokyo, Japan), ausgestattet mit einem WIB-Fluoreszenz-Würfel und einer digitalen CCD-Kamera (Orca IIIm, Hamamatsu) und C4742-95 Kamera-Controller) photographiert. Die Auswertung der Fluoreszenzaufnahmen erfolgte mit der analysis-Software 3.1 (Soft Imaging Sytem GmbH, Deutschland). Um die YFP-Fluoreszenz in Relation zur Zelldichte zu setzen, wurde eine Zellkernfärbung (Hoechst-Staining) durchgeführt. Dazu wurden die Zellen in 100 µl Methycarnoy (75% Methanol, 25% Eisessig) zuerst für 5 und danach nochmals für 10 Minuten in Methycarnoy fixiert. Nach dem Lufttrocknen wurden die fixierten Zellen für 30 Minuten im Dunkeln mit 100 µl pro Well Hoechst-Farbstoff (75 ng/ml) inkubiert. Nach 2maligem Waschen mit PBS (PBS Dulbecco w/o Ca²⁺, Mg²⁺, Biochrom) wurden die Hoechst-gefärbten Zellen unter dem Fluoreszenz-Mikroskop (Olympus, WU-Fluoreszenz-Würfel für Hoechst) photographiert.

In den Fig. 3 bis 9 sind die Ergebnisse zur Inhibition der YFP-Expression durch dsRNA in kultivierten Zellen zusammengefasst:

30

In Fig. 3, 4, 5 und 6 sind die Effekte von YFP-spezifischen dsRNAs und von Kontroll-dsRNAs auf die YFP-Expression in NIH/3T3-Mausfibroblasten nach transienter Transfektion zusammengefasst. Die Experimente wurden wie im Versuchsprotokoll

Die Fig. 10 bis 17 zeigen die Serumstabilität der dsRNA nach Inkubation mit humanem bzw. murinem Serum und nachfolgender elektrophoretischer Auftrennung im 20%igem 7M Harnstoffgel.

5 **Fig. 10: Inkubation von S1 (0-22-0) in Maus-Serum**

1. zum Zeitpunkt 0 (ohne Serum)
2. zum Zeitpunkt 0
3. für 30 Minuten
4. für 1 Stunde
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 12 Stunden
8. 2 μ l 100 μ M S1 ohne Inkubation
- S1A) Sinnstrang S1 (10 μ l 20 μ M S1A)
- 15 S1B) Antisinnstrang S1 (10 μ l 20 μ M S1B)

Fig. 11: Inkubation von S1 (0-22-0) in humanem Serum

1. 2 μ l 100 μ M S1 unbehandelt (ohne Inkubation)
2. für 30 Minuten
3. für 2 Stunden
- 20 4. für 4 Stunden
5. für 6 Stunden
6. für 8 Stunden
7. für 12 Stunden
8. für 24 Stunden
- 25 S1A) Sinnstrang S1 (10 μ l 20 μ M S1A)
- S1B) Antisinnstrang S1 (10 μ l 20 μ M S1B)

Fig. 12: Inkubation von S7 (2-19-2) in Maus-Serum

1. zum Zeitpunkt 0 (ohne Serum)
2. für 30 Minuten
- 30 3. für 4 Stunden
4. für 12 Stunden

Fig. 13: Inkubation von S7 (2-19-2) in humanem Serum

1. Sinnstrang S7 (10 μ l 20 μ M S7A)

2. Antisinnstrang S7 (10 μ l 20 μ M S7B)
3. für 30 Minuten
4. für 1 Stunde
5. für 2 Stunden
- 5 6. für 4 Stunden
7. für 6 Stunden
8. für 12 Stunden
9. für 24 Stunden
10. zum Zeitpunkt 0 (ohne Serum)

10 **Fig. 14: Inkubation von K3 (2-19-2) in Maus-Serum**

1. Sinnstrang K3 (10 μ l 20 μ M K3A)
2. Antisinnstrang K3 (10 μ l 20 μ M K3B)
3. zum Zeitpunkt 0 (ohne Serum)
4. zum Zeitpunkt 0 (mit Serum)
- 15 5. für 30 Minuten
6. für 1 Stunde
7. für 2 Stunden
8. für 4 Stunden
9. für 12 Stunden

20 **Fig. 15: Inkubation von PKC1/2 (0-22-2) in Maus-Serum**

1. für 30 Minuten
2. für 1 Stunde
3. für 2 Stunden
4. für 4 Stunden
- 25 5. für 12 Stunden
6. 2 μ l 100 μ M PKC1/2 (unbehandelt)

Fig. 16: Inkubation von S1A/S4B (0-22-2) in humanem Serum

1. zum Zeitpunkt 0 (ohne Serum)
2. für 24 Stunden
- 30 3. für 12 Stunden
4. für 8 Stunden
5. für 6 Stunden
6. für 4 Stunden

7. für 2 Stunden
8. für 30 Minuten
9. Sinnstrang S1A (10 μ l 20 μ M S1A)
10. Antisinnstrang S4B (10 μ l 20 μ M S4B)

5 **Fig. 17: Inkubation von K2 (2-22-2) in humanem Serum**

1. Sinnstrang K2 (10 μ l 20 μ M K2A)
2. Antisinnstrang K2 (10 μ l 20 μ M K2B)
3. zum Zeitpunkt 0 (ohne Serum)
4. für 30 Minuten
- 10 5. für 2 Stunden
6. für 4 Stunden
7. für 6 Stunden
8. für 8 Stunden
9. für 12 Stunden
- 15 10. für 24 Stunden

Ergebnisse:

dsRNAs ohne einzelsträngige Bereiche an den 3'-Enden sind im
20 Serum sowohl von Mensch und Maus wesentlich stabiler als
dsRNAs mit einzelsträngigen 2nt-Überhängen an den 3'-Enden
(Fig. 10 bis 14 und 17). Nach 12 bzw. 24 Stunden Inkubation
von S1 in murinem bzw. humanem Serum ist noch immer eine Ban-
de in der ursprünglichen Größe fast vollständig erhalten. Da-
25 gegen nimmt bei dsRNAs mit 2nt-Überhängen an beiden 3'-Enden
die Stabilität in humanem als auch im murinen Serum deutlich
ab. Bereits nach 4 Stunden Inkubation von S7 (Fig. 12 und 13)
oder K3 (Fig. 14) ist keine Bande in der Originalgröße mehr
detektierbar.

30

Um die Stabilität von dsRNA im Serum zu erhöhen, ist es aus-
reichend, wenn die dsRNA ein glattes Ende besitzt. Im Maus-
Serum ist nach 4 Stunden Inkubation (Fig. 15, Bahn 4) die

Bande in der Originalgröße kaum abgebaut im Vergleich zu S7 (nach 4 Stunden vollständiger Abbau; Fig. 12, Bahn 3).

- Als optimaler Kompromiß hinsichtlich der biologischen Wirksamkeit von dsRNA kann die Verwendung von dsRNA mit einem glatten Ende und einem einzelsträngigem Bereich von 2 Nukleotiden angesehen werden, wobei sich der einzelsträngige Überhang am 3'-Ende des Antisinn-Stranges befinden sollte.
- 10 Die hier verwendeten Sequenzen sind aus der nachstehenden Tabelle 2 und den Sequenzprotokollen SQ148-151 und 153-167 ersichtlich.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5'- CCACAUGAAGCAGCACGACUU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5'- ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3'- UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5'-GAUGAGGAUCGUUUCGCAUGA-3' (B) 3'-UCCUACUCCUAGCAAAGCGUA-5'	2-19-2
K2	SQ157 SQ158	(A) 5'- ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5'- CCACAUGAAGCAGCACGACUUC -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160 SQ161	(A) 5'- CUUCUCCGCCUCACACCGCUGCAA -3' (B) 3'- GAAGAGGCGGAGUGUGGCGACG -5'	2-22-0
S7/S12	SQ150 SQ162	(A) 5'- CCACAUGAAGCAGCACGACUU -3' (B) 3'- GGUGUACUUCGUCGUGCUGAA -5'	0-21-0
S7/S11	SQ150 SQ163	(A) 5'- CCACAUGAAGCAGCACGACUU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGAA -5'	0-21-2
S13	SQ164 SQ165	(A) 5'- CCACAUGAAGCAGCACGACU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGA -5'	0-20-2
S13/14	SQ164 SQ166	(A) 5'- CCACAUGAAGCAGCACGACU -3' (B) 3'- GGUGUACUUCGUCGUGCUGA -5'	0-20-0
S4	SQ167 SQ159	(A) 5'- CCACAUGAAGCAGCACGACUUCUU -3' (B) 3'- CUGGUGUACUUCGUCGUGCUGAAG -5'	2-22-2
K1A/ K2B	SQ153 SQ158	(A) 5'- ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3'- UCUGUCCUACUCCUAGCAAAGCGU -5'	0-22-2
K1B/ K2A	SQ154 SQ157	(A) 5'- ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3'- UGUCCUACUCCUAGCAAAGCGU -5'	2-22-0
S1B/ S4A	SQ149 SQ167	(A) 5'- CCACAUGAAGCAGCACGACUUCUU -3' (B) 3'- GGUGUACUUCGUCGUGCUGAAG -5'	2-22-0

Tabelle 2

IV. In vivo-Studie:

5

Es wurde „GFP-Labormäusen“, die das Grün-fluoreszierende Protein (GFP) in allen Proteinbiosynthese betreibenden Zellen exprimieren, doppelsträngige RNA (dsRNA), die aus der GFP-Sequenz abgeleitet wurde, bzw. unspezifische dsRNA intravenös in die Schwanzvene injiziert. Am Versuchsende wurden die Tie-

10

ta Cruz Biotechnology) in einer Verdünnung von 1:1000 erfolgte für 1h bei RT. Danach wurde 3 x 5 min gewaschen und für 1h bei RT mit dem Sekundärantikörper (donkey anti-goat IgG Horseradish Peroxidase gelabelt, Santa Cruz Biotechnology) in einer Verdünnung von 1 : 10.000 inkubiert. Die Detektion erfolgte mit dem ECL-System von Amersham nach den Angaben des Herstellers.

In den Fig. 18 bis 20 ist die Inhibition der GFP-Expression nach intravenöser Injektion von spezifisch gegen GFP gerichteter dsRNA mit Immunperoxidase-Färbungen gegen GFP an 3 µm Paraffinschnitten dargestellt. Im Versuchsverlauf wurde gegen GFP gerichtete dsRNA mit einem doppelsträngigen Bereich von 22 Nukleotid-(nt)paaren ohne Überhänge an den 3'-Enden (D) und die entsprechende unspezifische Kontroll-dsRNA (B) sowie spezifisch gegen GFP gerichtete dsRNA mit einem 19 Nukleotidpaare umfassenden Doppelstrangbereich mit 2nt-Überhängen an den 3'-Enden (E) und die entsprechende unspezifische Kontroll-dsRNA (C) im 12 Stunden-Turnus über 5 Tage hinweg appliziert. (F) erhielt 1/50 der Dosis von Gruppe D. Als weitere Kontrolle wurden Tiere ohne dsRNA-Gabe (A) bzw. WT-Tiere untersucht. Die Fig. 18 zeigt die Inhibition der GFP-Expression in Nierenschnitten, Fig. 19 in Herz- und Fig. 20 in Pankreasgewebe. In den Fig. 21 bis 23 sind Western Blot-Analysen der GFP-Expression in Plasma und Geweben dargestellt. In der Fig. 21 ist die Inhibition der GFP-Expression im Plasma, in Fig. 22 in der Niere und in Fig. 23 in Herz gezeigt. In Fig. 23 sind Gesamtproteinisolate aus verschiedenen Tieren aufgetragen. Es wurden jeweils gleiche Gesamtproteinmengen pro Bahn aufgetragen. In den Tieren, denen unspezifische Kontroll-dsRNA verabreicht wurde (Tiere der Gruppen B und C), ist die GFP-Expression gegenüber Tieren, die keinerlei dsRNA erhielten, nicht reduziert. Tiere, die spezifisch gegen GFP gerichtete dsRNA mit 2nt-Überhängen an den 3'-Enden

beider Stränge und einen 19 Nukleotidpaare umfassenden Doppelstrangbereich erhielten, zeigten eine signifikant inhibierte GFP-Expression in den untersuchten Geweben (Herz, Niere, Pankreas und Blut), verglichen mit unbehandelten Tieren (Fig. 18 bis 23). Bei den Tieren der Gruppen D und F, denen spezifisch gegen GFP gerichtete dsRNA mit glatten Enden und einem 22 Nukleotidpaare umfassenden Doppelstrangbereich appliziert wurde, zeigten nur jene Tiere, die die dsRNA in einer Dosis von 50 µg/kg Körpergewicht pro Tag erhielten, eine spezifische Inhibition der GFP-Expression, die allerdings weniger deutlich ausgeprägt war als die der Tiere in Gruppe E.

Die zusammenfassende Auswertung von GFP-Inhibition in den Gewebeschnitten und im Western Blot ergibt, dass die Inhibition der GFP-Expression im Blut und in der Niere am stärksten ist (Fig. 18, 21 und 22).

V. Hemmung der Genexpression des EGF-Rezeptors mit dsRNA als therapeutischer Ansatz bei Krebsformen mit EGFR-Überexpression oder EGFR-induzierter Proliferation:

Der Epidermal Growth Factor (=EGF)-Rezeptor (=EGFR) gehört zu den Rezeptor-Tyrosinkinasen, transmembranen Proteinen mit einer intrinsischen Tyrosinkinase-Aktivität, die an der Kontrolle einer Reihe von zellulären Prozessen wie Zellwachstum, Zelldifferenzierungen, migratorischen Prozessen oder der Zellvitalität beteiligt sind (Übersicht in: Van der Geer et al. 1994). Die Familie der EGFR besteht aus 4 Mitgliedern, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) und HER4 (ErbB4) mit einer transmembranen Domäne, einer cysteinreichen extrazellulären Domäne und einer intrazellulären katalytischen Domäne. Die Sequenz des EGFR, einem 170 kDa Protein, ist seit 1984 bekannt (Ullrich et al., 1984).

Aktiviert wird der EGFR durch Peptid-Wachstumsfaktoren wie EGF, TGF α (transforming growth factor), Amphiregulin, Beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) und Neureguline. Ligandenbindung induziert die Bildung von Homo- oder Heterodimeren mit nachfolgender Autophosphorylierung zytoplasmatischer Tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). Die phosphorylierten Aminosäuren bilden die Bindungsstellen für eine Vielzahl von Proteinen, die an den proximalen Schritten der Signalweiterleitung in einem komplexen Netzwerk beteiligt sind. Der EGFR ist an den verschiedensten Tumorerkrankungen beteiligt und damit ein geeignetes Target für therapeutische Ansätze (Huang & Harari, 1999). Die Mechanismen, die zu einer aberranten EGFR-Aktivierung führen, können auf Überexpression, Amplifikation, konstitutiver Aktivierung mutanter Rezeptor-Formen oder autokrinen Loops beruhen (Voldborg et al., 1997). Eine Überexpression des EGFR wurde für eine Reihe von Tumoren beschrieben, wie z.B. Brustkrebs (Walker & Dearing, 1999), Nicht-Klein-Lungenkarzinom (Fontanini et al., 1998), Pankreaskarzinom, Kolonkarzinom (Salomon et al., 1995) und Glioblastomen (Rieske et al., 1998). Insbesondere für maligne Glioblastome sind bisher keine effizienten und spezifischen Therapeutika verfügbar.

25 Ausführungsbeispiel:

Zum Nachweis der Wirksamkeit der dsRNA bei der spezifischen Inhibition der EGFR-Genexpression wurden U-87 MG-Zellen (humane Glioblastomzellen), ECCAC (European collection of animal cell culture) Nr. 89081402, verwendet, die mit spezifisch gegen den EGF-Rezeptor (Sequenzprotokoll SQ 51) gerichteten dsRNA transfiziert wurden. Nach ca. 72 Stunden Inkubation wurden die Zellen geerntet, Protein isoliert und im Western Blot Verfahren die EGFR-Expression untersucht.

Versuchsprotokoll:dsRNA-Synthese:

- 5 Mittels eines RNA-Synthesizers (Typ Expedite 8909, Applied Biosystems, Weiterstadt, Deutschland) und herkömmlicher chemischer Verfahren wurden die aus den Sequenzprotokollen ersichtlichen RNA-Einzelstränge und die zu ihnen komplementären Einzelstränge synthetisiert. Anschließend erfolgte die Reinigung der rohen Syntheseprodukte mit Hilfe der HPLC. Verwendet
- 10 wurde die Säule NucleoPac PA-100, 9x250 mm, der Fa. Dionex; als Niedersalz-Puffer 20 mM Tris, 10 mM NaClO₄, pH 6,8, 10% Acetonitril und als Hochsalz-Puffer 20 mM Tris, 400 mM NaClO₄, pH 6,8, 10% Acetonitril. Der Fluß betrug 3 ml/Minute.
- 15 Die Hybridisierung der Einzelstränge zum Doppelstrang erfolgte durch Erhitzen des stöchiometrischen Gemischs der Einzelstränge in 10 mM Natriumphosphatpuffer, pH 6,8, 100 mM NaCl, auf 80-90°C und nachfolgendes langsames Abkühlen über 6 Stunden auf Raumtemperatur.

20

Aussaat der Zellen:

- Alle Zellkulturarbeiten wurden unter sterilen Bedingungen in einer entsprechenden Werkbank (HS18, Hera Safe, Kendro, Heraeus) durchgeführt. Die Kultivierung der U-87 MG-Zellen
- 25 erfolgte im Brutschrank (CO₂-Inkubator T20, Hera cell, Kendro, Heraeus) bei 37°C, 5% CO₂ und gesättigter Luftfeuchtigkeit in DMEM (Dulbecco's modified eagle medium, Biochrom) mit 10% FCS (fetal calf serum, Biochrom), 2 mM L-Glutamin (Biochrom), 1 mM Natrium-Pyruvat (Biochrom), 1xNEAA (Non-
- 30 essetial Aminoacids, Biochrom) und Penicillin/Streptomycin (100 IE/100 µg/ml, Biochrom). Um die Zellen in der exponentiellen Wachstumsphase zu halten, wurden die Zellen alle 3 Tage passagiert. 24 Stunden vor der Applikation der dsRNA mittels Transfektion wurden die Zellen trypsiniert (10x Trypsin/EDTA,

Biochrom, Deutschland) und mit einer Zelldichte von 5×10^5 Zellen/Vertiefung in einer 6-Well-Platte (6-Well Schalen, Labor Schubert & Weiss GmbH) in 1,5 ml Wachstumsmedium ausgesät.

5

Applikation der dsRNA in kultivierte U-87 MG-Zellen:

Die Applikation der dsRNA erfolgte mittels Transfektion mit dem OLIGOFECTAMINE™ Reagent (Life Technologies) gemäß den Angaben des Herstellers. Das Gesamt-Transfektionsvolumen betrug
10 1 ml. Zuerst wurde die dsRNA in serumfreiem Medium verdünnt: Dazu wurden pro Well 0,5 µl einer 20 µM Stammlösung spezifisch gegen EGFR gerichteten dsRNA und 9,5 µl einer 20 µM Stammlösung unspezifischer dsRNA (K1A/K2B) mit 175 µl serumfreiem Medium verdünnt (200 nM dsRNA im Transfektionsansatz
15 bzw. 10 nM spezifische EGFR-dsRNA). Das OLIGOFECTAMINE™ Reagent wurde ebenfalls in serumfreiem Medium verdünnt: pro Well 3 µl mit 12 µl Medium und danach 10 min bei Raumtemperatur inkubiert. Danach wurde das verdünnte OLIGOFECTAMINE™ Reagent zu den in Medium verdünnten dsRNAs gegeben, gemischt und für
20 weitere 20 min bei RT inkubiert. Während der Inkubation wurde ein Mediumwechsel durchgeführt. Die Zellen wurden dazu 1 x mit 1 ml serumfreiem Medium gewaschen und mit 800 µl serumfreiem Medium bis zur Zugabe von dsRNA/OLIGOFECTAMINE™ Reagent weiter im Brutschrank inkubiert. Nach der Zugabe von 200 µl
25 dsRNA/OLIGOFECTAMINE™ Reagent pro Well wurden die Zellen bis zur Proteinisolierung weiter im Brutschrank inkubiert.

Proteinisolierung:

Ca. 72 Stunden nach der Transfektion wurden die Zellen geerntet und eine Proteinisolierung durchgeführt. Dazu wurde das
30 Medium abgenommen und das Zellmonolayer 1 x mit PBS gewaschen. Nach Zugabe von 200 µl Proteinisolierungspuffer (1x Protease-Inhibitor „Complete“, Roche, 50 mM HEPES, pH 7,5,

Kontrolle wurde eine unspezifische dsRNA-Sequenz, die keinerlei Homologie mit der MDR1-Gensequenz aufweist, eingesetzt (K) und eine MOCK-Transfektion durchgeführt, die alle Reagenzien außer dsRNA enthielt.

5

Die Zellen wurden nach 24, 48 und 72 Stunden geerntet und die Gesamt-RNA mit dem RNeasy-Mini-Kit von Qiagen extrahiert. 10 µg Gesamt-RNA jeder Probe wurden auf einem 1%igen Agarose-Formaldehyd-Gel elektrophoretisch aufgetrennt, auf eine Nylon-Membran geblottet und mit 5'-α³²P-dCTP random-markierten, spezifischen Sonden zuerst gegen MDR1 und nach dem Strippen des Blots gegen GAPDH als interne Kontrolle hybridisiert und auf Röntgenfilmen exponiert.

15 Die Röntgenfilme wurden digitalisiert (Image Master, VDS Pharmacia) und mit der Image-Quant-Software quantifiziert. Dabei wurde ein Abgleich der MDR1-spezifischen Banden mit den entsprechenden GAPDH-Banden durchgeführt.

20 Ergebnisse:

Die Fig. 25 und 26 zeigen Northern-Blots (Fig. 25a, 26a) mit quantitativer Auswertung der MDR1-spezifischen Banden nach Abgleich mit den entsprechenden GAPDH-Werten (Fig. 25b, 26b). Es konnte eine Reduktion der MDR1-mRNA um bis zu 55 % im Vergleich zur MOCK-Transfektion und um bis zu 45 % im Vergleich zur unspezifischen Kontroll-Transfektion beobachtet werden. Nach 48 h ist eine signifikante Reduktion des MDR1-mRNA-Niveaus mit den als R1, R2, R3 (Tabelle 4) bezeichneten dsRNA-Konstrukten erreicht worden. Mit den R4-dsRNA-Konstrukten wurde nach 48 h keine signifikante Reduktion gegenüber den Kontrollen beobachtet (Fig. 26a und 26b). Nach 74 h war eine deutlich stärkere Reduktion des MDR1-mRNA-Levels mit R1, R2 und R3 gegenüber den Kontrollen im Vergleich zu den 48 h-Werten zu beobachten (Fig. 25a und 25b).

Mit R4 konnte zu diesem Zeitpunkt ebenfalls eine signifikante Verringerung des MDR1-mRNA-Niveaus erzielt werden. Somit reduzieren die Konstrukte mit einem 2nt-Überhang am 3'-Ende des Antisinnstrangs und einem doppelsträngigen Bereich aus 22 Nukleotidpaaren, relativ unabhängig von dem jeweiligen zum MDR1-Gen homologen Sequenzbereich (nach 48 h; Fig. 26b) das MDR1-mRNA-Level effizienter als die Konstrukte mit mit 2nt-Überhängen an den 3'-Enden beider Stränge (Antisinn- und Sinnstrang) und einem Doppelstrangbereich von 19 Nukleotidpaaren. Die Ergebnisse bekräftigen damit die in Ausführungsbeispiel IV beschriebene Inhibition der EGFR-Genexpression durch spezifische dsRNAs nach Transfektion in U-87 MG-Zellen.

Die Transfektionseffizienz wurde in einem getrennten Experiment mit Hilfe eines Texas-Red-markierten DNA-Oligonukleotids (TexRed-A(GATC)₅T; ebenfalls 175 nM transfiziert) ermittelt (Fig. 27a, 27b; 400fache Vergrößerung, 48h nach Transfektion). Sie betrug etwa 50% auf der Grundlage der rot fluoreszierenden Zellen im Vergleich zur Gesamtzellzahl. Berücksichtigt man die Transfektionsrate der Zellen von etwa 50%, so legt die beobachtete Verringerung des MDR1-mRNA-Niveaus um ca. 45-55% liegt (verglichen mit den Kontrollen), den Schluss nahe, dass in allen Zellen, die mit spezifischer dsRNA erfolgreich transfiziert werden konnten, die MDR1-mRNA nahezu vollständig und spezifisch abgebaut wurde.

Literatur:

- Alroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.
- Bass, B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.
- Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.
- Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.
- Caplen, N.J., Fleenor, J., Fire, A., and Morgan, R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.
- Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Mamehama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc. Natl. Acad. Sci. USA 97, 6499-6503.
- Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

- has progressed after chemotherapy for metastatic disease.
Journal of Clinical Oncology 17: 2639-2648.
- Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11,
5 152-156.
- Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E.,
and Mello, C.C., 1998. Potent and specific genetic interfer-
ence by double-stranded RNA in *Caenorhabditis elegans*. Nature
10 391, 806-811.
- Fire, A., 1999. RNA-triggered gene silencing. Trends Genet.
15, 358-363.
- 15 Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruth-
ers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-
energy parameters for prediction of RNA duplex stability.
Proc. Natl. Acad. Sci. USA 83, 9373-9377 .
- 20 Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor
response elements mediate induction of intestinal MDR1 by ri-
fampin. J. Biol. Chem. 276 (18), 14581-14587.
- Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M,
25 Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR,
Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998):
Evaluation of epidermal growth factor-related growth factors
and receptors and of neoangiogenesis in completely resected
stage I-IIIa non-small-cell lung cancer: amphiregulin and mi-
30 crovessel count are independent prognostic factors of sur-
vival. Clinical Cancer Research 4: 241-249.

Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.

- 5 Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.

10

Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.

15

Kyhse-Anderson J (1984): Electrophoretic transfer of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.

20

Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.

- 25 Loo, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.

Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.

30

Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

47. Verwendung nach einem der Ansprüche 41 bis 47, wobei die dsRNA I und/oder die dsRNA II eine Länge von weniger als 25, vorzugsweise 19 bis 23, aufeinander folgenden Nukleotidpaaren aufweist/en.

48. Verwendung nach einem der Ansprüche 41 bis 47, wobei der erste (B1) und der zweite Bereich (B2) abschnittsweise überlappen oder aneinander grenzen.

49. Verwendung nach einem der Ansprüche 41 bis 48, wobei der erste (B1) und der zweite Bereich (B2) voneinander beabstandet sind.

50. Verwendung nach einem der Ansprüche 41 bis 49, wobei das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

51. Verwendung nach einem der Ansprüche 41 bis 50, wobei das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen, Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierenden Molekülen.

52. Verwendung nach einem der Ansprüche 41 bis 51, wobei das Zielgen das MRD1-Gens ist.

53. Verwendung nach einem der Ansprüche 41 bis 52, wobei als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.

54. Verwendung nach einem der Ansprüche 41 bis 53, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.
- 5 55. Verwendung nach einem der Ansprüche 41 bis 54, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimiert wird.
56. Verwendung nach einem der Ansprüche 41 bis 55, wobei das
10 Zielgen Bestandteil eines Virus oder Viroids ist.
57. Verwendung nach Anspruch 56, wobei das Virus ein humanpathogenes Virus oder Viroid ist.
- 15 58. Verwendung nach Anspruch 56, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.
59. Verwendung nach einem der Ansprüche 41 bis 58, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert
20 sind.
60. Verwendung nach einem der Ansprüche 41 bis 59, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.
25
61. Verwendung nach einem der Ansprüche 41 bis 60, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische
30 Verknüpfung erhöht wird.
62. Verwendung nach einem der Ansprüche 41 bis 61, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwir-

kungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

63. Verwendung nach einem der Ansprüche 41 bis 62, wobei die
5 chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

64. Verwendung nach einem der Ansprüche 41 bis 63, wobei die
10 chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

65. Verwendung nach einem der Ansprüche 41 bis 64, wobei die
15 chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

66. Verwendung nach einem der Ansprüche 41 bis 65, wobei die
20 chemische Verknüpfung durch Purinanaloga gebildet wird.

67. Verwendung nach einem der Ansprüche 41 bis 66, wobei die
chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

68. Verwendung nach einem der Ansprüche 41 bis 67, wobei zur
25 Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.

69. Verwendung nach einem der Ansprüche 41 bis 68, wobei die
30 chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet wird.

70. Verwendung nach einem der Ansprüche 41 bis 69, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.

5 71. Verwendung nach einem der Ansprüche 41 bis 70, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

72. Verwendung nach einem der Ansprüche 41 bis 71, wobei die
10 dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

15 73. Verwendung nach einem der Ansprüche 41 bis 72, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

74. Verwendung nach einem der Ansprüche 41 bis 73, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-
20 Protein 2 (VP2) des Polyomavirus enthält.

75. Verwendung nach einem der Ansprüche 41 bis 74, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kap-
25 sidartigen Gebildes gewandt ist.

76. Verwendung nach einem der Ansprüche 41 bis 75, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.

30

77. Verwendung nach einem der Ansprüche 41 bis 76, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.

78. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

79. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 80. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 81. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist;

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

82. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

126. Verfahren nach einem der vorhergehenden Ansprüche, wobei
zumindest eine entsprechend der dsRNA I nach einem der vor-
hergehenden Ansprüche ausgebildete weitere doppelsträngige
Ribonukleinsäure (dsRNA II) in die Zelle eingeführt wird,
5 wobei der eine Strang (as1) oder zumindest ein Abschnitt des
einen Strangs (as1) der dsRNA I komplementär zu einem ersten
Bereich (B1) des Zielgens ist, und wobei ein weiterer Strang
(as2) oder zumindest ein Abschnitt des weiteren Strangs (as2)
der dsRNA II komplementär zu einem zweiten Bereich (B2) des
10 Zielgens ist.

127. Verfahren nach einem der vorhergehenden Ansprüche, wobei
die dsRNA I und/oder die dsRNA II eine Länge von weniger als
25, vorzugsweis 19 bis 23, aufeinander folgenden Nukleo-
15 tidpaaren aufweist/en.

128. Verfahren nach einem der vorhergehenden Ansprüche, wobei
der erste (B1) und der zweite Bereich (B2) abschnittsweise
überlappen oder aneinander grenzen.
20

129. Verfahren nach einem der vorhergehenden Ansprüche, wobei
der erste (B1) und der zweite Bereich (B2) voneinander beab-
standet sind.

25 130. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen eine der Sequenzen SQ001 bis SQ140 aufweist.

131. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen aus der folgenden Gruppe ausgewählt ist: Onkogen,
30 Cytokin-Gen, Id-Protein-Gen, Priongen, Gene von Angiogenese
induzierenden Molekülen, von Adhäsions-Molekülen und von
Zelloberflächenrezeptoren, Gene von Proteinen, die an meta-
stasierenden und/oder invasiven Prozessen beteiligt sind, Ge-

ne von Proteinasen sowie Apoptose- und Zellzyklus-regulierenden Molekülen.

132. Verfahren nach einem der vorhergehenden Ansprüche, wobei
5 das Zielgen das MDR1-Gens ist.

133. Verfahren nach einem der vorhergehenden Ansprüche, wobei
als dsRNA I/II eine der Sequenzen SQ141 -173 bzw. ein aus
zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnse-
10 quenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen
SQ141 - 173 verwendet wird.

134. Verfahren nach einem der vorhergehenden Ansprüche, wobei
die Expression nach dem Prinzip der RNA-Interferenz gehemmt
15 wird.

135. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen in pathogenen Organismen, vorzugsweise in Plasmo-
dien, exprimiert wird.
20

136. Verfahren nach einem der vorhergehenden Ansprüche, wobei
das Zielgen Bestandteil eines Virus oder Viroids ist.

137. Verfahren nach Anspruch 16, wobei das Virus ein humanpa-
25 thogenes Virus oder Viroid ist.

138. Verfahren nach Anspruch 16, wobei das Virus oder Viroid
ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30 139. Verfahren nach einem der vorhergehenden Ansprüche, wobei
ungepaarte Nukleotide durch Nukleosidthiophosphate substitu-
iert sind.

140. Verfahren nach einem der vorhergehenden Ansprüche, wobei zumindest ein Ende (E1, E2) der dsRNA I/II modifiziert wird, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.

5

141. Verfahren nach einem der vorhergehenden Ansprüche, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht wird.

10

142. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

20

143. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

25

144. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicooxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

30

145. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

146. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Purinanaloga gebildet wird.

147. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

5 148. Verfahren nach einem der vorhergehenden Ansprüche, wobei zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.
10

149. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-
15 Gruppen gebildet wird.

150. Verfahren nach einem der vorhergehenden Ansprüche, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.
20

151. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

25 152. Verfahren nach einem der vorhergehenden Ansprüche, wobei die dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

30 153. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

154. Verfahren nach einem der vorhergehenden Ansprüche, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-Protein 2 (VP2) des Polyomavirus enthält.
- 5 155. Verfahren nach einem der vorhergehenden Ansprüche, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kapsidartigen Gebildes gewandt ist.
- 10 156. Verfahren nach einem der vorhergehenden Ansprüche, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.
- 15 157. Verfahren nach einem der vorhergehenden Ansprüche, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.
158. Verfahren nach einem der vorhergehenden Ansprüche, wobei

kungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet wird.

183. Verwendung nach einem der Ansprüche 41 bis 62, wobei die
5 chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

184. Verwendung nach einem der Ansprüche 41 bis 63, wobei die
chemische Verknüpfung mittels einer oder mehrerer Verbin-
10 dungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicooxy-1,3-propandiol)- und/oder Oligoethylenglycol-Ketten sind.

185. Verwendung nach einem der Ansprüche 41 bis 64, wobei die
15 chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet wird.

186. Verwendung nach einem der Ansprüche 41 bis 65, wobei die
chemische Verknüpfung durch Purinanaloga gebildet wird.

20

187. Verwendung nach einem der Ansprüche 41 bis 66, wobei die
chemische Verknüpfung durch Azabenzoleinheiten gebildet wird.

188. Verwendung nach einem der Ansprüche 41 bis 67, wobei zur
25 Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.

30 189. Verwendung nach einem der Ansprüche 41 bis 68, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet wird.

190. Verwendung nach einem der Ansprüche 41 bis 69, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt wird.

- 5 191. Verwendung nach einem der Ansprüche 41 bis 70, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen wird.

- 10 192. Verwendung nach einem der Ansprüche 41 bis 71, wobei die dsRNA I/II an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben wird/werden.

- 15 193. Verwendung nach einem der Ansprüche 41 bis 72, wobei das Hüllprotein vom Polyomavirus abgeleitet ist.

194. Verwendung nach einem der Ansprüche 41 bis 73, wobei das Hüllprotein das Virus-Protein 1 (VP1) und/oder das Virus-
20 Protein 2 (VP2) des Polyomavirus enthält.

195. Verwendung nach einem der Ansprüche 41 bis 74, wobei bei Bildung eines Kapsids oder kapsidartigen Gebildes aus dem Hüllprotein die eine Seite zum Inneren des Kapsids oder kap-
25 sidartigen Gebildes gewandt ist.

196. Verwendung nach einem der Ansprüche 41 bis 75, wobei der eine Strang (as1, as2) der dsRNA I/II zum primären oder prozessierten RNA-Transkript des Zielgens komplementär ist.

30

197. Verwendung nach einem der Ansprüche 41 bis 76, wobei die Zelle eine Vertebratenzelle oder eine menschliche Zelle ist.

198. Verwendung nach einem der Ansprüche 41 bis 77, wobei die dsRNA I/II in einer Menge von höchstens 5 mg je Kilogramm Körpergewicht pro Tag einem Säugetier, vorzugsweise einem Menschen, verabreicht wird.

5

199. Verwendung nach einem der Ansprüche 41 bis 78, wobei die dsRNA I/II zur Applikation in eine Pufferlösung aufgenommen ist.

10 200. Verwendung nach einem der Ansprüche 41 bis 79, wobei die dsRNA I/II oral oder mittels Injektion oder Infusion intravenös, intratumoral, inhalativ, intraperitoneal verabreicht wird.

15 201. Medikament zur Hemmung der Expression eines Zielgens in einer Zelle enthaltend eine doppelsträngige Ribonukleinsäure (dsRNA I) in einer zur Hemmung der Expression des Zielgens ausreichenden Menge,

20 wobei die dsRNA I eine doppelsträngige aus höchstens 49 aufeinander folgenden Nukleotidpaaren gebildete Struktur aufweist,

und wobei ein Strang (as1) oder zumindest ein Abschnitt des
25 einen Strangs (as1) der doppelsträngigen Struktur komplementär zum Zielgen ist,

und wobei die dsRNA I zumindest am einen Ende (E1, E2) einen aus 1 bis 4 Nukleotiden gebildeten Überhang aufweist.

30

202. Medikament nach Anspruch 81, wobei die dsRNA I den Überhang am 3'-Ende des einen Strangs (as1) und/oder am 3'-Ende des anderen Strangs (ss1) aufweist.

Cytokin-Gen, Id-Protein-Gen, Prionen, Gene von Angiogenese induzierenden Molekülen, von Adhäsions-Molekülen und von Zelloberflächenrezeptoren, Gene von Proteinen, die an metastasierenden und/oder invasiven Prozessen beteiligt sind, Gene von Proteinasen sowie von Apoptose- und Zellzyklusregulierende Molekülen.

211. Medikament nach einem der Ansprüche 81 bis 90, wobei das Zielgen das MRD1-Gen ist.

10

212. Medikament nach einem der Ansprüche 81 bis 91, wobei als dsRNA eine der Sequenzen SQ141 -173 bzw. ein aus zwei jeweils zusammengehörenden Antisinn- (as1/2) und Sinnsequenzen (ss1/2) kombiniertes dsRNA-Konstrukt der Sequenzen SQ141 - 173 verwendet wird.

15

213. Medikament nach einem der Ansprüche 81 bis 92, wobei die Expression nach dem Prinzip der RNA-Interferenz gehemmt wird.

214. Medikament nach einem der Ansprüche 81 bis 93, wobei das Zielgen in pathogenen Organismen, vorzugsweise in Plasmodien, exprimierbar ist.

20

215. Medikament nach einem der Ansprüche 81 bis 94, wobei das Zielgen Bestandteil eines Virus oder Viroids ist.

25

216. Medikament nach Anspruch 95, wobei das Virus ein humanpathogenes Virus oder Viroid ist.

217. Medikament nach Anspruch 95, wobei das Virus oder Viroid ein tier- oder pflanzenpathogenes Virus oder Viroid ist.

30

218. Medikament nach einem der Ansprüche 81 bis 97, wobei ungepaarte Nukleotide durch Nukleosidthiophosphate substituiert sind.

- 5 219. Medikament nach einem der Ansprüche 81 bis 98, wobei zumindest ein Ende (E1, E2) der dsRNA modifiziert ist, um einem Abbau in der Zelle oder einer Dissoziation in die Einzelstränge entgegenzuwirken.

- 10 220. Medikament nach einem der Ansprüche 81 bis 99, wobei der durch die komplementären Nukleotidpaare bewirkte Zusammenhalt der doppelsträngigen Struktur durch mindestens eine chemische Verknüpfung erhöht ist.

- 15 221. Medikament nach einem der Ansprüche 81 bis 100, wobei die chemische Verknüpfung durch eine kovalente oder ionische Bindung, eine Wasserstoffbrückenbindung, hydrophobe Wechselwirkungen, vorzugsweise van-der-Waals- oder Stapelungswechselwirkungen, oder durch Metall-Ionenkoordination gebildet
20 ist.

222. Medikament nach einem der Ansprüche 81 bis 101, wobei die chemische Verknüpfung in der Nähe des einen Endes (E1, E2) gebildet ist.

25

223. Medikament nach einem der Ansprüche 81 bis 102, wobei die chemische Verknüpfung mittels einer oder mehrerer Verbindungsgruppen gebildet wird, wobei die Verbindungsgruppen vorzugsweise Poly-(oxyphosphinicoxy-1,3-propandiol)- und/oder
30 Oligoethylenglycol-Ketten sind.

224. Medikament nach einem der Ansprüche 81 bis 103, wobei die chemische Verknüpfung durch anstelle von Nukleotiden benutzte verzweigte Nukleotidanaloga gebildet ist.

225. Medikament nach einem der Ansprüche 81 bis 104, wobei die chemische Verknüpfung durch Purinanaloga gebildet ist.

- 5 226. Medikament nach einem der Ansprüche 81 bis 105, wobei die chemische Verknüpfung durch Azabenzoleinheiten gebildet ist.

10 227. Medikament nach einem der Ansprüche 81 bis 106, wobei zur Herstellung der chemischen Verknüpfung mindestens eine der folgenden Gruppen benutzt wird: Methylenblau; bifunktionelle Gruppen, vorzugsweise Bis-(2-chlorethyl)-amin; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamin; 4-Thiouracil; Psoralen.

15

228. Medikament nach einem der Ansprüche 81 bis 107, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) des doppelsträngigen Bereichs angebrachte Thiophosphoryl-Gruppen gebildet ist.

20

229. Medikament nach einem der Ansprüche 81 bis 108, wobei die chemische Verknüpfung durch in der Nähe der Enden (E1, E2) befindliche Tripelhelix-Bindungen hergestellt ist.

- 25 230. Medikament nach einem der Ansprüche 81 bis 109, wobei die dsRNA I/II in micellare Strukturen, vorteilhafterweise in Liposomen, eingeschlossen ist.

30 231. Medikament nach einem der Ansprüche 81 bis 110, wobei die dsRNA I an mindestens ein von einem Virus stammendes, davon abgeleitetes oder ein synthetisch hergestelltes virales Hüllprotein gebunden, damit assoziiert oder davon umgeben ist/sind.

2/20




Fig. 3




Fig. 4

3/20




Fig. 5




Fig. 6

4/20




Fig. 7

5/20




Fig. 8

6/20




Fig. 9

7/20




Fig. 10




Fig. 11




Fig. 26b

20/20




Fig. 27

SEQUENZPROTOKOLL

<110> Ribopharma AG

5 <120> Verfahren zur Hemmung der Expression
eines Zielgens

<130>

10 <140>

<141>

<160> 142

15 <170> PatentIn Ver. 2.1

<210> 1

<211> 2955

<212> DNA

20 <213> Homo sapiens

<300>

<302> Eph A1

<310> NM00532

25

<300>

<302> ephrin A1

<310> NM00532

30 <400> 1

```

atggagcggc gctggccctt ggggctaggg ctggtgctgc tgctctgcgc cccgctgccc 60
ccggggggcgc gcgccaagga agttactctg atggacacaa gcaaggcaca gggagagctg 120
ggctggctgc tggatcccc aaaagatggg tggagtgaac agcaacagat actgaatggg 180
acacccctct acatgtacca ggactgccc atgcaaggac gcagagacac tgaccactgg 240
35 ctctcgctcca attggatcta ccgcggggag gaggttccc gcgtccacgt ggagctgcag 300
ttcacctgctc gggactgcaa gagtttccct gggggagccg ggcctctggg ctgcaaggag 360
accttcaacc ttctgtacat ggagagtgc caggatgtgg gcattcagct ccgacggccc 420
ttgttccaga aggttaaccac ggtggctgca gaccagagct tcaccattcg agaccttgcg 480
tctggctccg tgaagctgaa tgtggagcgc tgctctctgg gccgcctgac ccgcccgtggc 540
40 ctctacctcg ctttccacaa cccgggtgcc tgtgtggccc tgggtgtctgt ccgggtcttc 600
taccagcgct gtccctgagac cctgaatggc ttggcccaat tcccagacac tctgcctggc 660
ccgctgggt tgggtggaagt ggcgggcacc tgcttgcccc acgcgcgggc cagccccagg 720
ccctcaggtg caccocgcac gcactgcagc cctgatggcg agtggctggg gcctgtagga 780
cgggtgccact gtgagcctgg ctatgaggaa ggtggcagtg gcgaagcatg tgttgctgc 840
45 cctagcggct cctaccggat ggacatggac acacccatt gtctcacgtg cccccagcag 900
agcactgctg agtctgaggg ggccaccatc tgtacctgtg agagcggcca ttacagagct 960
ccgggggagg gccccagggt ggcattgcaca ggtccccct cggccccccg aaacctgagc 1020
ttctctgctt cagggactca gctctccctg cgttgggaac ccccagcaga tacgggggga 1080
cgccaggatg tcagatacag tgtgaggtgt tcccagtgct agggcacagc acaggacggg 1140
50 gggccctgcc agccctgtgg ggtgggctgt cacttctcgc cgggggcccg ggcgctcacc 1200
acacctgcag tgcattgtcaa tggccttgaa ccttatgcc actacacctt taatgtggaa 1260
gcccaaaatg gagggtcagg gctgggcagc tctggccatg ccagcacctc agtcagcatc 1320
agcattgggc actgcagtc actgtcaggc ctgtctctga gactggtgaa gaaagaaccg 1380
aggcaactag agctgacctg ggcggggtcc cggccccgaa gccctggggc gaacctgacc 1440
55 tatgagctgc acgtgctgaa ccaggatgaa gaacggatc agatgggtct agaaccagg 1500
gtcttgctga cagagctgca gcctgacacc acatacatcg tcagagtcag aatgctgacc 1560
ccactgggtc ctggcccttt ctcccctgat catgagtttc ggaccagccc accagtgtcc 1620
aggggcccga ctggaggaga gattgtagc gtcattcttg ggctgctgct tgggtgcaggc 1680
ttgctgcttg ggattctcgt tttccggtcc aggagagccc agcggcagag gcagcagagg 1740
60 cacgtgaccg cggccaccgat gtggatcgag aggacaagct gtgctgaagc cttatgtggg 1800
acctccaggc atacgaggac cctgcacagg gagccttggc ctttaccogg aggctggtct 1860
aattttcctt cccgggagct tgatccagcg tggctgatgg tggacactgt cataggagaa 1920

```

5 ggagagtttg gggaaagtgt tgcagggacc ctcaggtccc ccagccagga ctgcaagact 1980
 gtggccatta agaccttaaa agacacatcc ccaggtggcc agtgggtggaa cttcccttca 2040
 gaggcaacta tcatggggcca gtttagccac ccgcataatc tgcatactgga aggcgtcgtc 2100
 acaaagcgaa agccgatcat gatcatcaca gaatttatgg agaattgcagc cctgggatgcc 2160
 10 ttcctgaggg agcgggagga ccagctggtc cctgggcagc tagtggccat gctgcagggc 2220
 atagcatctg gcatgaacta cctcagtaat cacaattatg tccaccggga cctggctgcc 2280
 agaaacatct tggatgaatca aaacctgtgc tgcaagggtg ctgactttgg cctgactcgc 2340
 ctcctggatg actttgatgg cacatacgaa acccagggag gaaagatccc tatccgttgg 2400
 acagcccctg aagccattgc ccacggatc ttcaccacag ccagcgatgt gtggagcttt 2460
 15 gggattgtga tgtgggaggt gctgagcttt ggggacaagc cttatgggga gatgagcaat 2520
 caggaggtta tgaagagcat tgaggatggg taccggttgc cccctcctgt ggactgccct 2580
 gccctctctg atgagctcat gaagaactgc tgggcatatg accgtgcccg ccggccacac 2640
 ttccagaagc ttacggcaca tctggagcaa ctgcttgcca acccccactc cctggcagac 2700
 attgccaact ttgacccag ggtgactctt cgctgcccc gcctgagtgg ctcatagggg 2760
 20 atcccgatc gaaccgtctc tgagtggctc gattccatac gcatgaaacg ctacatcctg 2820
 cacttccact cggctgggct ggacaccatg gagtgtgtgc tggagctgac cgctgaggac 2880
 ctgacgcaga tgggaatcac actgcccggg caccagaagc gcattctttg cagtattcag 2940
 ggattcaagg actga 2955

20 <210> 2
 <211> 3042
 <212> DNA
 <213> Homo sapiens

25 <300>
 <302> ephrin A2
 <310> XM002088

30 <400> 2
 gaagttagcg gcaggccggc gggcgggagc ggacaccgag gccggcgctgc aggcgtgcgg 60
 gtgtgcggga gccgggctcg gggggatcgg accgagagcg agaagcgcgg catggagctc 120
 cgtgcagccc gcgcctgctt cgccctgctg tgggctgtg cgctggccgc ggccgcggcg 180
 35 gcgcagggca aggaagtggg actgctggac tttgctgcag ctggagggga gctcggctgg 240
 ctcacacacc cgtatggcaa agggtgggac ctgatgcaga acatcatgaa tgacatgccg 300
 atctacatgt actccgtgtg caacgtgatg tctggcgacc aggacaactg gctccgcacc 360
 aactgggtgt accgaggaga ggctgagcgt atcttcattg agctcaagtt tactgtacgt 420
 gactgcaaca gcttccctgg tggcgccagc tcttgcaagg agactttcaa cctctactat 480
 gccgagtcgg acctggacta cggcaccaac ttcagaagc gcctgttcac caagattgac 540
 40 accattgcgc ccgatgagat caccgtcagc agcgacttc aggcacgcca cgtgaagctg 600
 aacgtggagg agcgctccgt ggggcccgtc acccgcaaag gcttctacct ggcttccag 660
 gatccgggt cctgtgtggc gctgctctcc gtccgtgtct actacaagaa gtgccccag 720
 ctgctgcagg gccctggcca cttccctgag accatcgccg gctctgatgc acctccctg 780
 gccactgtgg ccggcacctg tgtggacat gccgtggtgc caccgggggg tgaagagccc 840
 45 cgtatgcact gtgcagtgga tggcgagtgg ctggtgcca ttgggcagtg cctgtgccag 900
 gcaggctacg agaagggtga ggtatgcctg caggcctgct cgctggatt ttttaagttt 960
 gaggcatctg agagcccctg cttggagtgc cctgagcaca cgctgccatc ccctgagggt 1020
 gccacctcct actacagtt ggaaggcttc ttccgggcac ctcaggaccc agcgtcgatg 1080
 ccttgacac gacccccctc cgccccacac tacctcacag ccgtgggcat gggtgccaag 1140
 50 gtggagctgc gctggacgcc ccctcaggac agcgggggccc gcgaggacat tgtctacagc 1200
 gtcacctgcg aacagtgtct gcccgagtct ggggaatgcg ggccgtgtga ggccagtgtg 1260
 cgctactcgg agcctcctca cggactgacc cgcaccagtg tgacagttag cgacctggag 1320
 cccacatga actacacctt cacgtggag ccccgcaatg gcgtctcagg cctggttaacc 1380
 agccgcagct tccgtactgc cagtgtcagc atcaaccaga cagagcccc caaggtagg 1440
 55 ctggaggggc gcagcaccac ctgccttagc gtctcctgga gcatcccccc gccgcagcag 1500
 agccgagtgt ggaagtacga ggtcacttac cgaagaagg gagactccaa cagctacaat 1560
 gtgcgcgcga ccgagggttt ctccgtgacc ctggacgacc tggccccaga caccacctac 1620
 ctggtccagg tgacggcact gacgcaggag ggcaggggg ccggcagcaa ggtgcacgaa 1680
 60 ttccagacgc tgtccccgga gggatctggc aacttgccgg tgattggcgg cgtggctgtc 1740
 ggtgtggtcc tgcttctggt gctggcagga gttggttct ttatccaccg caggaggaag 1800
 aaccagcgtg cccgccagtc cccggaggac gtttacttct ccaagtcaga acaactgaag 1860
 ccctgaaga catacgtgga cccccacaca tatgaggacc ccaaccaggc tgtgttgaag 1920

5 ttcactaccg agatccatcc atcctgtgtc actcggcaga aggtgatcgg agcaggagag 1980
 tttggggagg tgtacaaggg catgctgaag acatcctcgg ggaagaagga ggtgccgggtg 2040
 gccatcaaga cgctgaaagc cggctacaca gagaagcagc gagtggactt cctcggcgag 2100
 gccggcatca tggggcagtt cagccaccac aacatcatcc gcctagaggg cgtcatctcc 2160
 aaatacaagc ccatgatgat catcactgag tacatggaga atggggccct ggacaagttc 2220
 cttcgggaga aggatggcga gttcagcgtg ctgcagctgg tgggcatgct gcggggcatc 2280
 gcagctggca tgaagtacct ggccaacatg aactatgtgc accgtgacct ggctgcccgc 2340
 aacatcctcg tcaacagcaa cctggtctgc aaggtgtctg actttggcct gtcccgcgtg 2400
 ctggaggacg accccgaggc cacctacacc accagtggcg gcaagatccc catccgctgg 2460
 10 accgccccgg aggccatttc ctaccggaag ttacacctcg ccagcgacgt gtggagcttt 2520
 ggcatgtgca tgtgggaggt gatgacctat ggcgagcggc cctactggga gttgtccaac 2580
 cacgaggtga tgaagccat caatgatggc ttccggctcc ccacacccat ggactgcccc 2640
 tccgcatct accagctcat gatgcagtgc tggcagcagg agcgtgcccc ccgccccaaag 2700
 ttcgctgaca tcgtcagcat cctggacaag ctcatctgtg cccctgactc cctcaagacc 2760
 15 ctggctgact ttgacccccg cgtgtctatc cggtcccca gcacgagcgg ctcgaggagg 2820
 gtgccccttc gcacggtgtc cgagtggctg gattccatca agatgcagca gtatcggag 2880
 cacttcatgg cggccggcta cactgccatc gagaagggtg tgcatgatgac caacgacgac 2940
 atcaagagga ttgggggtgc gctgccccgc caccagaagc gcacgccta cagcctgctg 3000
 20 ggactcaagg accaggtgaa cactgtgggg atccccatct ga 3042

<210> 3
 <211> 2953
 <212> DNA
 25 <213> Homo sapiens

<300>
 <302> ephrin A3
 <310> NM005233
 30 <400> 3

atggattgtc agctctccat cctcctcctt ctcagctgct ctgttctcga cagcttcggg 60
 gaactgattc cgcagccttc caatgaagtc aatctactgg attcaaaaac aattcaaggg 120
 gagctgggct ggatctctta tccatcacat gggtagggaag agatcagtg tgtggatgaa 180
 35 cattacacac ccacagagac ttaccaggtg tgcaatgtca tggaccacag tcaaaaacaat 240
 tggctgagaa caaactgggt cccacggaac tcagctcaga agatttatgt ggagctcaag 300
 ttactcttac gagactgcaa tagcattcca ttgggttttag gaacttgcaa ggagacattc 360
 aacctgtact acatggagtc tgatgatgat catgggggtga aatttcgaga gcatcagttt 420
 acaaagattg acaccattgc agctgatgaa agtttcaactc aaatggatct tggggaccgt 480
 40 attctgaagc tcaacactga gattagagaa gtaggctctg tcaacaagaa gggattttat 540
 ttggcatttc aagatgttgg tgcttgtgtt gccttgggtg ctgtgagagt atacttcaaa 600
 aagtgcccat ttacagtga gaactctggct atgtttccag acacgggtacc catggactcc 660
 cagtcctctg tggaggttag aggtctctgt gtcaacaatt ctaaggagga agatcctcca 720
 aggatgtact gcagtacaga aggcgaatgg cttgtaccca ttggcaagtg ttcttgcaat 780
 45 gctggctatg aagaaagagg ttttatgtgc caagcttgtc gaccagggtt ctacaaggca 840
 ttggatggta atatgaagtg tgctaagtgc ccgcctcaca gttctactca ggaagatggt 900
 tcaatgaact gcaggtgtga gaataattac ttccgggcag acaaagaccc tccatccatg 960
 gtttgtacct gacctccatc ttcaccaaga aatgttatct ctaatatataa cgagacctca 1020
 gttatcctgg actggagttg gccctgggac acaggaggcc ggaaagatgt taccttcaac 1080
 50 atcatatgta aaaaatgtgg gtggaatata aaacagtggt agccatgcag cccaaatgtc 1140
 cgcttctctc ctgcagagtt tggactcacc aacaccacgg tgacagtgac agaccttctg 1200
 gcacatacta actacacctt tgagattgat gccgttaatg ggggtgtcaga gctgagctcc 1260
 ccaccaagac agtttgtctg ggtcagcatc acaactaatc aggtgtctcc atcacctgtc 1320
 ctgacgatta agaaagatcg gacctccaga aatagcatct ctttgcctg gcaagaacct 1380
 55 gaacatccta atgggatcat attggactac gaggtcaaat actatgaaaa gcaggaacaa 1440
 gaaacaagtt ataccattct gagggcaaga ggcacaaatg ttaccatcag tagcctcaag 1500
 cctgacacta tatacgtatt ccaaatccga gcccgaaacag ccgctggata tgggacgaac 1560
 agccgcaaat ttagtattga aactagtcca gactctttct ccatctcttg tgaaagtagc 1620
 caagtgggtca tgatcgccat ttcagcggga gtagcaatta ttctctcac tgttgtcatc 1680
 60 tatgttttga ttgggaggtt ctgtggctat aagtcaaaac atggggcaga tgaaaaaaga 1740
 cttcattttg gcaatgggca tttaaaactt ccagggtctca ggacttatgt tgaccacat 1800
 acatatgaag accctaccca agctgttcat gagtttgcca aggaattgga tgccaccaac 1860

5 tctcggggag aggaggttta tgtgaagaag acgatggggc gtctccctgt gcgctggatg 3060
 gccattgagt ccctgaacta cagtgtctat accaccaaga gtgatgtctg gtccttttga 3120
 gtccttcttt gggagatagt gagccttgga ggtacaccct actgtggcat gacctgtgcc 3180
 gaagctctatg aaaagctgcc ccagggtac cgcattggagc agcctcgaaa ctgtgacgat 3240
 gaagtgtacg agctgatgcg tcagtgtctg cgggaccgtc cctatgagcg accccctttt 3300
 gccagatttg cgctacagct aggcgcgatg ctggaagcca ggaaggccta tgtgaacatg 3360
 tcgctgtttg agaacttcac ttacgcgggc attgatgcca cagctgagga ggcctga 3417

10 <210> 9
 <211> 3375
 <212> DNA
 <213> Homo sapiens

15 <300>
 <302> TEK
 <310> L06139

20 <400> 9
 atggactctt tagccagctt agttctctgt ggagtcagct tgctcctttc tggaactgtg 60
 gaaggtgccg tggacttgat cttgatcaat tccctacctc ttgtatctga tgctgaaaca 120
 tctctcacct gcattgcctc tgggtggcgc ccccatgagc ccatcaccat aggaaggac 180
 tttgaagcct taatgaacca gcaccaggat ccgctggaag ttactcaaga tgtgaccaga 240
 gaatgggcta aaaaagtgtg ttggaagaga gaaaaggcta gtaagatcaa tgggtgcttat 300
 25 ttctgtgaag ggcgagtctg aggagaggca atcaggatac gaaccatgaa gatgcgtcaa 360
 caagcttcct tcctaccagc tactttaact atgactgtgg acaagggaga taacgtgaac 420
 atatctttca aaaaggtatt gattaaagaa gaagatgcag tgatttaca aaatggttcc 480
 ttcattccatt cagtgcctcg gcatgaagta cctgatattc tagaagtaca cctgcctcac 540
 gctcagcccc aggatgctgg agtgactcgc gccagggtata taggaggaaa cctcttcacc 600
 30 tcggccttca ccaggctgat agtccggaga tgtgaagccc agaagtgggg acctgaatgc 660
 aaccatctct gtactgcttg tatgaacaat ggtgtctgcc atgaagatac tggagaatgc 720
 atttgccctc ctgggtttat gggaaggacg tgtgagaagg cttgtgaact gcacacgttt 780
 ggcagaactt gtaagaaagt gtgcagtggg caagagggat gcaagctta tgtgttctgt 840
 ctccctgacc cctatgggtg ttctgtgccc acaggctgga agggctctga gtgcaatgaa 900
 35 gcatgccacc ctgggtttta cgggccagat tgtaagctta ggtgcagctg caacaatggg 960
 gagatgtgtg atcgcttcca aggatgtctc tgctctccag gatggcagg gctccagtgt 1020
 gagagagaag gcataccgag gatgacccca aagatagtgg atttgccaga tcatatagaa 1080
 gtaaacagtg gtaaatttaa toccatttgc aaagcttctg gctggccgct acctactaat 1140
 gaagaaatga ccttggtgaa gccggtatgg acagtgtctc atccaaaaga ctttaacct 1200
 40 acggatcatt tctcagtagc catattcacc atccaccgga tcctcccccc tgactcagga 1260
 gtttggtgtc gcagtgtgaa cacagtggct gggatgggtg aaaagccctt caacatttct 1320
 gttaaagtcc ttccaaagcc cctgaatgcc ccaaactgta ttgacactgg acataacttt 1380
 gctgtcatca acatcagctc tgagccttag tttggggatg gaccaatcaa atccaagaag 1440
 cttctataca aaccggttaa tcactatgag gcttggcaac atattcaagt gacaaatgag 1500
 45 attgttacac tcaactattt ggaacctcgg acagaatatg aactctgtgt gcaactggtc 1560
 cgtcgtggag aggggtggga agggcatcct ggacctgtga gacgcttcac aacagcttct 1620
 atcggactcc ctccctcaag aggtctaaat ctccctgcct aaagtcagac cactctaaat 1680
 ttgacctggc aaccaatatt tccaagctcg gaagatgact tttatgttga agtggagaga 1740
 aggtctgtgc aaaaaagtga tcagcagaat attaaagtcc caggcaactt gacttcggtg 1800
 50 ctacttaaca acttacatcc cagggagcag tacgtggtcc gagctagagt caacaccaag 1860
 gccagggggg aatggagtga agatctcact gcttggacct ttagtgacat tcttccctct 1920
 caaccagaaa acatcaagat ttccaacatt acacactcct cggctgtgat ttcttggaca 1980
 atattggatg gctattctat ttcttctatt actatccgtt acaaggttca aggcaagaat 2040
 gaagaccagc acgttgatgt gaagataaag taccaccaca tcattcagta tcagctcaag 2100
 55 ggcctagagc ctgaaacagc ataccaggtg gacatttttg cagagaacaa catagggtca 2160
 agcaaccagc ccttttctca tgaactggtg accctcccag aatctcaagc accagcggac 2220
 ctccgagggg ggaagatgct gcttatagcc atccttggct ctgctggaat gacctgctg 2280
 actgtgctgt tggcctttct gatcatattg caattgaaga gggcaaatgt gcaaaggaga 2340
 atggcccaag ccttccaaaa cgtgagggaa gaaccagctg tgcagttaa ctcagggact 2400
 60 ctggccctaa acaggaaggt caaaaacaac ccagatccta caatttatcc agtgcttgac 2460
 tggaatgaca tcaaatttca agatgtgatt ggggagggca attttggcca agttcttaag 2520
 gcgcgcacatc agaaggatgg gttacgatg gatgctgcca tcaaaagaat gaaagaatat 2580

5 gcctccaaag atgatcacag ggactttgca ggagaactgg aagttctttg taaacttgga 2640
 caccatccaa acatcatcaa tctcttagga gcatgtgaac atcgaggcta cttgtacctg 2700
 gccattgagt acgcgcccc a tggaaacett ctggacttcc ttcgcaagag ccgtgtgctg 2760
 gagacggacc cagcatttgc cattgccaat agcaccgct ccacactgtc ctcccagcag 2820
 10 ctcccttact tcgctgccga cgtggcccg ggcatggact acttgagcca aaaacagttt 2880
 atccacaggg atctggctgc cagaaacatt ttagttggtg aaaactatgt ggcaaaaata 2940
 gcagattttg gattgtcccg aggtcaagag gtgtacgtga aaaagacaat gggaaggctc 3000
 ccagtgcgct ggatggccat cgagtcactg aattacagtg tgtacacaac caacagtgat 3060
 gtatggctct atggtgtgtt actatgggag attgttagct taggaggcac accctactgc 3120
 15 gggatgactt gtgcagaact ctacgagaag ctgccccagg gctacagact ggagaagccc 3180
 ctgaactgtg atgatgaggt gtatgatcta atgagacaat gctggcgga gaagccttat 3240
 gagaggccat catttgccca gatattggtg tccttaaaca gaatgttaga ggagcgaaag 3300
 acctacgtga ataccacgct ttatgagaag tttacttatg caggaattga ctgttctgct 3360
 gaagaagcgg cctag 3375

<210> 10
 <211> 2409
 <212> DNA
 20 <213> Homo sapiens
 <300>
 <300>
 25 <302> beta5 integrin
 <310> X53002
 <400> 10
 30 ncbsncvwnr tgcgcgggc cccggcgccg ctgtacgcct gcctcctggg gctctgcgcg 60
 ctccctgcccc ggctcgcagg tctcaacata tgcactagtg gaagtgccac ctcatgtgaa 120
 gaatgtctgc taatccaccc aaaatgtgcc tgggtgctcca aagaggactt cggaagccca 180
 cggctccatca cctctcggtg tgatctgagg gcaaaccttg tcaaaaatgg ctgtggaggt 240
 gagatagaga gccacgccag cagcttccat gtccctgagga gcctgcccct cagcagcaag 300
 35 gggttcgggct ctgcaggctg ggacgtcatt cagatgacac cacaggagat tgccgtgaac 360
 ctccggccccg gtgacaagac caccttccag ctacagggtt gccagggtga ggactatcct 420
 gtggacctgt actacctgat ggacctctcc ctgtccatga aggatgactt ggacaatatc 480
 cggagccttg gcaccaaact cgcggaggag atgaggaagc tcaccagcaa cttccgggtg 540
 ggatttgggt cttttgttga taaggacatc tctcctttct cctacacggc accgaggtac 600
 40 cagaccaatc ctgtgcattgg ttacaagtgt tttccaaatt gcgtcccctc ctttgggttc 660
 cgccatctgc tgctctcac agacagagt gacagcttca atgaggaagt tcggaaacag 720
 aggggtgtccc ggaaccgaga tgcccctgag gggggctttg atgcagtact ccaggcagcc 780
 gtctgcaagg agaagattgg ctggcgaaag gatgcactgc atttgctggt gttcacaaca 840
 gatgatgtgc cccacatcgc attggatgga aaattgggag gcctggtgca gccacacgat 900
 45 ggccagtgcc acctgaacga ggccaacgag tacacagcat ccaaccagat ggactatcca 960
 tcccttgccct tgcttggaaga gaaattggca gagaacaaca tcaacctcat ctttgcatg 1020
 acaaaaaacc atttatgtct gtacaagaat tttacagccc tgatacctgg aacaacggtg 1080
 gagattttag atggagactc caaaaatatt attcaactga ttattaatgc atacaatagt 1140
 atccggtcta aagtggagtt gtcagtctgg gatcagcctg aggatcttaa tctcttcttt 1200
 50 actgctacct gccaaagatgg ggtatcctat cctggtcaga ggaagtgtga gggctctgaag 1260
 attggggaca cggcatcttt tgaagtatca ttggaggccc gaagctgtcc cagcagacac 1320
 acggagcatg tgtttgccct cgcggccggtg ggattccggg acagcctgga ggtgggggtc 1380
 acctacaact gcacgtgcgg ctgcagcgtg gggctggaac ccaacagcgc caggtgcaac 1440
 gggagcggga cctatgtctg cggcctgtgt cagtgacgcc ccggtacct gggcaccagg 1500
 55 tgcgagtgcc aggatgggga gaaccagagc gtgtaccaga acctgtgccg ggaggcagag 1560
 ggcaagccac tgtgcagcgg gcgtggggac tgcagctgca accagtgtct ctgcttcgag 1620
 agcgagtttg gcaagatcta tgggcctttc tgtgagtgcg acaacttctc ctgtgccagg 1680
 aacaagggag tcctctgctc aggccatggc gagtgtcact gcggggaatg caagtgccat 1740
 gcaggttaca tcggggacaa ctgtaactgc tgcacagaca tcagcacatg ccggggcaga 1800
 60 gatggccaga tctgcagcga gcgtgggac tgtctctgtg ggcagtgcca atgcacggag 1860
 ccgggggcct ttggggagat gtgtgagaag tgccccacct gcccgatgc atgcagcacc 1920
 aagagagatt gcgtcgagtg cctgctgctc cactctggga aacctgaca ccagacctgc 1980
 cacagcctat gcagggatga ggtgatcaca tgggtggaca ccatcgtgaa agatgaccag 2040

	gagcgtgtgc	tatgttttcta	caaaaaccgcc	aaggactgcg	tcatgtatgtt	cacctatgtg	2100
	gagctcccca	gtgggaagtc	caacctgacc	gtcctcaggg	agccagagtg	tggaaacacc	2160
	cccaacgcga	tgaccatcct	cctggctgtg	gtcggtagca	tcctccttgt	tgggcttgca	2220
5	ctcctggcta	tctggaagct	gcttgtcacc	atccacgacc	ggagggagtt	tgcaaagttt	2280
	cgagcgcagc	gatccagggc	ccgctatgaa	atggcttcaa	atccattata	cagaaagcct	2340
	atctccacgc	acactgtgga	cttcaccttc	aacaagttca	acaaatccta	caatggcact	2400
	gtggactga						2409
10	<210> 11						
	<211> 2367						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> beta3 integrin						
	<310> NM000212						
	<400> 11						
20	atgcgagcgc	ggccgcggcc	ccggccgctc	tgggcgactg	tgctggcgct	ggggggcgctg	60
	gcggggcggtg	gcgtaggagg	gcccacatc	tgtaccacgc	gaggtgtgag	ctcctgccag	120
	cagtgcctgg	ctgtgagccc	catgtgtgcc	tgtgtctctg	atgaggccct	gcctctgggc	180
	tcacctcgct	gtgacctgaa	ggagaatctg	ctgaaggata	actgtgcccc	agaatccatc	240
	gagttcccag	tgagtgaggc	ccgagtacta	gaggacaggc	ccctcagcga	caagggctct	300
25	ggagacagct	cccaggctcac	tcaagtcaag	cccagagga	ttgcactccg	gtcccgcca	360
	gatgattcga	agaattttct	catccaagt	cggcagggtg	aggattaccc	tgtggacatc	420
	tactacttga	tggacctgtc	ttactccatg	aaggatgatc	tgtggagcat	ccagaacctg	480
	ggtaccaagc	tggccaccca	gatgcgaaag	ctcaccagta	acctgcggat	tggcttcggg	540
	gcattttgtg	acaagcctgt	gtcaccatac	atgtatatct	cccaccaga	ggccctcgaa	600
30	aaccctctgt	atgatatgaa	gaccacctgc	ttgcccattg	ttggctacaa	acacgtgctg	660
	acgctaactg	accaggtgac	ccgcttcaat	gaggaagtga	agaagcagag	tgtgtcacgg	720
	aaccgagatg	cccagagggg	tggctttgat	gccatcatgc	aggctacagt	ctgtgatgaa	780
	aagattggct	ggaggaatga	tgcacccac	ttgtctggtg	ttaccactga	tgccaagact	840
	catatagcat	tggacgggaag	gctggcaggc	attgtccagc	ctaagtacgg	gcagtgtcat	900
35	gttggtagtg	acaatcatta	ctctgcctcc	actaccatgg	attatccctc	tttggggctg	960
	atgactgaga	agctatocca	gaaaaacatc	aatttgatct	ttgcagtgac	tgaaaatgta	1020
	gtcaatctct	atcagaacta	tagtgagctc	atcccaggga	ccacagttgg	ggttctgtcc	1080
	atggattcca	gcaatgtcct	ccagctcatt	gttgatgctt	atgggaaaaa	ccgttctaaa	1140
	gtagagctgg	aagtgcgtga	cctccctgaa	gagttgtctc	tatccttcaa	tgccacatgc	1200
40	ctcaacaatg	aggtcatccc	tggcctcaag	tcttgtatgg	gactcaagat	tggagacacg	1260
	gtgagcttca	gcattgaggc	caagggtgca	ggctgtcccc	aggagaagga	gaagtccctt	1320
	accataaagc	ccgtgggctt	caaggacagc	ctgatcgtcc	aggctcacct	tgattgtgac	1380
	tgtgtctgcc	aggcccaagc	tgaacctaat	agccatcgct	gcaacaatgg	caatgggacc	1440
	tttgagtgtg	gggtatgccg	ttgtgggcct	ggctggctgg	gatcccagtg	tgagtgcctc	1500
45	gaggaggact	atcgcccttc	ccagcaggac	gaatgcagcc	cccgggaggg	tcagcccgtc	1560
	tgcagccagc	ggggcgagtg	cctctgtggg	caatgtgtct	gccacagcag	tgactttggc	1620
	aagatcacgc	gcaagtactg	cgagtgtgac	gacttctcct	gtgtccgcta	caagggggag	1680
	atgtgtctcag	gccatggcca	gtgcagctgt	gggactgtcc	tgtgtgactc	cgactggacc	1740
	ggctactact	gcaactgtac	cacgcgtact	gacacctgca	tgtccagcaa	tgggctgctg	1800
50	tgcagcggcc	gcggcaagtg	tgaatgtggc	agctgtgtct	gtatccagcc	gggctcctat	1860
	ggggcaacct	gtgagaagtg	cccacactgc	ccagatgcct	gcacctttaa	gaaagaatgt	1920
	tgggagtgtg	agaagtttga	ccgggagccc	tacatgaccg	aaaataacctg	tcaccggtac	1980
	tgcgtgtgag	agatttgatc	agtgaagag	cttaaggaca	ctggcaagg	gaagtgaat	2040
	tgtacctata	agaatgagga	tgactgtgtc	gtcagattcc	agtactatga	agattctagt	2100
55	ggaaagtcca	tcctgtatgt	ggtagaagag	ccagagtgtc	ccaagggccc	tgacatcctg	2160
	gtggtcctgc	tctcagtgat	gggggccatt	ctgctcattg	gccttgccgc	cctgctcatc	2220
	tggaaactcc	tctcaccatc	ccacgaccga	aaagaattcg	ctaaatttga	ggaagaacgc	2280
	gccagagcaa	aatggggacac	agccaacaac	ccactgtata	aagaggccac	gtctaccttc	2340
60	accaatatca	cgtaccgggg	cacttaa				2367
	<210> 12						

<211> 3147
 <212> DNA
 <213> Homo sapiens

5 <300>
 <302> alpha v intergrin
 <310> NM0022210

<400> 12
 10 atggcttttc cgccgcggcg acggctgcgc ctccggtcccc gcggcctccc gcttctttctc 60
 tcgggactcc tgctacctct gtgccgcgcc ttcaacctag acgtggacag tcctgcccag 120
 tactctggcc ccgaggggaag ttacttcggc ttccgcgtgg atttcttcgt gcccgccg 180
 tcttcccggg tgtttcttct cgtgggagct cccaaagcaa acaccacca gcctgggatt 240
 gtggaaggag ggcaggtcct caaatgtgac tggctcttcta cccgcgggtg ccagccaatt 300
 15 gaatttgatg caacaggcaa tagagattat gccaaaggat atccattgga atttaagtcc 360
 catcagtggt ttggagcatc tgtgaggtcg aaacaggata aaattttggc ctgtgcccc 420
 ttgtaccatt ggagaactga gatgaaacag gagcgagagc ctggttggaac atgctttctt 480
 caagatggaa caaagactgt tgagtatgct ccatgtagat cacaagatat tgatgctgat 540
 ggacagggat tttgtcaagg aggattcagc attgatttta ctaaagctga cagagtactt 600
 20 cttggtgggtc ctggtagctt ttattggcaa ggtcagctta ttccggatca agtggcagaa 660
 atcgtatcta aatcacgccc caatgtttac agcatcaagt ataataacca attagcaact 720
 cggactgcac aagctatttt tgatgacagc tatttggggtt attctgtggc tgcggagat 780
 ttcaatggat atggcataga tgactttggt tcaggagttc caagagcagc aaggactttg 840
 ggaatgggtt atatttatga tgggaagaac atgtcctcct tatacaattt tactggcgag 900
 25 cagatggctg catatttcgg attttctgta gctgccactg acattaatgg agatgattat 960
 gcagatgtgt ttattggagc acctctcttc atggatcgtg gctctgatgg caaactccaa 1020
 gagggtggggc aggtctcagt gtctctacag agagcttcag gagacttcca gacgacaaag 1080
 ctgaatggat ttgaggtctt tgcacggttt gcagtgcca tagctccttt gggagatctg 1140
 gaccaggatg gtttcaatga tattgcaatt gctgctccat atgggggtga agataaaaaa 1200
 30 ggaattgttt atattctcaa tgggaagatca acaggcttga acgcagtcct atctcaaact 1260
 cttgaagggc agtgggctgc tcgaagcatg ccaccaagct ttggctattc aatgaaagga 1320
 gccacagata tagacaaaaa tggatatcca gacttaattg taggagcttt tgggtgtagat 1380
 cgagctatct tatcacgggc cagaccagtt atcactgtaa atgctggtct tgaagtgtac 1440
 cctagcattt taaatcaaga caataaaaacc tgctcactgc ctggaacagc tctcaaagtt 1500
 35 tcctgtttta atgttaggtt ctgcttaaaag gcagatggca aaggagtact tcccaggaaa 1560
 cttaattttc aggttgaact tctttttggat aaactcaagc aaaagggagc aattcgacga 1620
 ggactgtttc tctacagcag gtccccaagt cactccaaga acatgactat ttcaaggggg 1680
 ggcactgatg agtgtgagga attgtagcgt tatctgcggg atgaatctga atttagagac 1740
 aaactcactc caattactat ttttatggaa tatcggttgg attatagaac agctgctgat 1800
 40 acaacaggct tgcaacccat tcttaaccag ttcacgcctg ctaacattag tcgacaggct 1860
 cacattctac ttgactgtgg tgaagacaat gtctgtaaac ccaagctgga agtttctgta 1920
 gatagtgatc aaaagaagat ctatattggg gatgacaacc ctctgacatt gattgttaag 1980
 gctcagaatc aaggagaagg tgccctacgaa gctgagctca tcgtttccat tccactgcag 2040
 gctgatttca tcgggggtgt ccgaaacaat gaagccttag caagactttc ctgtgcattt 2100
 45 aagacagaaa accaaactcg ccaggttgga tgtgacctg gaaacccaat gaaggctgga 2160
 actcaactct tagctggtct tcgtttcagt gtgcaccagc agtcagagat ggatacttct 2220
 gtgaaatttg acttacaaat ccaaagctca aatctatttg acaaagtaag ccagttgta 2280
 tctcaciaag ttgatcttgc tgttttagct gcagttgaga taagaggagt ctcgagtcct 2340
 gatcatatct ttcttccgat tccaaactgg gagcacaagg agaaccctga gactgaagaa 2400
 50 gatgttgggc cagttgttca gcacatctat gagctgagaa acaatggtcc aagttcattc 2460
 agcaaggcaa tgctccatct tcagtgccct tacaaatata ataataacac tctgttgtat 2520
 atccttcatt atgatattga tggaccaatg aactgcactt cagatatgga gatcaaccct 2580
 ttgagaatta agatctcatc tttgcaaaaga atgacacggt tgccgggcaa 2640
 ggtgagcggg accatctcat cactaagcgg gatcttgccc tcagtgaagg agatattcac 2700
 55 actttgggtt gtggagttgc tcagtgtctg aagattgtct gccaaagtgg gagattagac 2760
 agaggaaaga gtgcaatctt gtacgtaaag tcattactgt ggactgagac ttttatgaat 2820
 aaagaaaatc agaatacttc ctattctctg aatgcgtctg cttcatttaa tgtcatagag 2880
 tttccttata agaatacttc aattgaggat atcccaact ccacattggt taccactaat 2940
 gtcacctggg gcattcagcc agcgcccatg cctgtgcctg tgtgggtgat catttttagca 3000
 60 gttctagcag gattgttgct actggctgtt ttggtatttg taatgtacag gatgggcttt 3060
 tttaaacggg tccggccacc tcaagaagaa caagaaaggg agcagcttca acctcatgaa 3120
 aatgggtgaag gaaactcaga aacttaa 3147

5 <210> 13
 <211> 402
 <212> DNA
 <213> Homo sapiens

 <300>
 <302> CaSm (cancer associated SM-like oncogene)
 10 <310> AF000177

 <400> 13
 atgaactata tgccctggcac cgccagcctc atcgaggaca ttgacaaaaa gcactttggtt 60
 ctgcttcgag atggaaggac acttataggc tttttaagaa gcattgatca atttgcaaac 120
 15 ttagtgctac atcagactgt ggagcgtatt catgtgggca aaaaatacgg tgatattcct 180
 cgaggggattt ttgtgggtcag aggagaaaat gtgggtcctac taggagaaat agacttggaa 240
 aaggagagtg acacacccct ccagcaagta tccattgaag aaattctaga agaacaaagg 300
 gtggaacagc agaccaagct ggaagcagag aagttgaaag tgcaggccct gaaggaccga 360
 20 ggtctttcca ttccctcgagc agatactctt gatgagtact aa 402

 <210> 14
 <211> 1923
 <212> DNA
 25 <213> Homo sapiens

 <300>
 <302> c-myb
 <310> NM005375
 30
 <400> 14
 atggcccga gaccccgga cagcatatat agcagtgacg aggatgatga ggactttgag 60
 atgtgtgacc atgactatga tgggctgctt cccaagtctg gaaagcgtca cttggggaaa 120
 35 acaaggtgga cccgggaaga ggatgaaaaa ctgaagaagc tgggtggaaca gaatggaaca 180
 gatgactgga aagttattgc caattatctc ccgaatcgaa cagatgtgca gtgccagcac 240
 cgatggcaga aagtactaaa ccctgagctc atcaagggtc cttggaccaaa agaagaagat 300
 cagagagtga tagagcttgt acagaaatac ggtccgaaac gttggtctgt tattgccaag 360
 cacttaaagg ggagaattgg aaaacaatgt agggagaggt ggcataacca cttgaatcca 420
 gaagttaaga aaacctcctg gacagaagag gaagacagaa ttatttacca ggcacacaag 480
 40 agactgggga acagatgggc agaaatcgca aagctactgc ctggacgaac tgataatgct 540
 atcaagaacc actggaattc tacaatgcgt cggaaggctg aacaggaagg ttatctgcag 600
 gagtcttcaa aagccagcca gccagcagtg gccacaagct tccagaagaa cagtcatttg 660
 atgggttttg ctcaggctcc gcctacagct caactccctg ccactggcca gccactgtt 720
 aacaacgact attcctatta ccacatttct gaagcacaaa atgtctccag tcatgttcca 780
 45 taccctgtag cgttacatgt aaatatagtc aatgtccctc agccagctgc cgcagccatt 840
 cagagacact ataatgatga agaccctgag aaggaaaaagc gaataaagga attagaattg 900
 ctctaattgt caaccgagaa tgagctaaaa ggacagcagg tgctaccaac acagaaccac 960
 acatgcagct accccgggtg gcacagcacc accattgccc accacaccag acctcatgga 1020
 gacagtgcac ctgtttcctg tttgggagaa caccactcca ctccatctct gccagcggat 1080
 50 cctggctccc tacctgaaga aagcgcctcg ccagcaaggt gcatgatcgt ccaccagggc 1140
 accattcttg ataattgtaa gaacctctta gaatttgag aaacactcca atttatagat 1200
 tctttcttaa acacttccag taacctgaa aactcagat tggaaatgcc ttctttaact 1260
 tccaccccc tcattgggtca caaattgac gttacaacac catttcatag agaccagact 1320
 gtgaaaactc aaaaggaaaa tactgttttt agaaccacag ctatcaaaaag gtcaatctta 1380
 55 gaaagctctc caagaactcc tacaccattc aaacatgcac ttgcagctca agaaattaaa 1440
 tacggtcccc tgaagatgct acctcagaca ccctctcatc tagtagaaga tctgcaggat 1500
 gtgatacaac aggaatctga tgaatctgga tttgttgctg agtttcaaga aaatggacca 1560
 cccttactga agaaaaatcaa acaagaggtg gaatctccaa ctgataaaatc aggaaacttc 1620
 ttctgtctac accactggga aggggacagt ctgaataccc aactgttcac gcagacctcg 1680
 60 cctgtgcgag atgcaccgaa tattcttaca agctccgttt taatggcacc agcatcagaa 1740
 gatgaagaca atgttctcaa agcattttaca gtacctaaaa acagggtccct ggcgagcccc 1800
 ttgcagcctt gtagcagtag ctgggaacct gcatcctgtg gaaagatgga ggagcagatg 1860

gtcccagatt acacaacctt cacgacagtt ggtgattggc tggatgccat caagatgggg 2820
cggtagaagg agagcttcgt cagtgcgggg tttgcattct ttgacctggg ggcccagatg 2880
acggcagaag acctgctccg tattgggggtc accctggccg gccaccagaa gaagatcctg 2940
agcagtatcc aggacatgcg gctgcagatg aaccagacgc tgctgtgca ggtctga 2997

5

<210> 24
<211> 2964
<212> DNA
10 <213> Homo sapiens

<400> 24
atggagctcc ggggtgctgct ctgctgggct tcgttggccg cagctttgga agagaccctg 60
ctgaacacaa aattggaaac tgctgatctg aagtgggtga cattccctca ggtggacggg 120
15 cagtgggagg aactgagcgg cctggatgag gaacagcaca gcgtgcgcac ctacgaagtg 180
tgtgaagtgc agcgtgcccc gggccaggcc cactggcttc gcacagggtg ggtcccacgg 240
cggggcgccg tccacgtgta cgccacgctg cgcttcacca tgctcgagtg cctgtccctg 300
cctcgggctg ggcgctcctg caaggagacc ttcaccgtct tctactatga gagcgatgcg 360
gacacggcca cggccctcac gccagcctgg atggagaacc cctacatcaa ggtggacacg 420
20 gtggcccgcg agcatctcac ccggaagcgc cctggggccg aggccaccgg gaaggtgaat 480
gtcaagacgc tgcgtctggg accgctcagc aaggctggct tctacctggc cttccaggac 540
caggggtgct gcatggccct gctatccctg cacctcttct acaaaaagtg cgcccagctg 600
actgtgaacc tgactcgatt cccggagact gtgcctcggg agctgggtgt gcccgtaggc 660
ggtagctgcg tggtagatgc cgtccccgcc cctggcccca gcccagcct ctactgccgt 720
25 gaggatggcc agtgggcca acagccgggc acgggctgca gctgtgctcc ggggttcgag 780
gcagctgagg ggaacaccaa gtgccgagcc tgtgccagg gcacctcaa gcccctgtca 840
ggagaagggt cctgccagcc atgcccagcc aatagccact ctaacacat tggatctgcc 900
gtctgccagt gccgcgtcgg ggacttccgg gcacgcacag acccccgggg tgcacctgc 960
accacccctc cttcggtctc gcggagcgtg gtttcccgcc tgaacggctc ctccctgcac 1020
30 ctggaatgga gtgccccctt ggagtctggt ggccgagagg acctcaccta cgccctccgc 1080
tgccgggagt gccgaccggg aggtcctctgt gcgccctgcg ggggagacct gacttttgac 1140
cccggccccc gggacctggt ggagccctgg gtgggtgggtc gagggtacg tccggacttc 1200
acctatacct ttgaggtcac tgcattgaac tgggtatcct ccttagccac ggggcccgtc 1260
ccatttgagc ctgtcaatgt caccactgac cgagaggtac ctctgcagt gtctgacatc 1320
35 cgggtgacgc ggtcctcacc cagcagcttg agcctggcct gggctgttcc ccgggcaccc 1380
agtggggcgt ggtcggacta cgaggtcaaa taccatgaga agggcgccga ggggtcccagc 1440
agcgtgcggt tcctgaagac gtcagaaaac cgggcagagc tgcgggggct gaagcgggga 1500
gccagctacc tgggtgcagg acgggcgcgc tctgaggccg gctacgggcc cttcggccag 1560
gaacatcaca gccagaccca actggatgag agcgagggct ggcgggagca gctggccctg 1620
40 attgcgggca cggcagtcgt ggggtgtggtc ctggctcctg tgggtcattgt ggtcgagtt 1680
ctctgcctca ggaagcagag caatgggaga gaagcagaat attcggacaa acacggacag 1740
tatctcatcg gacatggtac taaggctctac atcgacccct tcacttatga agacccta 1800
gaggctgtga ggaatattgc aaaagagatc gatgtctcct acgtcaagat tgaagaggtg 1860
attggtgcag gtgagtttgg cgaggtgtgc cggggggcggc tcaaggcccc agggagaaga 1920
45 gagagctgtg tggcaatcaa gacctgaag ggtggctaca cggagcggca gcggcgtag 1980
tttctgagcg aggcctccat catgggccag ttcgagcacc ccaatatcat ccgcctggag 2040
ggcgtggtca ccaacagcat gccgctcatg attctcacag agttcatgga gaacggcgcc 2100
ctggactcct tcctgaggct aaacgacgga cagttcacag tcatccagct cgtgggcatg 2160
ctgcggggca tcgctcggg catgcggtac cttgcccaga tgagctacgt ccaccgagac 2220
50 ctggctgctc gcaacatcct agtcaacagc aacctcgtct gcaaagtgtc tgactttggc 2280
ctttcccgat tcctggagga gaactcttcc gatccacact acacgagctc cctgggagga 2340
aagattccca tccgatggac tgccccggag gccattgcct tccggaagtt cacttccgcc 2400
agtgatcctt ggaattacgg gattgtgatg tgggaggtga tgtcatttgg ggagagggcg 2460
tactgggaca tgagcaatca ggacgtgatc aatgccattg aacaggacta ccggctgccc 2520
55 ccgccccag actgtccac ctccctccac cagctcatgc tggactgttg gcagaaagac 2580
cggaatgccc ggccccgctt cccccagggt gtcagcgccc tggacaagat gatccggaac 2640
cccggcagcc tcaaaatcgt ggccccggag aatggcgggg cctcacaccc tctcctggag 2700
cagcgcgacc ctcactactc agcttttggc tctgtgggcg agtggcttcg ggccatcaaa 2760
atgggaagat acgaagcccc tttcgcagcc gctggctttg gctccttcga gctggtcagc 2820
60 cagatctctg ctgaggacct gctccgaatc ggagtcactc tggcgggaca ccagaagaaa 2880
atcttggcca gtgtccagca catgaagtcc caggccaagc cgggaacccc ggggtgggaca 2940
ggaggaccgg ccccgagta ctga 2964

<210> 25
<211> 1041
5 <212> DNA
<213> Homo sapiens

<300>
<302> ephrin-B1
10 <310> NM004429

<400> 25
atggctcggc ctgggcagcg ttggctcggc aagtggcttg tggcgatggg cgtgtgggcg 60
ctgtgccggc tcgccacacc gctggccaag aacctggagc ccgtatcctg gagctccctc 120
15 aacccaagt tcctgagtgg gaagggcttg gtgatctatc cgaaaatttg agacaagctg 180
gacatcatct gcccccgagc agaagcaggg cggccctatg agtactacaa gctgtacctg 240
gtgcggcctg agcaggcagc tgcctgtagc acagttctcg accccaacgt gttggtcacc 300
tgcaataggc cagagcagga aatacgcttt accatcaagt tccaggagtt cagccccaac 360
20 tacatgggcc tggagttcaa gaagcaccat gattactaca ttacctcaac atccaatgga 420
agcctggagg ggctggaaaa ccgggagggc ggtgtgtgcc gcacacgcac catgaagatc 480
atcatgaagg ttgggcaaga tccaatgct gtgacgcctg agcagctgac taccagcagg 540
cccagcaagg aggcagacaa cactgtcaag atggccacac agggcccttg tagtcggggc 600
tccttgggtg actctgatgg caagcatgag actgtgaacc aggaagagaa gagtggccca 660
25 ggtgcaagtg ggggcagcag cggggaccct gatggcttct tcaactcaa ggtggcattg 720
ttcgcggctg tcggtgccgg ttgcgtcatc ttctgtctca tcatcatctt cctgacggtc 780
ctactactga agctacgcaa gcggcaccgc aagcacacac agcagcgggc ggttgcctc 840
tcgctcagta ccctggccag tcccaagggg ggcagtggca cagcgggcac cgagcccagc 900
gacatcatca ttcccttacg gactacagag aacaactact gcccccacta tgagaagggtg 960
30 agtggggact acgggcaccc tgtctacatc gtccaagaga tgccgccccca gagcccgggc 1020
aacatctact acaagggtctg a 1041

<210> 26
<211> 1002
35 <212> DNA
<213> Homo sapiens

<300>

<400> 26
atggctgtga gaagggactc cgtgtggaag tactgctggg gtgttttgat ggttttatgc 60
agaactgcga ttccaaatc gatagtttta gacctatct attggaattc ctcgaaactc 120
aaatttctac ctggacaagg actggtacta taccacaga taggagacaa attggatatt 180
45 atttgcacca aagtggactc taaaactggt ggccagtatg aatattataa agtttatatg 240
gttgataaag accaagcaga cagatgcact attaagaagg aaaatacccc tctcctcaac 300
tgtgccaaac cagaccaaga tatcaaattc accatcaagt ttcaagaatt cagccctaac 360
ctctggggtc tagaatttca gaagaacaaa gattattaca ttatatctac atcaaattgg 420
tctttggagg gcctggataa ccaggaggga ggggtgtgcc agacaagagc catgaagatc 480
ctcatgaaag ttggacaaga tgcaagttct gctggatcaa ccaggaataa agatccaaca 540
50 agacgtccag aactagaagc tggtaaaat ggaagaagtt cgacaacaag tccctttgta 600
aaaccaaactc caggttctag cacagacggc aacagcgccg gacattcggg gaacaacatc 660
ctcgggtccg aagtggcctt atttgcaggg attgcttcag gatgcatcat ctctcatcgc 720
atcatcatca cgctgggtgt cctcttgctg aagtaaccgga ggagacacag gaagcactcg 780
ccgcagcaca cgaccacgct gtcgctcagc acactggcca caccacaagc cagcggcaac 840
55 aacaacggct cagagcccag tgacattatc atcccgttaa ggactgcgga cagcgtcttc 900
tgccctcact acgagaagggt cagcggcgac tacgggcacc cgggtgtacat cgtccaggag 960
atgcccccgc agagcccggc gaacattttac tacaaggctc ga 1002

<210> 27
60 <211> 1023
<212> DNA

<213> Homo sapiens

<400> 27

5	atggggcccc	cccattcttg	gccggggggc	gtgcgagtcg	gggccctgct	gctgctgggg	60
	gttttggggc	tgggtgtctg	gctcagcctg	gagcctgtct	actggaactc	ggcgaataag	120
	aggttccagg	cagaggggtg	ttatgtgctg	taccctcaga	tcggggaccg	gctagacctg	180
	ctctgcccc	gggcccggcc	tcctggccct	cactcctctc	ctaattatga	gttctacaag	240
	ctgtacctgg	taggggggtg	tcagggcccg	cgctgtgagg	cacccccctg	cccaaacctc	300
	cttctcactt	gtgatcgccc	agacctggat	ctccgcttca	ccatcaagtt	ccaggagtat	360
10	agccctaata	tctggggcca	cgagttccgc	tcgcaccacg	attactacat	cattgccaca	420
	tcggatggga	cccgggaggg	cctggagagc	ctgcagggag	gtgtgtgcct	aaccagaggc	480
	atgaaggtgc	ttctccgagt	gggacaaaag	ccccgaggag	gggctgtccc	ccgaaaacct	540
	gtgtctgaaa	tgcccatgga	aagagaccga	ggggcagccc	acagcctgga	gcctgggaag	600
	gagaacctgc	caggtgaccc	caccagcaat	gcaacctccc	ggggtgctga	aggccccctg	660
15	ccccctccca	gcattgcctg	agtggctggg	gcagcagggg	ggctggcgct	gctcttgctg	720
	ggcgtggcag	gggctggggg	tgccatgtgt	tggcggagac	ggcggggcaa	gccttcggag	780
	agtgcgccac	ctggctcctg	ctccttcggg	aggggagggg	ctctgggcct	gggggggtga	840
	gggtgggatg	gacctcgga	ggctgagcct	ggggagctag	ggatagctct	gcgggggtgc	900
	ggggctgcag	atccccctt	ctgccccac	tatgagaagg	tgagtgggtg	ctatgggcat	960
20	cctgtgtata	tcgtgcagga	tgggcccccc	cagagccctc	caaacatcta	ctacaaggta	1020
	tga						1023

<210> 28

25 <211> 3399

<212> DNA

<213> Homo sapiens

<300>

30 <302> telomerase reverse transcriptase

<310> AF015950

<400> 28

35	atgcgcgcgc	ctccccgctg	ccgagccgctg	cgctccctgc	tgcgcagcca	ctaccgcgag	60
	gtgctgccgc	tggccacgtt	cgtgcggcgc	ctggggcccc	agggctggcg	gctgggtgcag	120
	cgccggggacc	cggcggtttt	ccgcgcgctg	gtggcccagt	gcctgggtgtg	cgtgcccttg	180
	gacgcacggc	cgccccccgc	cgccccctcc	ttccgccagg	tgctcctgcct	gaaggagctg	240
	gtggcccagag	tgctgcagag	gctgtgcgag	cgcggcgcga	agaacgtgct	ggccttcggc	300
	ttcgcgctgc	tggacggggc	ccgcgggggg	ccccccgagg	ccttcaccac	cagcgtgcgc	360
40	agctacctgc	ccaacacggt	gaccgacgca	ctgcggggga	gcggggcgctg	ggggctgctg	420
	ctgcgcgcgc	tgggcgacga	cgtgctgggt	cacctgctgg	cacgtgcgc	gctctttgtg	480
	ctgggtggctc	ccagctgcgc	ctaccaggtg	tgcggggcgc	cgctgtacca	gctcggcgct	540
	gccactcagg	cccggccccc	gccacacgct	agtggacccc	gaaggcgtct	gggatgcgaa	600
	cgggcctgga	accatagcgt	cagggaggcc	ggggctcccc	tgggcctgcc	agccccgggt	660
45	gcgaggaggc	gcgggggcag	tgccagccga	agtctgccgt	tgcccaagag	gcccaggcgt	720
	ggcgctgccc	ctgagccgga	gcggacgccc	gttgggcagg	ggctcctggg	ccacccgggc	780
	aggacgcgctg	gaccgagtga	ccgtgggtttc	tgtgtggtgt	cacctgccag	acccgccgaa	840
	gaagccacct	ctttggaggg	tgcgctctct	ggcacgcgcc	actcccaccc	atccgtgggc	900
	cgccagcacc	acgcggggcc	cccatccaca	tcgcggccac	cacgtccctg	ggacacgcct	960
50	tgtcccccg	tgtacgcga	gaccaagcac	ttcctctact	cctcaggcga	caaggagcag	1020
	ctgcggccct	ccttctact	cagctctctg	aggcccagcc	tgactggcgc	tcggaggctc	1080
	gtggagacca	tctttctggg	ttccaggccc	tggatgccag	ggactccccg	caggttgccc	1140
	cgcttgcgcc	agcgctactg	gcaaatgcgg	cccctgtttc	tggagctgct	tgggaaccac	1200
	gcgcagtgcc	cctacggggg	gctcctcaag	acgcactgcc	cgctgcgagc	tgccggctacc	1260
55	ccagcagccg	gtgtctgtgc	ccgggagaag	ccccagggct	ctgtggcgcc	ccccgaggag	1320
	gaggacacag	acccccgtcg	cctgggtgcag	ctgctccgcc	agcacagcag	cccctggcag	1380
	gtgtacggct	tcgtgcgggc	ctgcctgcgc	cggctggtgc	ccccaggcct	ctggggctcc	1440
	aggcacaac	aacgcgcgtt	cctcaggga	accaagaagt	tcatctccct	ggggaagcat	1500
	gccaaactct	cgtgcagga	gctgacgtgc	aagatgagcg	tgccgggactg	cgcttggtcg	1560
60	cgcaggagcc	caggggttgg	ctgtgttccg	gccgcagagc	accgtctgcg	tgaggagatc	1620
	ctggccaagt	tcttcgactg	gctgatgagt	gtgtacgtcg	tcgagctgct	caggtctttc	1680
	ttttatgtca	cggagaccac	gtttcaaaag	aacaggctct	ttttctaccg	gaagagtgtc	1740

5 tggagcaagt tgcaaagcat tggaaatcaga cagcacttga agaggggtgca gctgcgggag 1800
 ctgtcgggaag cagaggtcag gcagcatcgg gaagccaggc ccgccctgct gacgtccaga 1860
 ctccgcttca tccccaaagcc tgacgggctg cggccgattg tgaacatgga ctacgtcgtg 1920
 ggagccagaa cgttccgcag agaaaagagg gccgagcgtc tcacctcgag ggtgaaggca 1980
 ctgttcagcg tgctcaacta cgagcgggcg cggcgccccg gcctcctggg cgcctctgtg 2040
 ctgggcctgg acgatatcca cagggcctgg cgcaccttcg tgctgcgtgt gcgggcccag 2100
 gaccgcgcgc ctgagctgta ctttgtcaag gtggatgtga cgggcgcgta cgacaccatc 2160
 ccccaggaca ggctcacgga ggtcatcgcc agcatcatca aaccccagaa cacgtactgc 2220
 gtgcgtcggg atgccgtggg ccagaaggcc gcccatgggc acgtccgcaa ggcttcaag 2280
 10 agccacgtct ctaccttgac agacctccag ccgtacatgc gacagtctgt ggctcacctg 2340
 caggagacca gccgcctgag ggatgcctgc gtcatcgagc agagctcctc cctgaatgag 2400
 gccagcagtg gccctcttca cgtcttctca cgttctcatgt gccaccacgc cgtgcgcac 2460
 aggggcaagt cctacgtcca gtgccagggg atcccgagg gctccatcct ctccacgtg 2520
 ctctgcagcc tgtgtacgg cgacatggag aacaagctgt ttgcggggat tcggcgggac 2580
 15 gggctgctcc tgcgtttggg ggatgatttc ttgttgggtg cacctcacct caccacgcg 2640
 aaaaccttcc tcaggacctt ggtccgagg gtccctgagt atggctgcgt ggtgaacttg 2700
 cggaagacag tgggtaactt cctcttagaa gacgagggcc tgggtggcac ggcttttgtt 2760
 cagatgcgcg cccacggcct attcccctgg tgcggcctgc tgctggatac ccggaccctg 2820
 gaggtgcaga gcgactactc cagctatgcc cggacctcca tcagagccag tctcaccttc 2880
 20 aaccgcggct tcaaggctgg gaggaacatg cgtcgcaaac tctttggggg cttgcggctg 2940
 aagtgtcaca gccgtgttct ggatttgag gtgaacagcc tcacagcggg gtgcaccaac 3000
 atctacaaga tctcctgct gcaggcgtac aggtttcacg catgtgtgct gcagctccca 3060
 tttcatcagc aagtttggaa gaaccccaca ttttctctgc gcgtcatctc tgacacggcc 3120
 tccctctgct actccatcct gaaagccaag aacgcaggga tgtcgctggg ggccaagggc 3180
 25 gccgcgggcc ctctgccttc cgaggccgtg cagtggctgt gccaccaagc attcctgctc 3240
 aagctgactc gacaccgtgt cacctacgtg ccactcctgg ggctcactcag gacagcccag 3300
 acgcagctga gtcggaagct cccggggacg acgctgactg ccctggaggc cgcagccaac 3360
 ccggcactgc cctcagactt caagaccatc ctggactga 3399

30 <210> 29
 <211> 567
 <212> DNA
 <213> Homo sapiens

35 <300>
 <302> K-ras
 <310> M54968

40 <400> 29
 atgactgaat ataaaacttgt ggtagttgga gcttgtggcg taggcaagag tgccttgacg 60
 atacagctaa ttcagaatca ttttgtggac gaatatgac caacaataga ggattcctac 120
 aggaagcaag tagtaattga tggagaaacc tgtctcttgg atattctcga cacagcagg 180
 45 caagaggagt acagtgcaat gagggaccag tacatgagga ctggggaggg ctttctttgt 240
 gtatttgcca taaataatac taaatcattt gaagatattc accattatag agaacaaatt 300
 aaaagagtta aggactctga agatgtacct atggctcctag taggaaataa atgtgatttg 360
 cttctagaa cagtagacac aaaacaggct caggacttag caagaagtta tggaattcct 420
 tttattgaaa catcagcaaa gacaagacag ggtgttgatg atgccttcta tacattagtt 480
 cgagaaattc gaaaacataa agaaaagatg agcaaagatg gtaaaaagaa gaaaaagaag 540
 50 tcaaagacaa agtgtgtaat tatgtaa 567

55 <210> 30
 <211> 3840
 <212> DNA
 <213> Homo sapiens

60 <300>
 <302> mdr-1
 <310> AF016535

<400> 30

	atggatcttg	aaggggaccg	caatggagga	gcaaagaaga	agaacttttt	taaactgaac	60
	aataaaagt	aaaaagataa	gaaggaaaa	aaaccaactg	tcagtgtatt	ttcaatgttt	120
	cgctattcaa	attggcttga	caagttgtat	atgggtgggtg	gaactttggc	tgccatcatc	180
	catgggggctg	gacttctctc	catgatgctg	gtgtttggag	aaatgacaga	tatcttttga	240
5	aatgcaggaa	atttagaaga	tctgatgtca	aacatcacta	atagaagtga	tatcaatgat	300
	acaggggttct	tcataaatct	ggaggaagac	atgaccaggt	atgcctatta	ttacagtggg	360
	attgggtgctg	gggtgctggg	tgtctgttac	attcagggtt	catttttggtg	cctggcagct	420
	ggaagacaaa	tacacaaaat	tagaaaacag	ttttttcatg	ctataatgctg	acaggagata	480
	ggctgggtttg	atgtgcacga	tgttggggag	cttaacaccc	gacttacaga	tgatgtctcc	540
10	aagattaatg	aaggaattgg	tgacaaaatt	ggaatgttct	ttcagtcaat	ggcaacattt	600
	ttcactgggt	ttatagtagg	atttacacgt	ggttgggaagc	taacccttgt	gattttggcc	660
	atcagtcctg	ttcttggact	gtcagctgct	gtctgggcaa	agatactatc	ttcattttact	720
	gataaagaac	tcttagcgta	tgcaaaagct	ggagcagtag	ctgaagaggt	cttggcagca	780
	attagaactg	tgattgcatt	tggaggacaa	aagaaagaac	ttgaaaggta	caacaaaaat	840
15	ttagaagaag	ctaaaagaat	tgggataaag	aaagctatta	cagccaatat	ttctataggt	900
	gctgctttcc	tgctgatcta	tgcactcttat	gctctggcct	tctggtatgg	gaccaccttg	960
	gtcctctcag	gggaatatct	tattggacaa	gtactcactg	tattttctgt	attaattggg	1020
	gcttttagtg	ttggacaggc	atctccaagc	attgaagcat	ttgcaaagtc	aagaggagca	1080
	gcttatgaaa	tcttcaagat	aattgataat	aagccaagta	ttgacagcta	ttcgaagagt	1140
20	gggcacaaac	cagataatat	taagggaaat	ttggaattca	gaaatgttca	cttcagttac	1200
	ccatctcgaa	aagaagttaa	gatcttgaag	ggtctgaacc	tgaagggtgca	gagtgggcag	1260
	acgggtggccc	tggttggaaa	cagtggtgtg	gggaagagca	caacagtcga	gctgatgcag	1320
	aggctctatg	acccacacaga	ggggatgggt	agtgttgatg	gacaggatat	taggaccata	1380
	aatgtaagg	ttctacggga	aatcattggc	gtggtgagtc	aggaacctgt	attgtttgoc	1440
25	accacgatag	ctgaaaacat	tcgctatggc	cgtgaaaatg	tcaccatgga	tgagattgag	1500
	aaagctgtca	aggaagccaa	tgcttatgac	tttatcatga	aactgcctca	taaatttgac	1560
	accctgggtg	gagagagagg	ggcccagttg	agtgggtggc	agaagcagag	gatcgccatt	1620
	gcacgtgccc	tggttcgcaa	ccccaaagtc	ctcctgctgg	atgaggccac	gtcagccttg	1680
	gacacagaaa	gcgaagcagt	ggttcagggt	gctctggata	aggccagaaa	aggctcgacc	1740
30	accattgtga	tagctcatcg	tttgtctaca	gttcgtaatg	ctgacgtcat	cgctggtttc	1800
	gatgatggag	tcatttgtga	gaaaggaaat	catgatgaac	tcataaaaaga	gaaaggcatt	1860
	tacttcaaac	ttgtcacaat	gcagacagca	ggaaatgaag	ttgaattaga	aaatgcagct	1920
	gatgaatcca	aaagtgaat	tgatgccttg	gaaatgtctt	caaatgattc	aagatccagt	1980
	ctaataagaa	aaagatcaac	tcgtaggagt	gtccgtggat	cacaagccca	agacagaaa	2040
35	cttagtacca	aagaggctct	ggatgaaagt	atacctccag	tttccctttg	gaggattatg	2100
	aagctaaatt	taactgaatg	gccttatttt	gttgttgggt	tattttgtgc	cattataaat	2160
	ggaggcctgc	aaccagcatt	tgcaataata	ttttcaaaga	ttataggggt	ttttacaaga	2220
	attgatgatc	ctgaaacaaa	acgacagaa	agtaacttgt	tttcactatt	gtttctagcc	2280
	cttggtaatta	ttctttttat	tacatttttc	cttcagggtt	tcacatttgg	caaagctgga	2340
40	gagatcctca	ccaagcggct	ccgatacatg	gttttccgat	ccatgctcag	acaggatgtg	2400
	agttgggtttg	atgaccctaa	aaacaccact	ggagcattga	ctaccaggct	cgccaatgat	2460
	gctgctcaag	ttaaaggggc	tatagggttc	aggcttgctg	taattacca	gaatatagca	2520
	aatcttggga	caggaataat	tatatccttc	atctatgggt	ggcaactaac	actgttactc	2580
	ttagcaattg	tacccatcat	tgcaaatagca	ggagttgttg	aaatgaaaat	gttgtttgga	2640
45	caagcactga	aagataagaa	agaactagaa	ggtgctggga	agatcgctac	tgaagcaata	2700
	gaaaacttcc	gaaccgttgt	ttctttgact	caggagcaga	agtttgaaca	tatgtatgct	2760
	cagagtttgc	aggtaccata	cagaaaactct	ttgaggaaa	cacacatctt	tggaattaca	2820
	ttttccttca	cccaggcaat	gatgtatttt	tcctatgctg	gatgtttccg	gtttggagcc	2880
	tacttgggtg	cacataaaact	catgagcttt	gaggatgttc	tgtagtatt	ttcagctgtt	2940
50	gtcttttggtg	ccatggcctg	ggggcaagtc	agttcatttg	ctcctgacta	tgccaaagcc	3000
	aaaatatcag	cagccacat	catcatgatc	attgaaaaaa	cccctttgat	tgacagctac	3060
	agcacggaag	gcctaattgc	gaacacattg	gaaggaaaat	tcacatttgg	tgaagttgta	3120
	ttcaactatc	ccacccgacc	ggacatccca	gtgcttcagg	gactgagcct	ggaggtgaag	3180
	aaggggccaga	cgctggctct	ggtgggcagc	agtggctgtg	ggaagagcac	agtgtgtccg	3240
55	ctcctggagc	ggtttacga	ccccttggca	gggaaagtgc	tgcttgatgg	caaagaaata	3300
	aagcgactga	atgttcagtg	gctccgagca	caactgggca	tcgtgtccca	ggagcccatc	3360
	ctgtttgact	gcagcattgc	tgagaacatt	gcctatggag	acaacagccg	ggtggtgtca	3420
	caggaagaga	ttgtgagggc	agcaaaggag	gccaacatac	atgccttcac	cgagtcagt	3480
	cctaataaat	atagcactaa	agtaggagac	aaaggaaactc	agctctctgg	tggccagaaa	3540
60	caacgcattg	ccatagctcg	tgcccttggt	agacagcctc	atattttgct	tttgatgaa	3600
	gccacgtcag	ctctggatac	agaaagtga	aagggtgtcc	aagaagccct	ggacaaagcc	3660
	agagaaggcc	gcacctgcat	tgtgattgct	caccgcctgt	ccaccatcca	gaatgcagac	3720

<300>
<302> ID2B
<310> M96843

5

<400> 40
tgaaagcctt cagtcccgtg aggtccatta ggaaaaacag cctgttggac caccgcctgg 60
gcatctccca gagcaaaacc ccggtggatg acctgatgag cctgctgtaa 110

10

<210> 41
<211> 486
<212> DNA
<213> Homo sapiens

15

<300>
<302> ID4
<310> Y07958

20

<400> 41
atgaaggcgg tgagcccgtt gcgcccctcg ggccgcaagg cgccgtcggg ctgcggcggc 60
ggggagctgg cgctgcgctg cctggccgag cacggccaca gcctgggtgg ctccgcagcc 120
gcggcgggcg cgccggcggc agcgcgctgt aaggcgggcg agggggcggc cgacgagccg 180
gcgctgtgcc tgcagtgcga tatgaacgac tgctatagcc gcctgcggag gctggtgccc 240
25 accatcccgc ccaacaagaa agtcagcaaa gtggagatcc tgcagcacgt tatcgactac 300
atcctggacc tgcagctggc gctggagacg caccggggcc tgctgaggca gccaccaccg 360
cccgcgccgc cacaccaccc ggccggggacc tgtccagccg cgccgcgcgc gaccccgctc 420
actgcgctca acaccgaccc ggccggcgcg gtgaacaagc agggcgacag cattctgtgc 480
cgctga 486

30

<210> 42
<211> 462
<212> DNA
<213> Homo sapiens

35

<300>
<302> IGF1
<310> NM000618

40

<400> 42
atgggaaaaa tcagcagctt tccaacccaa ttattttaagt gctgcttttg tgatttcttg 60
aaggtgaaga tgcacacccat gtcctcctcg catctcttct acctggcgct gtgcctgctc 120
accttcacca gctctgccac ggctggaccg gagacgctct gcggggctga gctggtggat 180
45 gctcttcagt tcgtgtgtgg agacaggggc ttttatttca acaagccac aggggtatggc 240
tcagcagtc ggagggcgcc tcagacaggc atcgtggatg agtgctgctt ccggagctgt 300
gatctaagga ggctggagat gtattgcgca cccctcaagc ctgccaaagc agctcgctct 360
gtccgtgccc agcgccacac cgacatgccc aagaccaga aggaagtaca tttgaagaac 420
gcaagtagag ggagtgcagg aaacaagaac tacaggatgt ag 462

50

<210> 43
<211> 591
<212> DNA
<213> Homo sapiens

55

<300>
<302> PDGFA
<310> NM002607

60

<400> 43
atgaggacct tggcttgccct gctgctcctc ggctgcggat acctcgccca tgttctggcc 60

gaggaagccg agatcccccg cgaggtgata gagaggtcgg cccgcagtc gatccacagc 120
 atccgggacc tccagcgact cctggagata gactccgtag ggagtggagg ttctttggac 180
 accagcctga gagctcacgg ggtccacgcc actaagcatg tgcccgagaa gcggcccctg 240
 cccattcggg ggaagagaag catcgaggaa gctgtccccg ctgtctgcaa gaccaggacg 300
 5 gtcattttacg agattcctcg gagtcaggtc gacccacagt ccgccaactt cctgatctgg 360
 cccccgtgcg tggaggtgaa acgctgcacc ggctgctgca acacgagcag tgtcaagtgc 420
 cagccctccc gcgtccacca ccgcagcgtc aaggtggcca aggtggaata cgtcaggaag 480
 aagcaaaaat taaaagaagt ccaggtgagg ttagaggagc atttgagtg cgctgcgcg 540
 accacaagcc tgaatccgga ttatcgggaa gaggacacgg atgtgaggtg a 591
 10

<210> 44
 <211> 528
 <212> DNA
 15 <213> Homo sapiens

<300>
 <302> PDGFRA
 <310> XM003568
 20

<400> 44
 atggccaagc ctgaccacgc taccagttaa gtctacgaga tcatggtgaa atgctggaac 60
 agtgagccgg agaagagacc ctcccttttac cactgagtg agattgtgga gaatctgctg 120
 cctggacaat ataaaaagag ttatgaaaaa attcacctgg acttcctgaa gagtgacat 180
 25 cctgctgtgg cagcgtgctg tgtggactca gacaatgcat acattggtgt cactacaaa 240
 aacgaggaag acaagctgaa ggactgggag ggtggtctgg atgagcagag actgagcgt 300
 gacagtggct acatcattcc tctgcctgac attgaccctg tccctgagga ggaggacctg 360
 ggcaagagga acagacacag ctgcgagacc tctgaagaga gtgccattga gacgggttcc 420
 agcagttcca ccttcatcaa gagagaggac gagaccattg aagacatcga catgatggat 480
 30 gacatcggca tagactcttc agacctgggt gaagacagct tctgtaa 528

<210> 45
 <211> 1911
 35 <212> DNA
 <213> Homo sapiens

<300>
 <302> PDGFRB
 40 <310> XM003790

<400> 45
 atgcggcttc cgggtgcat gccagctctg gccctcaaag gcgagctgct gttgctgtct 60
 45 ctctgtttac ttctggaacc acagatctct cagggcctgg tcgtcacacc cccggggcca 120
 gagcttgtcc tcaatgtctc cagcaccttc gttctgacct gctcgggttc agctccgtg 180
 gtgtgggaac ggatgtccca ggagccccca caggaaatgg ccaaggccca ggatggcacc 240
 ttctccagcg tgctcacact gaccaacctc actgggctag acacgggaga atacttttgc 300
 accacaatg actcccgctg actggagacc gatgagcgga aacggctcta catctttgtg 360
 ccagatccca ccgtgggctt cctccctaata gatgccgagg aactattcat ctttctcacg 420
 50 gaaataactg agatcaccat tccatgccga gtaacagacc cacagctggt ggtgacactg 480
 cagcagaaga aaggggacgt tgcactgcct gtcccctatg atcaccaacg tggcttttct 540
 ggtatctttg aggcagaaag ctacatctgc aaaaccacca ttggggacag ggaggtggat 600
 tctgatgcct actatgtcta cagactccag gtgtcatcca tcaacgtctc tgtgaacgca 660
 gtgcagactg tgggtccgcca ggtgagaac atcacctca tgtgcattgt gatcgggaat 720
 55 gaggtgtgca acttcgagt gacatacccc cgcaaagaaa gtgggcggct ggtggagccg 780
 gtgactgact tcctcttggg tatgccttac cacatccgct ccatcctgca catccccagt 840
 gccgagttag aagactcggg gacctacacc tgcaatgtga cggagagtgt gaatgacct 900
 caggatgaaa aggccatcaa catcacctg gttgagagcg gctacgtgcg gctcctggga 960
 gaggtgggca cactacaatt tgctgagctg catcgagacc ggacactgca ggtagtgttc 1020
 60 gaggcctacc caccgcccac tgtcctgtgg ttcaaagaca accgcaccct gggcgactcc 1080
 agcgtggcg aaatcgccct gtccacgcgc aacgtgtcgg agaccggta tgtgtcagag 1140
 ctgacactgg ttccgctgaa ggtggcagag gctggccact acaccatgcg ggccttccat 1200

gaggatgctg aggtccagct ctccctccag ctacagatca atgtccctgt ccgagtgtg 1260
 gagctaagtg agagccaccc tgacagtggg gaacagacag tccgctgtcg tggccggggc 1320
 atgccccagc cgaacatcat ctggtctgcc tgcagagacc tcaaaagggtg tccacgtgag 1380
 ctgccgcccc cgctgtgtggg gaacagttcc gaagaggaga gccagctgga gactaacgtg 1440
 5 acgtactggg aggaggagca ggagtttgag gtggtgagca cactgcgtct gcagcacgtg 1500
 gatcggccac tgtcgggtgc ctgcacgctg cgcaacgctg tgggccagga cacgcaggag 1560
 gtcacgtggtg tgccacactc cttgcccttt aagggtggtg tgatctcagc catcctggcc 1620
 ctggtggtgc tcacatcat ctcccttata atcctcatca tgctttggca gaagaagcca 1680
 cgttacgaga tccgatggaa ggtgattgag tctgtgagct ctgacggcca tgagtacatc 1740
 10 tacgtggacc ccatgcagct gccctatgac tccacgtggg agctgccgag ggaccagctt 1800
 gtgctgggac gcaccctcgg ctctggggcc tttgggcagg tgggtggaggc cacggttcat 1860
 ggccctgagcc attttcaagc cccaatgaaa gtggccgtca aaaatgctta a 1911

15 <210> 46
 <211> 1176
 <212> DNA
 <213> Homo sapiens

20 <300>
 <302> TGFbeta1
 <310> NM000660

25 atgccgcccct ccgggctgag gctgctgccc ctgctgtctac cgctgctgtg gctactgggtg 60
 ctgacgcctg gcccgccggc cgcgggacta tccacctgca agactatcga catggagctg 120
 gtgaagcgga agcgcacga ggccatccgc ggccagatcc tgtccaagct gcggctcgcc 180
 agccccccga gccaggggga ggtgccgccc ggcccgctgc ccgaggccgt gctcgccctg 240
 tacaacagca cccgcgaccg ggtggccggg gagagtgcag aaccggagcc cgagcctgag 300
 30 gccgactact acgccaagga ggtcaccgag gtgctaagtg tggaaaccca caacgaaatc 360
 tatgacaagt tcaagcagag tacacacagc atatatatgt tcttcaacac atcagagctc 420
 cgagaagcgg tacctgaacc cgtgttgctc tcccgggcag agctgcgtct gctgaggagg 480
 ctcaagttaa aagtggagca gcacgtggag ctgtaccaga aatacagcaa caattcctgg 540
 cgatacctca gcaaccggct gctggcacc agcgaactgc cagagtgggt atcttttgat 600
 35 gtcaccggag ttgtgcggca gtggttgagc cgtggagggg aaattgaggg ctttgcgctt 660
 agcggccact gtcctgtgta cagcagggat aacacactgc aagtggacat caacgggttc 720
 actaccggcc gccgaggtga cctggccacc attcatggca tgaaccggcc tttcctgctt 780
 ctcatggcca cccgctgga gagggccag catctgcaaa gctcccggca ccgcccagcc 840
 ctggacacca actattgctt cagctccagc gagaagaact gctgcgtgag gcagctgtac 900
 40 attgacttcc gcaaggacct cggctggaag tggatccacg agcccaaggg ctaccatgcc 960
 aacttctgcc tcgggcccctg cccctacatt tggagcctgg acacgcagta cagcaaggct 1020
 ctggccctgt acaaccagca taacccgggc gcctcggcgg cgccgtgctg cgtgccgcag 1080
 gcgctggagc cgtgcccac cgtgtactac gtgggcgcga agcccaagggt ggagcagctg 1140
 tccaacatga tcgtgcgctc ctgcaagtgc agctga 1176

45 <210> 47
 <211> 1245
 <212> DNA
 <213> Homo sapiens

50 <300>
 <302> TGFbeta2
 <310> NM003238

55 <400> 47
 atgcactact gtgtgctgag cgcttttctg atcctgcata tggtcacggt cgcgctcagc 60
 ctgtctacct gcagcacact cgatatggac cagttcatgc gcaagaggat cgagggcagc 120
 cgcgggcaga tctgagcaa gctgaagctc accagtcccc cagaagacta tctgagccc 180
 60 gaggaagtcc ccccgagggt gatttccatc tacaacagca ccagggactt gctccaggag 240
 aaggcgagcc ggagggcgcc cgcctgcgag cgcgagagga gcgacgaaga gtactacgcc 300
 aaggagggtt acaaaataga catgccgccc ttcttccctt ccgaaaatgc catcccgcgc 360

```

actttctaca gaccctactt cagaattggt cgatttgacg tctcagcaat ggagaagaat 420
gcttccaatt tgggtgaaagc agagttcaga gtctttcggt tgcagaaccc aaaagccaga 480
gtgectgaac aacggattga gctatatcag attctcaagt ccaaagattt aacatctcca 540
accagcgct acatcgacag caaagttgtg aaaacaagag cagaaggcga atggctctcc 600
5 ttcgatgtaa ctgatgctgt tcatgaatgg cttcaccata aagacaggaa cctgggattt 660
aaaataagct tacactgtcc ctgctgcact tttgtacat ctaataatta catcatccca 720
aataaaagtg aagaactaga agcaagattt gcaggtattg atggcacctc cacatatacc 780
agtgggtgatc agaaaactat aaagtccact aggaaaaaaa acagtgggaa gaccccat 840
ctcctgctaa tgttattgcc ctctacaga cttgagtcac aacagaccaa ccggcggaag 900
10 aagcgtgctt tggatgcggc ctattgcttt agaaatgtgc aggataattg ctgcctacgt 960
ccactttaca ttgatttcaa gagggatcta ggggtgaaat ggatacacga acccaaagg 1020
tacaatggca acttctgtgc tggagcatgc ccgtatttat ggagttcaga cactcagcac 1080
agcagggtcc tgagcttata taataccata aatccagaag catctgcttc tcttctgtgc 1140
gtgtcccaag atttagaacc tctaaccatt ctctactaca ttggcaaaac acccaagatt 1200
15 gaacagcttt ctaatatgat tgtaaagtct tgcaaatgca gctaa 1245

```

```

<210> 48
<211> 1239
20 <212> DNA
    <213> Homo sapiens

```

```

<300>
<302> TGFbeta3
25 <310> XM007417

```

```

<400> 48
atgaagatgc acttgcaaag ggctctgggt gtcctggccc tgctgaactt tgccacggtc 60
agcctctctc tgtccacttg caccaccttg gacttcggcc acatcaagaa gaagaggggtg 120
30 gaagccatta ggggacagat cttgagcaag ctcaggctca ccagccccc tgagccaacg 180
gtgatgaccc acgtccccta tcaggctctg gccctttaca acagcacccg ggagctgctg 240
gaggagatgc atggggagag ggaggaaggc tgcaccacag aaaacaccga gtcggaatac 300
tatgccaaag aaatccataa attcgacatg atccaggggc tggcggagca caacgaactg 360
gctgtctgcc ctaaaggaaat tacctccaag gttttccgct tcaatgtgtc ctcagtggag 420
35 aaaaatagaa ccaacctatt ccgagcagaa ttccgggtct tgcggtgtgc caacccacg 480
tctaagcgga atgagcagag gatcgagctc ttccagatcc ttcggccaga tgagcacatt 540
gccaaacagc gctatatcgg tggcaagaat ctgcccacac ggggactgc cgagtggctg 600
tcttttgatg tcactgacac tgtgcgtgag tggctgttga gaagagagtc caacttaggt 660
ctagaaatca gcattcactg tccatgtcac acctttcagc ccaatggaga tctcctggaa 720
40 aacattcacg aggtgatgga aatcaaattc aaaggcgtgg acaatgagga tgaccatggc 780
cgtggagatc tggggcgccct caagaagcag aaggatcacc acaacctca tctaactctc 840
atgatgattc cccacacccg gctcgacaac ccgggcccag ggggtcagag gaagaagcgg 900
gctttggaca ccaattactg cttccgcaac ttggaggaga actgctgtgt gcgccccctc 960
tacattgact tccgacagga tctgggctgg aagtgggtcc atgaacctaa gggctactat 1020
45 gccaaactct gctcaggccc ttgcccatac ctccgcagtg cagacacaac ccacagcacg 1080
gtgctgggac tgtacaacac tctgaacctt gaagcatctg cctcgctctg ctgcgtgccc 1140
caggacctgg agccctgac catcctgtac tatgttggga ggaccccaa agtgagagcag 1200
ctctccaaca tgggtggtgaa gtcttgtaaa tgtagctga 1239

```

```

50 <210> 49
    <211> 1704
    <212> DNA
    <213> Homo sapiens

```

```

55 <300>
    <302> TGFbetaR2
    <310> XM003094

```

```

60 <400> 49
atgggtcggg ggctgctcag gggcctgtgg ccgctgcaca tcgtcctgtg gacgcgtatc 60
gccagcacga tcccaccgca cgttcagaag tcggttaata acgacatgat agtcactgac 120

```

5 aacaacgggtg cagtcaagtt tccacaactg tgtaaatttt gtgatgtgag attttccacc 180
 tgtgacaacc agaaatcctg catgagcaac tgcagcatca cctccatctg tgagaagcca 240
 caggaagtct gtgtggctgt atggagaaaag aatgacgaga acataacact agagacagtt 300
 tgccatgacc ccaagctccc ctaccatgac tttattctgg aagatgctgc ttctccaaag 360
 10 tgattatga aggaaaaaaa aaagcctggg gagactttct tcatgtgttc ctgtagctct 420
 gatgagtga atgacaacat catctttctca gaagaatata acaccagcaa tcctgacttg 480
 ttgctagtca tatttcaagt gacaggcatc agcctcctgc caccactggg agttgccata 540
 tctgtcatca tcatcttcta ctgctaccgc gttaaccggc agcagaagct gaggttcaacc 600
 tgggaaaccg gcaagacgcg gaagctcatg gaggttcagcg agcactgtgc catcatcctg 660
 15 gaagatgacc gctctgacat cagctccacg tgtgccaaca acatcaacca caacacagag 720
 ctgctgcccc ttgagctgga caccctgggt gggaaagggtc gctttgtgta ggtctataag 780
 gccaagctga agcagaacac ttcagagcag tttgagacag tggcagtcaa gatctttccc 840
 tatgaggagt atgcctcttg gaagacagag aaggacatct tctcagacat caatctgaag 900
 catgagaaca tactccagtt cctgacggct gaggagcggg agacggagtt ggggaaacaa 960
 20 tactggctga tcaccgcctt ccacgccaag ggcaacctac aggagtacct gacgcggcat 1020
 gtcatcagct gggaggacct gcgcaagctg ggcagctccc tcgcccgggg gattgtctac 1080
 ctccacagtg atcacactcc atgtgggagg cccaagatgc ccatcgtgca cagggacctc 1140
 aagagctcca atatcctcgt gaagaacgac ctaacctgct gcctgtgtga ctttgggctt 1200
 25 tccctgctgc tggaccctac tctgtctgtg gatgacctgg ctaacagtgg gcaggtggga 1260
 actgcaagat acatggctcc agaagtccta gaatccagga tgaatttgga gaatgttgag 1320
 tctttcaagc agaccgatgt ctactccatg gctctggtgc tctgggaaat gacatctcgc 1380
 tgtaatgcag tgggagaagt aaaagattat gagcctccat ttggttccaa ggtgcgggag 1440
 caccctgtg tcgaaaagcat gaaggacaac gtgttgagag atcgaggggc accagaaatt 1500
 30 cccagcttct ggctcaacca ccagggcatc cagatggtgt gtgagacgtt gactgagtgc 1560
 tgggaccacg acccagaggc ccgtctcaca gccagtggtg tggcagaacg cttcagtgag 1620
 ctggagcatc tggacaggct ctcggggagg agctgctcgg aggagaagat tcctgaagac 1680
 35 ggctccctaa acactaccaa atag 1704

30 <210> 50
 <211> 609
 <212> DNA
 <213> Homo sapiens

35 <300>
 <302> TGFbeta3
 <310> XM001924

40 <400> 50
 atgtctcatt acaccattat tgagaatatt tgcctctaaag atgaatctgt gaaattctac 60
 agtcccaaga gagtgcactt tcctatcccc caacacctca ctgctctttc tacagtgtga gctgacgctg 120
 tttgtcttca agcctgtctt caacacctca ctgctctttc tacagtgtga gctgacgctg 180
 45 tgtacgaaga tggagaagca cccccagaag ttgcttaagt gtgtgcctcc tgacgaagcc 240
 tgcacctcgc tggacgcctc gataatctgg gccatgatgc agaataagaa gacgttccact 300
 aagccccctg ctgtgatcca ccatgaagca gaatctaaag aaaaagggtc aagcatgaag 360
 gaaccaaatt caattttctc accaattttc catggtctgg acaccctaac cgtgatgggc 420
 attgcgcttg cagccttttg gatcggagca ctctgacgg gggccttggt gtacatctat 480
 tctcacacag gggagacagc aggaaggcag caagtcccca cctccccgcc agcctcggaa 540
 50 aacagcagtg ctgcccacag catcggcagc acgcagagca cgccttgctc cagcagcagc 600
 acggcctag 609

55 <210> 51
 <211> 3633
 <212> DNA
 <213> Homo sapiens

60 <300>
 <302> EGFR
 <310> X00588

<400> 51

<300>
 <302> FGF4
 <310> NM002007

5

<400> 67
 atgtcggggc cggggacggc cgcggtagcg ctgctcccgg cggtcctgct ggccttgctg 60
 gcgccctggg cgggccgagg gggcgcgcgc gcacccactg caccacaacg cacgctggag 120
 gccgagctgg agcgcgcgct ggagagcctg gtggcgctct cgttggcgcg cctgccgggtg 180
 10 gcagcgcagc ccaaggaggc ggccgtccag agcggcgccg gcgactacct gctgggcatc 240
 aagcggctgc ggcggctcta ctgcaacgtg ggcatcggct tccacctcca ggcgctcccc 300
 gacggccgca tcggcggcgc gcacgcggac acccgcgaca gcctgctgga gctctcgccc 360
 gtggagcggg gcgtggtgag catcttcggc gtggccagcc ggctcttcgt ggccatgagc 420
 agcaagggca agctctatgg ctgcgccctt ttaccgatg agtgacggtt caaggagatt 480
 15 ctcccttccc acaactacaa cgcctacgag tctacaagt acccggcat gttcatcgcc 540
 ctgagcaaga atgggaagac caagaagggg aaccgagtg cgccacccat gaaggtcacc 600
 cacttctctc ccaggctgtg a 621

20 <210> 68
 <211> 597
 <212> DNA
 <213> Homo sapiens

25 <300>
 <302> FGF6
 <310> NM020996

<400> 68
 30 atgtcccggg gagcaggacg tctgcagggc acgctgtggg ctctcgtctt cctaggcatc 60
 ctagtgggca tgggtggtgcc ctgcctgca ggcacccgtg ccaacaacac gctgctggac 120
 tcgaggggct ggggcacccct gctgtccagg tctgcgcgcg ggctagctgg agagattgcc 180
 ggggtgaact gggaaagtgg ctatttgggt gggatcaagc ggcagcggag gctctactgc 240
 aacgtgggca tcggctttca cctccagggt ctccccgacg gccggatcag cgggacccac 300
 35 gaggagaacc cctacagcct gctggaaatt tccactgtgg agcgaggcgt ggtgagtctc 360
 tttggagtga gaagtgcctt cttcgttgcc atgaacagta aaggaagatt gtacgcaacg 420
 cccagcttcc aagaagaatg caagtccaga gaaaccctcc tgcccaacaa ttacaatgcc 480
 tacgagtcag acttgtacca agggacctac attgccctga gcaaatacgg acgggtaaag 540
 40 cggggcagca aggtgtcccc gatcatgact gtcactcatt tccttcccag gatctaa 597

45 <210> 69
 <211> 150
 <212> DNA
 <213> Homo sapiens

<300>
 <302> FGF7
 <310> XM007559

50

<400> 69
 atgtcttggc aatgcacttc atacacaatg actaatctat actgtgatga tttgactcaa 60
 aaggagaaaa gaaattatgt agttttcaat tctgattcct attcaccctt tgtttatgaa 120
 tggaaagctt tgtgcaaaat atacatataa 150

55

<210> 70
 <211> 628
 <212> DNA
 60 <213> Homo sapiens

<300>

<302> FGF9
<310> XM007105

<400> 70
5 gatggctccc ttaggtgaag ttgggaacta tttcgggtgtg caggatgcgg taccgtttgg 60
gaatgtgccc gtgttgccgg tggacagccc ggttttgtta agtgaccacc tgggtcagtc 120
cgaagcaggg gggctcccca ggggacccgc agtcacggac ttggatcatt taaaggggat 180
tctcaggcgg aggcagctat actgcaggac tggatttcac ttagaaatct tccccaatgg 240
tactatccag ggaaccagga aagaccacag ccgatttggc attctggaat ttatcagtat 300
10 agcagtgggc ctgggtcagca ttcgagggcg ggacagtggc ctctacctcg ggatgaatga 360
gaagggggag ctgtatggat cagaaaaact aacccaagag tgtgtattca gagaacagtt 420
cgaagaaaaa tgggtataata cgtactcatc aaacctatat aagcacgtgg acactggaag 480
gcgataactat gttgcattaa ataaagatgg gaccccgaga gaagggacta ggactaaaacg 540
gcaccagaaa ttcacacatt ttttacctag accagtggac cccgacaaag tacctgaact 600
15 gtataaggat attctaagcc aaagttga 628

<210> 71
<211> 2469
20 <212> DNA
<213> Homo sapiens

<300>
<302> FGFR1
25 <310> NM000604

<400> 71
atgtggagct ggaagtgcct cctcttcttg gctgtgctgg tcacagccac actctgcacc 60
gctaggccgt ccccgacctt gctgaacaa gccagccct ggggagcccc tgtggaagtg 120
30 gagtccttcc tgggtccaccc cggtgacctg ctgcagcttc gctgtcggct gcgggacgat 180
gtgcagagca tcaactggct gcgggacggg gtgcagctgg cggaaagcaa ccgcacccgc 240
atcacagggg aggaggtgga ggtgcaggac tccgtgcccg cagactccgg cctctatgct 300
tgcgtaacca gcagcccctc gggcagtgac accacctact tctccgtcaa tgtttcagat 360
gctctcccct cctcggagga tgatgatgat gatgatgact cctcttcaga ggagaaagaa 420
35 acagataaca ccaaaccaaa ccgtatgccc gtagctccat attggacatc cccagaaaag 480
atggaaaaga aattgcatgc agtgccggct gccaaagacag tgaagttcaa atgcccttcc 540
agtgggaccc caaacccac actgcgctgg ttgaaaaatg gcaaagaatt caaacctgac 600
cacagaattg gaggtacaa ggtccgttat gccacctgga gcatcataat ggactctgtg 660
gtgccctctg acaagggcaa ctacacctgc attgtggaga atgagtacgg cagcatcaac 720
40 cacacatacc agctggatgt cgtggagcgg tccctcacc ggcccatcct gcaagcaggg 780
ttgcccgcca acaaaacagt ggccctgggt agcaacgtgg agttcatgtg taaggtgtac 840
agtgacccgc agccgcacat ccagtggcta aagcacatg aggtgaatgg gagcaagatt 900
ggcccagaca acctgcctta tgtccagatc ctggaactg ctggagttaa taccaccgac 960
aaagagatgg aggtgcttca cttaagaaat gtctcctttg aggacgcagg ggagtatacg 1020
45 tgcttggcgg gtaactctat cggactctcc catcactctg catggttgac cgttctggaa 1080
gccctggaag agaggccggc agtgatgacc tcgcccctgt acctggagat catcatctat 1140
tgcacagggg ccttcctcat ctctgcctg gtggggctcg tcatcgtcta caagatgaag 1200
agtggtacca agaagagtga cttccacagc cagatggctg tgcacaagct ggccaagagc 1260
atccctctgc gcagacaggt aacagtgtct gctgactcca gtgcatccat gaactctggg 1320
50 gttcttcttg ttcggccatc acggctctcc tccagtggga ctcccattgct agcaggggtc 1380
tctgagtatg agcttcccga agaccctcgc tgggagctgc ctcgggacag actggtctta 1440
ggcaaaccct tgggagaggg ctgctttggg caggtggtgt tggcagaggc tatcgggctg 1500
gacaaggaca aacccaaccg tgtgaccaa gtggctgtga agatgttga gtcggagca 1560
acagagaaag acttgtcaga cctgatctca gaaatggaga tgatgaagat gatcgggaag 1620
55 cataagaata tcatcaacct gctgggggcc tgcacgcagg atggtccctt gtatgtcatc 1680
gtggagtatg cctccaaggg caacctgcgg gagtacctgc aggcccgagg gccccaggg 1740
ctggaatact gctacaacc cagccacac ccagaggagc agctctcctc caaggacctg 1800
gtgtcctgcg cctaccaggt ggcccagagg atggagtatc tggcctccaa gaagtgcata 1860
caccgagacc tggcagccag gaatgtcctg gtgacagagg acaatgtgat gaagatagca 1920
60 gactttggcc tcgcacggga cattcaccac atcgactact ataaaaagac aaccaacggc 1980
cgactgctg tgaaagtggat ggcacccgag gcattatttg accggatcta caccaccag 2040
agtgatgtgt ggtcttctcg ggtgctcctg tgggagatct tcactctggg cggctcccca 2100

	taccccggtg	tgctgtgga	ggaacttttc	aagctgctga	aggaggggtca	ccgcatggac	2160
	aagcccagta	actgcaccaa	cgagctgtac	atgatgatgc	gggactgctg	gcatgcagtg	2220
	ccctcacaga	gacccacott	caagcagctg	gtggaagacc	tggacogcat	cgtggccttg	2280
	acctccaacc	aggagtacct	ggacctgtcc	atgcccctgg	accagtactc	ccccagcttt	2340
5	cccgcacccc	ggagctctac	gtgctcctca	ggggaggatt	ccgtcttctc	tcatgagccg	2400
	ctgcccaggg	agccctgcct	gccccgacac	ccagcccagc	ttgccaatgg	cggactcaaa	2460
	cgcgctga						2469
10	<210> 72						
	<211> 2409						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> FGFR4						
	<310> XM003910						
	<400> 72						
20	atgcggctgc	tgctggccct	gttgggggtc	ctgctgagtg	tgctggggcc	tccagtcttg	60
	tccctggagg	cctctgagga	agtggagctt	gagccctgcc	tggctcccag	cctggagcag	120
	caagagcagg	agctgacagt	agcccttggg	cagcctgtgc	ggctgtgctg	tgggggggct	180
	gagcgtgggt	gccactggta	caaggagggc	agtgcctgg	cacctgctgg	cgtgtacgg	240
	ggctggaggg	cccgcctaga	gattgccagc	ttcctacctg	aggatgctgg	ccgctacctc	300
25	tgcttggcac	gaggtccat	gatcgctctg	cagaatctca	ccttgattac	aggtgactcc	360
	ttgacctcca	gcaacgatga	tgaggacccc	aagtcccata	gggacctctc	gaataggcac	420
	agttaccccc	agcaagcacc	ctactggaca	cacccccagc	gcatggagaa	gaaactgcat	480
	gcagtacctg	cggggaacac	cgtcaagttc	cgtgttccag	ctgcaggcaa	ccccacgccc	540
	accatccgct	ggcttaagga	tggacaggcc	tttcatgggg	agaaccgcat	tggaggcatt	600
30	cggctgcgcc	atcagcactg	gagtctcgtg	atggagagcg	tgggtgccctc	ggaccgcggc	660
	acatacacct	gcctggtaga	gaacgctgtg	ggcagcatcc	gttataacta	cctgctagat	720
	gtgctggagc	ggtccccgca	ccggcccac	ctgcaggccg	ggctcccggc	caacaccaca	780
	gccgtggtag	gcagcgacgt	ggagctgctg	tgcaagggtg	acagcgatgc	ccagccccac	840
	atccagtggc	tgaagcacat	cgtcatcaac	ggcagcagct	tcggagccga	cggtttcccc	900
35	tatgtgcaag	tctaaagac	tgcagacatc	aatagctcag	aggtggaggt	cctgtacctg	960
	cggaaacgtg	cagccgagga	cgcaggcgag	tacacctgcc	tcgcaggcaa	ttccatcggc	1020
	ctctcctacc	agtcctgcctg	gctcacggtg	ctgccagagg	aggacccac	atggaccgca	1080
	gcagcgcccg	aggccaggta	tacggacatc	atcctgtacg	cgtcgggctc	cctggccttg	1140
	gctgtgctcc	tgctgctggc	caggctgtat	cgagggcagg	cgtccacgg	ccggcaccac	1200
40	cgcccgcgcc	ccactgtgca	gaagctctcc	cgtctccctc	tggcccgaca	gttctccctg	1260
	gagtcaggct	cttccggcaa	gtcaagctca	tccctggtag	gaggcgtgcg	tctctcctcc	1320
	agcggccccc	ccttgctcgc	cggcctcgtg	agtctagatc	tacctctcga	cccactatgg	1380
	gagttcccc	gggacaggct	ggtgcttggg	aagcccctag	gcgagggctg	ctttggccag	1440
	gtagtacgtg	cagaggcctt	tggcatggac	cctgcccggc	ctgaccaagc	cagcactgtg	1500
45	gccgtcaaga	tgctcaaaga	caacgcctct	gacaaggacc	tggccgacct	ggtctcggag	1560
	atggagggtga	tgaagctgat	cggccgacac	agaacatca	tcaacctgct	tgggtgtctg	1620
	accaggaag	ggcccctgta	cgtgatcgtg	gagtgcgccg	ccaaggga	cctgcccggg	1680
	ttcctgctgg	cccggcgccc	cccaggcccc	gacctcagcc	ccgacggctc	tcggagcagt	1740
	gagggggccgc	tctccttccc	agtcctggtc	tctgctgcct	accagggtggc	ccgaggcatg	1800
50	cagtatctgg	agtcccggaa	gtgtatccac	cgggacctgg	ctgcccgcaa	tgtgctggtg	1860
	actgaggaca	atgtgatgaa	gattgctgac	tttgggctgg	cccgcggcgt	ccaccacatt	1920
	gactactata	agaaaaccag	caacggccgc	ctgcctgtga	agtggatggc	gcccagggcc	1980
	ttgtttgacc	gggtgtacac	acaccagagt	gacgtgtggt	cttttgggat	cctgctatgg	2040
	gagatcttca	ccctcggggg	ctccccgtat	cctggcatcc	cgggtggagga	gctgttctcg	2100
55	ctgctgcggg	agggacatcg	gatggaccga	ccccacact	gccccccaga	gctgtacggg	2160
	ctgatgcgtg	agtgtcggca	cgcagcgccc	tcccagaggc	ctacctcaa	gcagctggtg	2220
	ttcggacctg	acaaggtcct	gctggccgtc	tctgaggagt	acctcgacct	ccgcctgacc	2280
	gtcttccagcc	atccccctc	tggtggggac	gccagcagca	cctgctcctc	cagcgattct	2340
60	cagacatga		gccattggga	tccagctcct	tccccttcgg	gtctgggggtg	2400
							2409

<210> 73
 <211> 1695
 <212> DNA
 <213> Homo sapiens

5

<300>
 <302> MT2MMP
 <310> D86331

10

<400> 73
 atgaagcggc cccgctgtgg ggtgccagac cagttcgggg tacgagtga agccaacctg 60
 cggcggcgctc ggaagcgcta cgccctcacc gggaggaagt ggaacaacca ccatctgacc 120
 ttttagcatcc agaactacac ggagaagtgg ggctggtagg actcgatgga ggcgggtgagc 180
 agggccttcc gcgtgtggga gcaggccacg cccctgggtct tccaggaggt gccctatgag 240
 15 gacatccggc tgcggcgaca gaaggaggcc gacatcatgg tactctttgc ctctggcttc 300
 cacggcgaca gctcgccgtt tgatggcacc ggtggctttc tggcccacgc ctatttccct 360
 ggccccggcc tagggcggga caccattttt gacgcagatg agccctggac cttctccagc 420
 actgacctgc atggaaacaa cctcttcctg gtggcagtg atgagctggg ccacgcgctg 480
 gggctggagc actccagcaa ccccaatgcc atcatggcg cgttctacca gtggaaggac 540
 20 gttgacaact tcaagctgcc cgaggacgat ctccgtggca tccagcagct ctacggtagc 600
 ccagacggtc agccacagcc taccacagct ctcccactg tgacgccacg gcggccaggc 660
 cggcctgacc accggccgcc ccggcctccc cagccaccac ccccagggtg gaagccagag 720
 cggcccccaa agccgggccc ccagtcacg ccccgagcca cagagcggcc cgaccagtat 780
 ggcccccaaca tctgcgacgg ggactttgac acagtggcca tgcttcgcgg ggagatgttc 840
 25 gtgttcaagg gccgctgggt ctggcgagtc cggcacaacc gcgtcctgga caactatccc 900
 atgcccctcg ggcacttctg cgtgggtctg cccggtgaca tcagtgtgc ctacgagcgc 960
 caagacggtc gttttgtctt tttcaaaggc gaccgctact ggctctttcg agaagcgaac 1020
 ctggagcccg gctaccacac gccgctgacc agctatggcc tgggcatccc ctatgaccgc 1080
 attgacacgg ccatctgggt ggagcccaca ggccacacct tcttcttcca agaggacagg 1140
 30 tactggcgct tcaacgagga gacacagcgt ggagaccctg ggtaccccaa gcccatcagt 1200
 gtctggcagg ggatccctgc ctcccctaaa ggggccttcc tgagcaatga cgcagcctac 1260
 acctacttct acaagggcac caaatactgg aaattcgaca atgagcgcct gcggatggag 1320
 ccggctacc ccaagtcct cctgcgggac ttcattgggt gccaggagca cgtggagcca 1380
 ggcccccgat ggcccgacgt ggcccgcccg cccttcaacc cccacggggg tgcagagccc 1440
 35 ggggcgagaca gcgcagaggg cgacgtgggg gatggggatg gggactttgg ggccgggggtc 1500
 aacaaggaca ggggcagccg cgtgggtggt cagatggagg aggtggcacg gacggtgaac 1560
 gtgggtgatg tgctggtgcc actgctgctg ctgctctgcg tcctgggcct cacctacgcg 1620
 ctgggtgcaga tgcagcgcaa ggggtgcgcca cgtgtcctgc tttactgcaa gcgctcgctg 1680
 caggagtggg tctga 1695

40

<210> 74
 <211> 1824
 <212> DNA
 <213> Homo sapiens

45

<300>
 <302> MT3MMP
 <310> D85511

50

<400> 74
 atgatcttac tcacattcag cactggaaga cggttggatt tcgtgcatca ttcgggggtg 60
 tttttcttgc aaaccttgct ttggatttta tgtgctacag tctgcggaac ggagcagtat 120
 55 ttcaatgtgg aggtttggtt acaaaagtac ggctaccttc caccgactga cccagaaatg 180
 tcagtgtgct gctctgcaga gaccatgcag tctgccctag ctgccatgca gcagttctat 240
 ggcattaaca tgacaggaaa agtggacaga aacacaattg actggatgaa gaagccccga 300
 tgccgtgtac ctgaccagac aagaggtagc tccaaatttc atattcgtcg aaagcgatat 360
 gcattgacag gacagaaatg gcagcacaag ccatcactt acagtataaa gaacgtaact 420
 ccaaaagtag gagaccctga gactcgtaaa gctattcgcc gtgcctttga tgtgtggcag 480
 60 aatgtaactc ctctgacatt tgaagaagtt ccctacagtg aattagaaaa tggcaaacgt 540
 gatgtggata taaccattat ttttgcattc ggtttccatg gggacagctc tccctttgat 600
 ggagagggag gatttttggc acatgcctac ttccctggac caggaaattgg aggagatacc 660

	cattttgact	cagatgagcc	atggacacta	ggaaatccta	atcatgatgg	aatgactta	720
	tttctttag	cagtccatga	actgggacat	gctctgggat	tggagcattc	caatgacccc	780
	actgccatca	tggctccatt	ttaccagtac	atggaaacag	acaacttcaa	actaccta	840
	gatgatattac	agggcatcca	gaagatata	gggccacctg	acaagattcc	tccacctaca	900
5	agacctctac	cgacagtgcc	cccacaccgc	tctattcctc	cggtgaccc	aaggaaaaat	960
	gacaggccaa	aacctoctcg	gcctccaacc	ggcagaccct	cctatcccgg	agccaaaccc	1020
	aacatctgtg	atgggaactt	taacactcta	gctattcttc	gtcgtgagat	gtttgttttc	1080
	aaggaccagt	ggttttggcg	agtgagaaac	aacagggtga	tggatggata	cccaatgcaa	1140
	attacttact	tctggcgggg	cttgccctct	agtatcgatg	cagtttatga	aaatagcgac	1200
10	gggaattttg	tgttctttta	aggtaacaaa	tattgggtgt	tcaaggatac	aactcttcaa	1260
	cctgggttacc	ctcatgactt	gataaccctt	ggaagtggaa	ttccccctca	tgggtattgat	1320
	tcagccattt	ggtgggagga	cgctcgggaaa	acctatttct	tcaagggaga	cagatattgg	1380
	agatatagtg	aagaaatgaa	aacaatggac	cctggctatc	ccaagccaat	cacagtctgg	1440
	aaagggatcc	ctgaatctcc	tcagggaagca	tttgtaacaca	aagaaaatgg	ctttacgtat	1500
15	ttctacaaag	gaaaggagta	ttggaaattc	aacaaccaga	tactcaaggt	agaacctgga	1560
	tatccaagat	ccatcctcaa	ggattttatg	ggctgtgatg	gaccaacaga	cagagttaaa	1620
	gaaggacaca	gcccaccaga	tgatgtagac	attgtcatca	aactggacaa	cacagccagc	1680
	actgtgaaag	ccatagctat	tgctattccc	tgcatcttgg	ccttatgcct	ccttgatttg	1740
	gtttacactg	tgttccagtt	caagagga	ggaacacccc	gccacatact	gtactgtaaa	1800
20	cgctctatgc	aagagtgggt	gtga				1824

<210> 75

<211> 1818

25 <212> DNA

<213> Homo sapiens

<300>

<302> MT4MMP

30 <310> AB021225

<400> 75

	atgcggcgcc	gcgcagcccc	gggacccggc	ccgcgcggcc	cagggcccg	actctcgcg	60
	ctgcgcgtgc	tgcgcgtgcc	gctgctgctg	ctgctggcgc	tggggaccgc	cgggggctgc	120
35	gccgcgcgg	aaaccgcgcg	gcgcgcggag	gacctcagcc	tgggagtggg	gtggctaagc	180
	aggttcgggt	acctgcccc	ggctgacccc	acaacagggc	agctgcagac	gcaagaggag	240
	ctgtctaagg	ccatcacagc	catgcagcag	tttggtggcc	tggaggccac	cggcatectg	300
	gacgaggcca	cctggccct	gatgaaaacc	ccacgctgct	ccctgccaga	cctccctgtc	360
	ctgaccacgg	ctcgcaggag	acgccaggct	ccagcccca	ccaagtggaa	caagaggaa	420
40	ctgtcgtgga	gggtccggac	gttcccacgg	gactcaccac	tggggcacga	cacggtgcgt	480
	gcaactcatgt	actacgccct	caaggtctgg	agcgacattg	cgccccctgaa	cttccacgag	540
	tgggcgggca	gcaccgcgca	catccagatc	gacttctcca	aggccgacca	taacgacggc	600
	taccctctcg	acgcccggcg	gcaccgtgcc	acgccttct	tccccggcca	ccaccacacc	660
	gccgggtaca	cccactttta	cgatgacgag	gcctggacct	tccgctcctc	ggatgcccac	720
45	gggatggacc	tgtttgcagt	ggctgtccac	gagtttgcc	acgccattgg	gttaagccat	780
	gtggccgctg	cacactccat	catgcccggc	tactaccagg	gcccgggtgg	tgacccgctg	840
	cgctacgggc	tcccctacga	ggacaagggt	cgcgtctggc	agctgtacgg	tgtgcccggg	900
	tctgtgtctc	ccacggcgca	gcccaggag	cctcccctgc	tgccggagcc	cccagacaac	960
	cggtccagcg	ccccgcccag	gaaggacgtg	ccccacagat	gcagcactca	ctttgacgcg	1020
50	gtggcccaga	tccgggggtga	agctttcttc	ttcaaaggca	agtacttctg	gcggctgacg	1080
	cgggaccggc	acctgggtgtc	cctgcagccg	gcacagatgc	accgcttctg	gcggggcctg	1140
	ccgctgcacc	tggacagcgt	ggacgccgtg	tacgagcgca	ccagcgacca	caagatcgtc	1200
	ttctttaaag	gagacaggta	ctgggtgttc	aaggacaata	acgtagagga	aggataccgc	1260
	cgcgccgtct	ccgacttcag	cctcccgcct	ggcgcatcgc	acgctgcctt	ctcctggggc	1320
55	cacaatgaca	ggactttatt	ctttaaggac	cagctgtact	ggcgctacga	tgaccacacg	1380
	aggcacatgg	accccggcta	ccccgcccag	agccccctgt	ggaggggtgt	ccccagcagc	1440
	ctggacgacg	ccatgcgctg	gtccgacggg	gcctcctact	tcttccgtgg	ccaggagtac	1500
	tggaaagtgc	tggatggcga	gctggaggcg	gacccgggtg	accacagtc	cacggcccg	1560
	gactggctgg	tgtgtggaga	ctcacaggcc	catggatctg	tggctgcggg	cgtggacgcg	1620
60	gcagaggggg	ccgcgcggcc	tccaggacaa	catgaccaga	gccgctcgga	ggacgggttac	1680
	gaggtctgct	catgcacctc	tggggcatcc	tctcccccg	gggccccagg	cccactggtg	1740
	gctgccacca	tgtgtgctgt	gctgccgcca	ctgtcaccag	gcgcctctgt	gacagcgggc	1800

	atgttggggg	cccgccctcag	gctctggggtc	tgtgccttgt	gcagcgtctg	cagcatgagc	60
	gtcctcagag	cctatcccaa	tgccctccca	ctgctcggct	ccagctgggg	tgccctgac	120
	cacctgtaca	cagccacagc	caggaacagc	taccacctgc	agatccacaa	gaatggccat	180
	gtggatggcg	caccccatca	gacctctac	agtgcctga	tgatcagatc	agaggatgct	240
5	ggctttgtgg	tgattacagg	tgtgatgagc	agaagatacc	tctgcatgga	tttcagaggc	300
	aacatttttg	gatcacacta	tttcgacccg	gagaactgca	ggttccaaca	ccagacgctg	360
	gaaaacgggt	acgacgtcta	ccactctcct	cagtatcact	tcctgggtcag	tctggggccg	420
	gcgaagagag	ccttcctgcc	aggcatgaac	ccacccccgt	actcccagtt	cctgtcccgg	480
	aggaacgaga	tcccccta	tcacttcaac	acccccatac	cacggcgcca	cacccggagc	540
10	gccgaggagc	actcggagcg	ggacccccctg	aacgtgctga	agccccgggc	ccggatgacc	600
	ccggcccccg	cctcctgttc	acaggagctc	ccgagcgccg	aggacaacag	cccgatggcc	660
	agtgacccat	taggggtggt	cagggggcgt	cgagtgaaca	cgcacgctgg	gggaacgggc	720
	ccggaaggct	gccgccccct	cgccaagtgc	atctag			756
15	<210> 82						
	<211> 720						
	<212> DNA						
	<213> Homo sapiens						
20	<300>						
	<302> FGF3						
	<310> NM005247						
25	<400> 82						
	atgggcctaa	tctggctgct	actgctcagc	ctgctggagc	ccggtggcc	cgcagcgggc	60
	cctggggcgc	ggttgccggc	cgatgcgggc	ggccgtggcg	gcgtctacga	gcaccttggc	120
	ggggcgcccc	ggcgccgcaa	gctctactgc	gccacgaagt	accacctcca	gctgcacccg	180
	agcgcccgcg	tcaacggcag	cctggagaac	agcgccctaca	gtatttttga	gataacggca	240
30	gtggaggtgg	gcattgtggc	catcaggggt	ctcttctccg	ggcggtacct	ggccatgaac	300
	aagaggggac	gactctatgc	ttcggagcac	tacagcgccg	agtgcgagtt	tgtggagcgg	360
	atccacgagc	tgggctataa	tacgtatgcc	tcccggctgt	accggacggt	gtctagtacg	420
	cctggggccc	gcgggcagcc	cagcgccgag	agactgtggt	acgtgtctgt	gaacggcaag	480
	ggccggcccc	gcaggggctt	caagaccgcg	cgcacacaga	agtcctccct	gttcctgccc	540
35	cgcgtgctgg	accacaggga	ccacgagatg	gtgcggcagc	tacagagtgg	gctgcccaga	600
	ccccctggta	aggggggtcca	gccccgacgg	cggcggcaga	agcagagccc	ggataacctg	660
	gagccctctc	acgttcaggc	ttcgagactg	ggctcccagc	tggaggccag	tgcgccactag	720
40	<210> 83						
	<211> 807						
	<212> DNA						
	<213> Homo sapiens						
45	<300>						
	<302> FGF5						
	<310> NM004464						
50	<400> 83						
	atgagcttgt	ccttcctcct	cctcctcttc	ttcagccacc	tgatcctcag	cgcctgggct	60
	cacggggaga	agcgtctcgc	ccccaaagg	caaccggac	ccgctgccac	tgatagggaac	120
	cctataggct	ccagcagcag	acagagcagc	agtagcgcta	tgtcttcttc	ttctgcctcc	180
	tcctcccccg	cagcttctct	gggcagccaa	ggaagtggct	tggagcagag	cagttttccag	240
	tggagccctc	cggggcgccg	gaccggcagc	ctctactgca	gagtgggcat	cggttttccat	300
55	ctgcagatct	acccggtatg	caaagtcaat	ggatcccacg	aagccaatat	gttaagtgtt	360
	ttggaaatat	ttgctgtgtc	tcaggggatt	gtaggaatac	gaggagtgtt	cagcaacaaa	420
	tttttagcga	tgtcaaaaaa	aggaaaaactc	catgcaagtg	ccaagttcac	agatgactgc	480
	aagttcaggg	agcgttttca	agaaaaatagc	tataatacct	atgcctcagc	aatacataga	540
	actgaaaaaa	cagggcgggg	gtgggtatgtt	gccctgaata	aaagaggaaa	agccaaacga	600
60	gggtgcagcc	cccggtttaa	acccagcat	atctctaccc	atcttcttcc	aagattcaag	660
	cagtcggagc	agccagaact	ttctttcacg	gttactgttc	ctgaaaagaa	aaatccacct	720
	agccctatca	agtcaaagat	tcccttttct	gcacctcgga	aaaataccaa	ctcagtgaag	780

tacagactca agtttcgctt tggataa

807

5 <210> 84
 <211> 649
 <212> DNA
 <213> Homo sapiens

10 <300>
 <302> FGF8
 <310> NM006119

<400> 84
 15 atgggcagcc cccgctccgc gctgagctgc ctgctgttgc acttgctggt cctctgcctc 60
 caagcccagg taactgttca gtcctcacct aattttacac agcatgtgag ggagcagagc 120
 ctgggtgacgg atcagctcag ccgcccgcctc atccggacct accaactcta cagccgcacc 180
 agcgggaagc acgtgcaggt cctggccaac aagcgcacat acgcatggc agaggacggc 240
 gacccttcg caaagctcat cgtggagacg gacaccttg gaagcagagt tcgagtcga 300
 ggagccgaga cgggcctcta catctgcatg aacaagaagg ggaagctgat cgccaagagc 360
 20 aacggcaaag gcaaggactg cgtcttcacg gagattgtgc tggagaacaa ctacacagcg 420
 ctgcagaatg ccaagtacga gggctggtac atggccttca cccgcaaggg ccggccccgc 480
 aagggctcca agacgcggca gcaccagcgt gaggtccact tcatgaagcg gctgccccgg 540
 ggccaccaca ccaccgagca gagcctgcgc ttcgagttcc tcaactacc gcccttcacg 600
 cgcagcctgc gcggcagcca gaggacttgg gcccggaaac cccgatagg 649
 25

<210> 85
 <211> 2466
 <212> DNA
 30 <213> Homo sapiens

<300>
 <302> FGFR2
 <310> NM000141

35 <400> 85
 atggctcagct ggggtcgctt catctgcctg gtcgtggtca ccatggcaac cttgtccctg 60
 gcccgccct ccttcagttt agttgaggat accacattag agccagaaga gccaccaacc 120
 40 aaataccaaa tctctcaacc agaagtgtac gtggctgcgc caggggagtc gctagagggtg 180
 cgctgcctgt tgaagatgc gcctgtgatc agttggacta aggatgggtg gcacttgggg 240
 cccaacaata ggacagtgc tattggggag tacttgacaga taaagggcgc cagcctaga 300
 gactccggcc tctatgcttg tactgccagt aggactgtag acagtgaac ttggtacttc 360
 atggtgaatg tcacagatgc catctcatcc ggagatgatg aggatgacac cgatggtgcg 420
 gaagattttg tcagtgcagaa cagtaacaac aagagagcac catactggac caacacagaa 480
 45 aagatggaaa agcggctcca tgctgtgcct gcggccaaca ctgtcaagtt tcgctgcccc 540
 gccgggggga acccaatgcc aaccatgcgg tggctgaaaa acgggaagga gtttaagcag 600
 gagcatcgca ttggaggcta caaggtacga aaccagcact ggagcctcat tatggaaagt 660
 gtgggtcccat ctgacaaggg aaattatacc tgtgtggtgg agaataata cggtccatc 720
 aatcacacgt accacctgga tgtgtgggag cgatgcctc accggcccat cctccaagcc 780
 50 ggactgccgg caaatgcctc cacagtggtc ggaggagacg tagagtttgt ctgcaagggt 840
 tacagtgatg cccagcccca catccagtgg atcaagcacg tggaaaagaa cggcagtaaa 900
 tacggggccc acgggctgcc ctacctcaag gttctcaagg ccgcccgtgt taacaccacg 960
 gacaaagaga ttgaggttct ctatattcgg aatgtaactt ttgaggacgc tggggaatat 1020
 acgtgcttgg cgggtaattc tattgggata tcctttcact ctgcatggtt gacagttctg 1080
 55 ccagcgcctg gaagagaaaa ggagattaca gcttccccag actacctgga gatagccatt 1140
 tactgcatag ggttcttctt aatcgctgt atggtggtaa cagtcacctt gtgccgaatg 1200
 aagaacacga ccaagaagcc agacttcagc agccagccgg ctgtgcacaa gctgacaaa 1260
 cgtatcccc ctcggagaca ggtaacagt tccgctgagt ccagctcctc catgaaactc 1320
 aacacccgc tggtgaggat aacaacacgc ctctcttcaa cggcagacac ccccatgctg 1380
 60 gcaggggtct ccgagtatga acttcagag gacccaaaat gggagtttcc aagagataag 1440
 ctgacactgg gcaagcccct gggagaaggt tgctttgggc aagtggctcat ggccgaagca 1500
 gtgggaattg acaaagacaa gcccaaggag gcggtcaccg tggccgtgaa gatgttgaaa 1560

gatgatgcca cagagaaaga cctttctgat ctggtgtcag agatggagat gatgaagatg 1620
 attgggaaac acaagaatat cataaatctt ctgggagcct gcacacagga tgggcctctc 1680
 tatgtcatag ttgagtatgc ctctaaaggc aacctccgag aatacctccg agcccgagg 1740
 ccaccgggga tggagtactc ctatgacatt aaccgtgttc ctgaggagca gatgaccttc 1800
 5 aaggacttgg tgtcatgcac ctaccagctg gccagaggca tggagtactt ggcttcccaa 1860
 aaatgtattc atcgagattt agcagccaga aatgttttgg taacagaaaa caatgtgatg 1920
 aaaatagcag actttggact cgccagagat atcaacaata tagactatta caaaaagacc 1980
 accaatgggc ggcttccagt caagtggatg gctccagaag cctgtttga tagagtatac 2040
 actcatcaga gtgatgtctg gtccctcggg gtgttaatgt gggagatctt cactttaggg 2100
 10 ggctcgcctt acccagggat tcccgaggag gaacttttta agctgctgaa ggaaggacac 2160
 agaatggata agccagccaa ctgcaccaac gaactgtaca tgatgatgag ggactgttgg 2220
 catgcagtgc cctccagag accaacgttc aagcagttgg tagaagactt ggatcggaatt 2280
 ctcaactctca caaccaatga ggaatacttg gacctcagcc aacctctcga acagtattca 2340
 cctagttacc ctgacacaag aagttcttgt tcttcaggag atgattctgt tttttctcca 2400
 15 gaccccatgc cttacgaacc atgccttctt cagtatccac acataaacgg cagtgttaaa 2460
 acatga 2466

<210> 86
 20 <211> 2421
 <212> DNA
 <213> Homo sapiens

<300>
 25 <302> FGFR3
 <310> NM000142

<400> 86
 30 atgggcgccc ctgcctgcgc cctcgcgctc tgcgtggcgc tggccatcgt ggccggcgcc 60
 tcctcggagt ccttggggac ggagcagcgc gtcgtggggc gagcggcaga agtcccgggc 120
 ccagagcccg gccagcagga gcagttgggtc ttccggcagcg gggatgctgt ggagctgagc 180
 tgtcccccg cgggggttgg tcccatgggg cccactgtct gggtaagga tggcacaggg 240
 ctggtgcctt cggagcgtgt cctggtgggg cccagcggc tgcaggtgct gaatgcctcc 300
 cagcaggact ccggggccta cagctgcggg cagcggctca cgcagcgcgt actgtgccac 360
 35 ttcaagtgtgc ggttgacaga cgtccatcc tccggagatg acgaagacgg ggaggacgag 420
 gctgaggaca caggtgtgga cacaggggccc ccttactgga cacggcccga gcggatggac 480
 aagaagctgc tggccgtgccc ggccgccaac accgtccgct tccgctgccc agccgctggc 540
 aaccccaact cctccatctc ctggctgaag aacggcaggg agttccgcgg cgaaccggc 600
 attggaggca tcaagctgcg gcacagcagc tggagcctgg tcatggaaag cgtggtgccc 660
 40 tcggaccgcg gcaactacac ctgcgtcgtg gagaacaagt ttggcagcat ccggcagacg 720
 tacacgctgg acgtgctgga gcgctccccg cacgggccc tctgcaggc ggggctgccc 780
 gccaacccga cggcggtgct gggcagcgac gtggagttcc actgcaaggt gtacagtga 840
 gcacagcccc acatccagt gctcaagcac gtggaggtga acggcagcaa ggtgggccc 900
 gacggcacac cctacgttac cgtgctcaag acggcgggcg ctaacaccac cgacaaggag 960
 45 ctgagaggtt tctccttgca caacgtcacc tttgaggacg ccggggagta cacctgcctg 1020
 gcgggcaatt ctattgggtt ttctcatcac tctgcgtggc tgggtggtgt gccagccgag 1080
 gaggagctgg tggaggctga cgaggcgggc agtgtgtatg caggcatcct cagctacggg 1140
 gtgggcttct tctgtttcat cctggtggtg gcggctgtga cgtctgccc cctgcgcagc 1200
 50 cccccaaga aaggcctggg cccccccacc gtgcacaaga tctcccgctt cccgctcaag 1260
 cgacaggtgt ccttgagtc caacgcgtcc atgagctcca acacaccact ggtgcgcac 1320
 gcaaggctgt cctcagggga gggccccacg ctggccaatg tctccgagct cgagctgcct 1380
 gccgacccca aatgggagct gtctcggggc cggctgaccc tgggcaagcc ccttggggag 1440
 ggctgcttcg gccaggtggt catggcggag gccatcgga ttgacaagga ccgggcggc 1500
 aagcctgtca ccgtagccgt gaagatgctg aaagacgatg ccaactgaca ggacctgtcg 1560
 55 gacctggtgt ctgagatgga gatgatgaag atgatcgga aacacaaaaa catcatcaac 1620
 ctgctggggc cctgcacgca gggcggggccc ctgtacgtgc tgggtggagta cgcggccaag 1680
 ggtaacctgc gggagtctt cggggcgcg cgcccccg gcttgacta ctctctcgac 1740
 acctgcaagc cgcggagga gcagctcacc ttcaaggacc tgggtctctg tgcttaccag 1800
 gtggcccggg gcatggagta cttggcctcc cagaagtga tccacaggga cctggctgcc 1860
 60 cgcaatgtgc tggtgaccga ggacaacgtg atgaagatcg cagacttcgg gctggcccgg 1920
 gacgtgcaca acctcgacta ctacaagaag acaaccaacg gccggctgcc cgtgaagtgg 1980
 atggcgccgt aggccttggt tgaccgagtc tacactcacc agagtgcagt ctggctcttt 2040

5	ggggctctgc	tctgggagat	cttcacgctg	gggggctccc	cgtaccccg	cataccctgtg	2100
	gaggagctct	tcaagctgct	gaaggagggc	caccgcctgg	acaagcccg	caactgcaca	2160
	cacgacctgt	acatgatcat	gcgggagtg	tggcatgccg	cgcctccca	gaggccacc	2220
	ttcaagcagc	tgggtggagga	cctggaccgt	gtccttaccg	tgacgtccac	cgacgagtac	2280
	ctggacctgt	cgggcgccttt	cgagcagtac	tccccgggtg	gccaggacac	ccccagctcc	2340
	agctcctcag	gggacgactc	cgtgtttgce	cacgacctgc	tgcccccggc	cccaccagc	2400
	agtgggggct	cgcggacgtg	a				2421
10	<210> 87						
	<211> 2102						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> HGF						
	<310> E08541						
	<400> 87						
20	atgcagaggg	acaaaggaaa	agaagaata	caattcatga	attcaaaaa	tcagcaaa	60
	ctaccctaata	caaaatagat	ccagcactga	agataaaaa	caaaaaagt	aatactgcag	120
	accaatgtgc	taatagatgt	actaggaata	aaggacttcc	attcacttgc	aaggcttttg	180
	tttttgataa	agcaagaaaa	caatgcctct	ggttccctt	caatagcatg	tcaagtggag	240
	tgaaaaaaga	atgttgccat	gaatttgacc	tctatgaaaa	caaagactac	attagaaact	300
25	gcatcattgg	taaaggacgc	agctacaagg	gaacagtatc	tatcactaag	agtggcatca	360
	aatgtcagcc	ctggagttcc	atgataccac	acgaacacag	ctttttgcct	tcgagctatc	420
	ggggtaaaga	cctacaggaa	aactactgtc	gaaatcctcg	aggggaagaa	gggggaccct	480
	ggtgtttcac	aagcaatcca	gaggtacgct	acgaagtctg	tgacatttct	cagtgttcag	540
	aagttgaatg	catgacctgc	aatggggaga	gttatcgagg	tctcatggat	catacagaat	600
30	caggcaagat	ttgtcagcgc	tgggatcatc	agacaccaca	ccggcacaaa	ttcttgcttg	660
	aaagatatcc	cgacaagggc	tttgatgata	attattgcgc	caatcccgat	ggccagccga	720
	ggccatggtg	ctatactctt	gacctcaca	cccgttggga	gtactgtgca	attaaaaact	780
	gcgctgacaa	tactatgaat	gacactgatg	ttcctttgga	aacaactgaa	tgcatccaag	840
	gtcaaggaga	aggctacagg	ggcactgtca	ataccatttg	gaatggaatt	ccatgtcagc	900
35	gttgggatcc	tcagtatcct	cacgagcatg	acatgactcc	tgaaaatttc	aagtgcraag	960
	acctacgaga	aaattactgc	cgaatccag	atgggtctga	atcacccctg	tgttttacca	1020
	ctgatccaaa	catccgagtt	ggctactgct	cccaaatctc	aaactgtgat	atgtcacatg	1080
	gacaagattg	ttatcgtggg	aatggcaaaa	attatatggg	caacttatcc	caaacaagat	1140
	ctggactaac	atgttcaatg	tgggacaaga	acatggaaga	cttacatcgt	catatcttct	1200
40	gggaaccaga	tgcaagtaag	ctgaatgaga	attactgccg	aaatccagat	gatgatgctc	1260
	atggaccctg	gtgtctacag	ggaaatccac	tcattctctg	ggattattgc	cctatttctc	1320
	gttgtgaagg	tgataccaca	cctacaatag	tcaattttaga	ccatcccgta	atatcttgtg	1380
	ccaaaaggaa	acaattgcga	gttgtaaatg	ggattccaac	acgaacaaac	ataggatgga	1440
	tggttagtgt	gagatacaga	aataaacata	tctgcggagg	atcattgata	aaggagagtt	1500
45	gggttcttcc	tgcacgacag	tgtttccctt	ctcgagactt	gaaagattat	gaagcttggc	1560
	ttggaattca	tgtgtccac	ggaagaggag	atgagaaatg	caaacaggtt	ctcaatgttt	1620
	cccagctggt	atatggccct	gaaggatcag	atctggtttt	aatgaagctt	gccaggcctg	1680
	ctgtcctgga	tgattttgtt	agtacgattg	atttacctaa	ttatggatgc	acaattcctg	1740
	aaaagaccag	ttgcagtgtt	tatggctggg	gctacactgg	attgatcaac	tatgatggcc	1800
50	tattacagat	ggcacatctc	tataataatg	gaaatgagaa	atgcagccag	catcatcgag	1860
	ggaaggtgac	tctgaatgag	tctgaatatat	gtgctggggc	tgaaaagatt	ggatcaggac	1920
	catgtgaggg	ggattatggt	ggcccaactg	tttgtgagca	acataaaatg	agaatggttc	1980
	ttggtgtcat	tgttctcgtg	cgtggatgtg	ccattccaaa	tcgtcctggt	atthtttgtcc	2040
	gagtagcata	ttatgcaaaa	tggatacaca	aaattatttt	aacatataag	gtaccacagt	2100
55	ca						2102
	<210> 88						
	<211> 360						
	<212> DNA						
	<213> Homo sapiens						
60							

<300>
 <302> ID3
 <310> XM001539

5 <400> 88
 atgaaggcgc tgagcccggg gcgcgggctgc tacgaggcgg tgtgctgcct gtcggaacgc 60
 agtctggcca tcgcccgggg ccgagggaag ggcccggcag ctgaggagcc gctgagcttg 120
 ctggacgaca tgaaccactg ctactcccgc ctgcgggaac tggtaaccgg agtcccgaga 180
 ggcaactcagc ttagccaggt ggaaatccta cagcgcgtca tcgactacat tctcgacctg 240
 10 caggtagtcc tggccgagcc agcccctgga ccccctgatg gcccacacct tcccatccag 300
 acagccgagc tcactccgga acttgtcatc tccaacgaca aaaggagctt ttgccactga 360

<210> 89
 15 <211> 743
 <212> DNA
 <213> Homo sapiens

<300>
 20 <302> IGF2
 <310> NM000612

<400> 89
 25 atgggaatcc caatggggaa gtcgatgctg gtgcttctca ccttcttggc cttcgctcgc 60
 tgctgcattg ctgcttaccg ccccagtgag accctgtgcg gcggggagct ggtggacacc 120
 ctccagttcg tctgtgggga ccgcggtctc tacttcagca ggcccgcgaag ccgtgtgagc 180
 cgctgcagcc gtggcatcgt tgaggagtgc tgtttccgca gctgtgacct ggccctcctg 240
 gagacgtact gtgctacccc cgccaagtcc gagaggacg tgcgacccc tccgacctg 300
 cttccggaca acttccccag ataccccgct ggcaagtctc tccaatatga cacctggaag 360
 30 cagtccaccc agcgcctgcg caggggcctg cctgcctcc tgcgtgcccg ccgggggtcac 420
 gtgctcgcca aggagctcga ggcggttcagg gaggccaaac gtcaccgtcc cctgattgct 480
 ctaccacccc aagaccccgc ccacgggggc gcccccacag agatggccag caatcggaag 540
 tgagcaaaac tgccgcaagt ctgcagcccg gcgccaccat cctgcagcct cctcctgacc 600
 acggacgttt ccatcaggtt ccatcccga aatctctcgg ttccacgtcc cctgggggct 660
 35 tctcctgacc cagtccccgt gccccgcctc ccgaaacag gctactctcc tcggccccct 720
 ccatcgggct gaggaagcac agc 743

<210> 90
 40 <211> 7476
 <212> DNA
 <213> Homo sapiens

<300>
 45 <302> IGF2R
 <310> NM000876

<400> 90
 50 atggggggccg ccgcccggccg gagccccac ctggggcccg cgcccggccg ccgcccgcag 60
 cgctctctgc tcctgctgca gctgctgctg ctgcctgcctg ccccgggggtc cagcgaggcc 120
 caggccgccc cgttccccga gctgtgcagt tatacatggg aagctgttga taccaaaaat 180
 aatgtacttt ataaaatcaa catctgtgga agtgtggata ttgtccagtg cgggcccata 240
 agtgcgtgtt gtatgcacga cttgaagaca cgcacttata attcagtggtg tgactctgtt 300
 ttgagaagtgc caaccagatc tctcctggaa ttcaacacaa cagtgcagctg tgaccagcaa 360
 55 ggcacaaaatc acagagtcca gagcagcatt gccttcctgt gtgggaaaac cctgggaact 420
 cctgaatttg taactgcaac agaattgtgtg cactactttg agtggaggac cactgcagcc 480
 tgcaagaaag acatatttaa agcaaataag gaggtgccat gctatgtgtt tgatgaagag 540
 ttgaggaagc atgatctcaa tcctctgata gagcttagtg gtgcctactt ggtggatgac 600
 tccgatccgg acatttctct attcatcaat gttttagtag acatagacac actacgagac 660
 60 ccaggttcac agctgcgggc ctgtcccccc ggcaactgccg cctgcctggt aagaggacac 720
 caggcggttg atgttgcca gcccccggac ggactgaagc tgggtgcgcaa ggacaggctt 780
 gtccctgagtt acgtgaggga agaggcagga aagctagact tttgtgatgg tcacagccct 840

	cctgaagttc	togatgattc	cataaatatg	aaacattttg	aatccttcaa	acgtgctgac	1200
	atctatgcaa	tgggcttagt	attctgggaa	attgctcgac	gatgttccat	tggtggaatt	1260
	catggaagatt	accaactgcc	ttattatgat	cttgtaacct	ctgacccatc	agttgaagaa	1320
	atgagaaaag	ttgtttgtga	acagaagtta	aggccaaata	tcccaaacag	atggcagagc	1380
5	tgtgaagcct	tgagagtaat	ggctaaaatt	atgagagaat	gttggtatgc	caatggagca	1440
	gctaggctta	cagcattgcg	gattaagaaa	acattatcgc	aactcagtc	acaggaaggc	1500
	atcaaaatgt	aa					1512
10	<210> 94						
	<211> 4044						
	<212> DNA						
	<213> Homo sapiens						
15	<300>						
	<302> Flk1						
	<310> AF035121						
	<400> 94						
20	atgcagagca	agggtgctgct	ggccgtcgcc	ctgtggctct	gcgtggagac	ccgggcccgc	60
	tctgtgggtt	tgccctagtgt	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggctttggc	ccaataatca	gagtggcagt	gagcaaaagg	tggaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
25	tacaagtgtc	tctaccggga	aactgacttg	gcctcggtca	tttatgtcta	tgttcaagat	360
	tacagatctc	catttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcctgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
30	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagttgt	cgttgtaggg	660
	tataggattt	atgatgtggt	tctgagtcgg	tctcatggaa	ttgaactatc	tgttggagaa	720
	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataaccc	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaaccag	840
	tctgggagtg	agatgaagaa	atttttgagc	accttaacta	tagatgggtg	aacccggagt	900
35	gaccaaggat	tgtacacctg	tgacagcatc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	acctttttgt	gctttttgaa	gtggcatgga	atctctggtg	1020
	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttgggta	cccaccccca	1080
	gaaataaaaat	ggataaaaaa	tgggaataccc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgagtga	agagacacag	gaaattacac	tgatcatcct	1200
40	accaatccca	tttcaaagga	gaagcagagc	catgtgggtc	ctctgggtgt	gtatgtccca	1260
	ccccagattg	gtgagaaatc	tctaattctc	cctgtggatt	cctaccagta	cggcaccact	1320
	caaacgctga	catgtacggg	ctatgccatt	cctcccccgc	atcacatcca	ctggtatttg	1380
	cagttggagg	aagagtgccg	caacgagccc	agcccaagctg	tctcagtgac	aaaccctac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccaggagg	gaaataaaaat	tgaagttaat	1500
45	aaaaatcaat	ttgctcta	tgaaggaaaa	aacaaaactg	taagtaccct	tggtatccaa	1560
	gcggcaaatg	tgtcagcttt	gtacaaatgt	gaagcgggtc	acaaagtcgg	gagaggagag	1620
	agggtgatct	ccttccacgt	gaccaggggt	cctgaaatta	ctttgcaacc	tgacatgcag	1680
	ccactgagc	aggagagcgt	gtcttttggtg	tgcaactgcag	acagatctac	gtttgagaac	1740
	ctcacatggt	acaagcttgg	cccacagcct	ctgccaatcc	atgtggggaga	gttgcccaca	1800
50	cctgttttga	agaacttgga	tactctttgg	aaattgaatg	ccaccatggt	ctctaatagc	1860
	acaaatgaca	ttttgatcat	ggagcttaag	aatgcacctc	tgacaggacca	aggagactat	1920
	gtctgccttg	ctcaagacag	gaagaccaat	aaaagacatt	gcgtgggtcag	gcagctcaca	1980
	gtcctagagc	gtgtggcacc	cacgatcaca	ggaaacctgg	agaatcagac	gacaagattt	2040
	ggggaaagca	tcgaagtctc	atgcacggca	tctgggaatc	cccctccaca	gatcatgtgg	2100
55	tttaaagata	atgagaccct	tgtagaagac	tcaggcattg	tattgaagga	tgggaaccgg	2160
	aacctcacta	tccgcagagt	gaggaaggag	gacgaaggcc	tctacacctg	ccaggcatgc	2220
	agtgttcttg	gctgtgcaaa	agtggaggca	tttttcataa	tagaagggtg	ccaggaaaag	2280
	acgaacttgg	aaatcattat	tctagtaggc	acggcggtga	ttgccatgtt	cttctggcta	2340
	cttcttgtca	tcattcctacg	gaccgttaag	cgggccaatg	gagggggaact	gaagacaggc	2400
60	tacttgtcca	tcgtcatgga	tccagatgaa	ctcccattgg	atgaacattg	tgaacgactg	2460
	ccttatgatg	ccagcaaatg	ggaattcccc	agagaccggc	tgaagctagg	taagcctctt	2520
	ggccgtgggtg	cctttggcca	agtgattgaa	gcagatgcct	ttggaattga	caagacagca	2580

	acttgcagga	cagtagcagt	caaaatggtg	aaagaaggag	caacacacag	tgagcatcga	2640
	gctctcatgt	ctgaactcaa	gatcctcatt	catattgggtc	accatctcaa	tgtgggtcaac	2700
	cttctaggtg	cctgtaccaa	gccaggagg	ccactcatgg	tgattgtgga	attctgcaaa	2760
	tttggaacc	tgtccactta	cctgaggagc	aagagaaatg	aatttgtccc	ctacaagacc	2820
5	aaagggggcac	gattccgtca	agggaaagac	tacgttggag	caatccctgt	ggatctgaaa	2880
	cggcgcttgg	acagcatcac	cagtagccag	agctcagcca	gctctggatt	tgtggaggag	2940
	aagtcctca	gtgatgtaga	agaagaggaa	gctcctgaag	atctgtataa	ggacttccctg	3000
	accttggagc	atctcatctg	ttacagcttc	caagtggcta	agggcatgga	gttcttggca	3060
	tcgcgaaagt	gtatccacag	ggacctggcg	gcacgaaata	tcctcttatac	ggagaagaac	3120
10	gtgggttaaaa	tctgtgactt	tggcttggcc	cgggatattt	ataaagatcc	agattatgtc	3180
	agaaaaggag	atgctcgcct	ccctttgaaa	tggatggccc	cagaaacaat	ttttgacaga	3240
	gtgtacacaa	tccagagtga	cgtctggtct	tttgggtgtt	tgtgtggga	aatattttcc	3300
	ttaggtgctt	ctccatatcc	tgggttaaag	attgatgaag	aattttgtag	gcgattgaaa	3360
	gaaggaacta	gaatgagggc	ccctgattat	actacaccag	aaatgtacca	gaccatgctg	3420
15	gactgctggc	acggggagcc	cagtcagaga	cccacgtttt	cagagttagt	ggaacatttg	3480
	ggaaatctct	tgcagactaa	tgctcagcag	gatggcaaa	actacattgt	tcttccgata	3540
	tcagagactt	tgagcatgga	agaggattct	ggactctctc	tgctacctc	acctgtttcc	3600
	tgtatggagg	aggaggaagt	atgtgacccc	aaattccatt	atgacaacac	agcaggaatc	3660
	agtcagtatc	tcgagaacag	taagcgaaag	agccggcctg	tgagtgtaaa	aacatttgaa	3720
20	gatatcccg	tagaagaacc	agaagtaaaa	gtaatcccag	atgacaacca	gacggacagt	3780
	ggtatgggtc	ttgcctcaga	agagctgaaa	actttggaag	acagaaccaa	attatctcca	3840
	tcttttgggtg	gaatgggtgc	cagcaaaagc	agggagtctg	tggcatctga	aggctcaaac	3900
	cagacaagcg	gctaccagtc	cggatatcac	tccgatgaca	cagacaccac	cgtgtactcc	3960
	agtgaggaag	cagaactttt	aaagctgata	gagattggag	tgcaaaccgg	tagcacagcc	4020
25	cagattctcc	agcctgactc	gggg				4044

<210> 95

<211> 4017

30 <212> DNA

<213> Homo sapiens

<300>

<302> Flt1

35 <310> AF063657

<400> 95

	atgggtcagct	actgggacac	cggggtcctg	ctgtgcgcgc	tgctcagctg	tctgcttctc	60
	acaggatcta	gttcagggtc	aaaattaaaa	gatcctgaac	tgagttttaa	aggcaccag	120
40	cacatcatgc	aagcaggcca	gacactgcat	ctccaatgca	ggggggaagc	agcccataaa	180
	tggtctttgc	ctgaaatggt	gagtaaggaa	agcgaaaggc	tgagcataac	taaatctgcc	240
	tgtggaagaa	atggcaaaac	attctgcagt	actttaacct	tgaacacagc	tcaagcaaac	300
	cacactggct	tctacagctg	caaatatcta	gctgtacctc	cttcaaagaa	gaaggaaaca	360
	gaatctgcaa	tctatatatt	tattagtgat	acaggtagac	ctttcgtaga	gatgtacagt	420
45	gaaatccccg	aaattataca	catgactgaa	ggaaggagc	tcgtcattcc	ctgccgggtt	480
	acgtcaccta	acatcactgt	tactttaaaa	aagtttccac	ttgacacttt	gatccctgat	540
	ggaaaacgca	taatctggga	cagtagaaag	ggcttcatca	tatcaaagtc	aacgtacaaa	600
	gaaatagggc	ttctgacctg	tgaagcaaca	gtcaatgggc	atttgtataa	gacaaactat	660
	ctcacacatc	gacaaaccaa	tacaatcata	gatgtccaaa	taagcacacc	acgcccagtc	720
50	aaattactta	gaggccatac	tcttgtcctc	aatgttactg	ctaccactcc	cttgaacacg	780
	agagttcaaa	tgacctggag	ttaccctgat	gaaaaaaaata	agagagcttc	cgtaaggcga	840
	cgaattgacc	aaagcaattc	ccatgccaac	atatcttaca	gtgttcttac	tattgacaaa	900
	atgcagaaca	aagacaaagg	actttatact	tgctgtgtaa	ggagtggacc	atcattcaaa	960
	tctgttaaca	cctcagtgca	tatatatgat	aaagcattca	tcactgtgaa	acatcgaaaa	1020
55	cagcaggtgc	ttgaaaccgt	agctggcaag	cggctcttacc	ggctctctat	gaaagtgaag	1080
	gcatttccct	cgccggaagt	tgtatgggtt	aaagatgggt	tacctgcgac	tgagaaatct	1140
	gctcgctatt	tgactcgtgg	ctactcgtta	attatcaagg	acgtaactga	agaggatgca	1200
	gggaattata	caatcttgct	gagcataaaa	cagtcaaaatg	tgtttaaaaa	cctcactgcc	1260
	actctaattg	tcaatgtgaa	accccagatt	tacgaaaagg	ccgtgtcatc	gtttccagac	1320
60	ccggctctct	acccactggg	cagcagacaa	atcctgactt	gtaccgcata	tggtatccct	1380
	caacctacaa	tcaagtgggt	ctggcaccct	tgttaaccata	atcattccga	agcaaggtgt	1440
	gacttttgg	ccaataatga	agagtccttt	atcctggatg	ctgacagcaa	catgggaaac	1500

	agaattgaga	gcatcactca	gcgcatggca	ataatagaag	gaaagaataa	gatggctagc	1560
	accttggttg	tggtgactc	tagaatttct	ggaatctaca	tttgcatagc	ttccaataaa	1620
	gttgggactg	tggaagaaa	cataagcttt	tatatcacag	atgtgccaaa	tggttttcat	1680
	gttaacttgg	aaaaaatgcc	gacggaagga	gaggacctga	aactgtcttg	cacagttaac	1740
5	aagttcttat	acagagacgt	tacttggatt	ttactgcgga	cagttaataa	cagaacaatg	1800
	cactacagta	ttagcaagca	aaaaatggcc	atcactaagg	agcactccat	cactcttaat	1860
	cttaccatca	tgaatgtttc	cctgcaagat	tcaggcacct	atgcctgcag	agccaggaat	1920
	gtatacacag	gggaagaaat	cctccagaag	aaagaaatta	caatcagaga	tcaggaagca	1980
	ccataacctc	tgcgaaacct	cagtgatcac	acagtggcca	tcagcagttc	caccacttta	2040
10	gactgtcatg	ctaattggtg	ccccgagcct	cagatcactt	ggtttaaaaa	caaccacaaa	2100
	atacaacaag	agcctggaat	tatttttagga	ccaggaagca	gcacgctggt	tattgaaaga	2160
	gtcacagaag	aggatgaagg	tgtctatcac	tgcaaagcca	ccaaccagaa	gggctctgtg	2220
	gaaagtccag	catacctcac	tgttcaagga	acctcggaca	agtctaattc	ggagctgac	2280
	actctaaccat	gcacctgtgt	ggctgcgact	ctcttctggc	tcctattaac	cctctttatc	2340
15	cgaaaaatga	aaaggtcttc	ttctgaaata	aagactgact	acctatcaat	tataatggac	2400
	ccagatgaag	ttcctttgga	tgagcagtg	gagcggctcc	cttatgatgc	cagcaagtgg	2460
	gagtttgccc	gggagagact	taaactgggc	aaatcacttg	gaagaggggc	ttttggaaaa	2520
	gtggttcaag	catcagcatt	tggcattaa	aaatcaccta	cgtgccggac	tgtggctgtg	2580
	aaaatgctga	aagagggggc	cacggccagc	gagtacaaag	ctctgatgac	tgagctaaaa	2640
20	atcttgaccc	acattggcca	ccatctgaac	gtggttaacc	tgctgggagc	ctgcaccaag	2700
	caaggagggc	ctctgatggg	gattgttgaa	tactgcaaat	atggaaatct	ctccaactac	2760
	ctcaagagca	aacgtgactt	attttttctc	aacaaggatg	cagcactaca	catggagcct	2820
	aagaaagaaa	aaatggagcc	aggcctggaa	caaggcaaga	aaccaagact	agatagcgtc	2880
	accagcagcg	aaagctttgc	gagctccggc	tttcagggaag	ataaaaagtct	gagtgatgtt	2940
25	gaggaagagg	aggattctga	cggtttctac	aaggagccca	tcactatgga	agatctgatt	3000
	tcttacagtt	ttcaagtggc	cagaggcatg	gagttcctgt	cttcagaaa	gtgcattcat	3060
	cgggacctgg	cagcgagaaa	cattctttta	tctgagaaca	acgtggtgaa	gatttgtgat	3120
	tttggccttg	cccgggatat	ttataagaac	cccgattatg	tgagaaaagg	agatactcga	3180
	cttctctga	aatggatggc	tcctgaatct	atctttgaca	aaatctacag	caccaagagc	3240
30	gacgtgtggt	cttacggagt	attgctgtgg	gaaatcttct	ccttaggtgg	gtctccatac	3300
	ccaggagtac	aaatggatga	ggacttttgc	agtcgcctga	gggaaggcat	gaggatgaga	3360
	gtccttgagt	actctactcc	tgaaatctat	cagatcatgc	tggaactgctg	gcacagagac	3420
	caaaaagaaa	ggccaagatt	tgcaagaactt	gtggaaaac	taggtgattt	gcttcaagca	3480
	aatgtacaac	aggatggtaa	agactacatc	ccaatcaatg	ccatactgac	aggaaaatagt	3540
35	gggtttacat	actcaactcc	tgcttctctc	gaggacttct	tcaaggaaag	tatttccagct	3600
	ccgaagttta	attcaggaag	ctctgatgat	gtcagatatg	taaatgcttt	caagttcatg	3660
	agcctggaaa	gaatcaaaac	ctttgaagaa	cttttaccga	atgccacctc	catgtttgat	3720
	gactaccagga	gcgacagcag	cactctgttg	gcctctccca	tgctgaagcg	cttcacctgg	3780
	actgcgagact	aacccaaggc	ctcgctcaag	attgacttga	gagtaaccag	taaaagtaag	3840
40	gagtcggggc	tgtctgatgt	cagcaggccc	agtttctgcc	attccagctg	tgggcacgtc	3900
	agcgaaggca	agcgcaggtt	cacctacgac	cacgctgagc	tggaaggaa	aatcgcgctg	3960
	tgtccccgc	ccccagacta	caactcgggtg	gtcctgtact	ccacccacc	catctag	4017
45	<210> 96						
	<211> 3897						
	<212> DNA						
	<213> Homo sapiens						
50	<300>						
	<302> Flt4						
	<310> XM003852						
	<400> 96						
55	atgcagcggg	gcgcgcgcgt	gtgcctgcga	ctgtggctct	gcctgggact	cctggacggc	60
	ctgggtgagtg	gctactccat	gacccccccg	accttgaaca	tcacggagga	gtcacacgtc	120
	atcgacacccg	gtgacagcct	gtccatctcc	tgacggggac	agcaccacct	cgagtgggct	180
	tgccacaggag	ctcaggaggc	gccagccacc	ggagacaagg	acagcgagga	cacgggggtg	240
	gtgcgagact	gcgagggcac	agacgccagg	ccctactgca	agggtgtgct	gctgcacgag	300
60	gtacatgccca	acgacacagg	cagctacgtc	tgctactaca	agtacatcaa	ggcacgcac	360
	gagggcacca	cggccgccag	ctcctacgtg	tctgtgagag	actttgagca	gccattcatc	420
	aacaagcctg	acacgctctt	ggtcaacagg	aaggacgcca	tgtgggtgcc	ctgtctggtg	480

	tccatccccg	gcctcaatgt	cacgctgcgc	tcgcaaaget	cggtgctgtg	gccagacggg	540
	caggaggtgg	tgtgggatga	ccggcggggc	atgctcgtgt	ccacgccact	gctgcacgat	600
	gccctgtacc	tgcagtgcga	gaccacctgg	ggagaccagg	acttcctttc	caaccccttc	660
	ctggtgcaca	tcacaggcaa	cgagctctat	gacatccagc	tgttgcccag	gaagtgcgtg	720
5	gagctgctgg	taggggagaa	gctgggtcctg	aactgcaccg	tgtgggctga	gtttaactca	780
	ggtgtcacct	ttgactggga	ctaccocaggg	aagcaggcag	agcggggtaa	gtgggtgccc	840
	gagcgacgct	cccagcagac	ccacacagaa	ctctccagca	tcctgaccat	ccacaacgtc	900
	agccagcacg	acctgggctc	gtatgtgtgc	aaggccaaca	acggcatcca	gcgatttcgg	960
	gagagcacgg	aggtcattgt	gcatgaaaat	cccttcacat	gcgtcgagt	gctcaaagga	1020
10	cccacctctg	aggccacggc	aggagacgag	ctgggtgaagc	tgcccgtgaa	gctggcagcg	1080
	taccccccg	ccgagttcca	gtgggtacaag	gatggaaagg	cactgtccgg	gcgccacagt	1140
	ccacatgccc	tgggtgctcaa	ggaggtgaca	gaggccagca	caggcaccta	caccctcgcc	1200
	ctgtggaact	ccgctgctgg	cctgaggcgc	aacatcagcc	tggagctggg	ggtgaattgt	1260
	ccccccagaa	tacatgagaa	ggaggcctcc	tccccagca	tctactcgcg	tcacagccgc	1320
15	caggccctca	cctgcacggc	ctacgggggtg	cccctgcctc	tcagcatcca	gtggcactgg	1380
	cggccctgga	caccctgcaa	gatgtttgcc	cagcgtagtc	tcggcgcgcg	gcagcagcaa	1440
	gacctcatgc	cacagtgcgc	tgactggagg	gcggtgaccg	cgcaggatgc	cgtgaacccc	1500
	atcgagagcc	tggacacctg	gaccgagttt	gtggagggaa	agaataagac	tgtgagcaag	1560
	ctgggtgatcc	agaatgccaa	cggtgtctgc	atgtacaagt	gtgtggtctc	caacaagggtg	1620
20	ggccaggatg	agcggctcat	ctacttctat	gtgaccacca	tccccgacgg	cttcaccatc	1680
	gaatccaagc	catccgagga	gctactagag	ggccagccgg	tgctcctgag	ctgccaaagcc	1740
	gacagctaca	agtacgagca	tctgcgctgg	taccgcctca	acctgtccac	gctgcacgat	1800
	gcgcacggga	accgccttct	gctcgactgc	aagaacgtgc	atctgttcgc	caccctctg	1860
	gcccgcagcc	tggaggagggt	ggcacctggg	gcgcgccacg	ccacgctcag	cctgagtatc	1920
25	ccccgcgtcg	cgcccagca	cgagggccac	tatgtgtgcg	aagtgcgaaga	ccggcgccagc	1980
	catgacaagc	actgccacaa	gaagtacctg	tcggtgcagg	ccctggaagc	ccctcggtctc	2040
	acgcagaact	tgaccgacct	cctggtgaac	gtgagcgact	cgctggagat	gcagtgcctg	2100
	gtggccggag	cgcacgcgcc	cagcatcgtg	tggtaaaaag	acgagaggct	gctggaggaa	2160
	aagtctggag	tgcacttgcc	ggactccaac	cagaagctga	gcatccagcg	cgtgcgcgag	2220
30	gaggatgcgg	gacgctatct	gtgcagcgtg	tgcacgcca	agggctgcgt	caactcctcc	2280
	gccagcgtgg	ccgtggaagg	ctccgaggat	aagggcagca	tggagatcgt	gatccttgtc	2340
	ggtaccggcg	tcactcgtgt	cttcttcttg	gtcctcctcc	tcctcatctt	ctgtaacatg	2400
	aggaggccgg	cccacgcaga	catcaagacg	ggctacctgt	ccatcatcat	ggaccccggg	2460
	gaggtgcctc	tggaggagca	atgcgaatac	ctgtcctacg	atgccagcca	gtgggaattc	2520
35	ccccgagagc	ggctgcacct	ggggagagt	ctcggctacg	gcgccttcgg	gaagggtggg	2580
	gaagcctccg	ctttcggcat	ccacaagggc	agcagctgtg	acaccgtggc	cgtgaaaatg	2640
	ctgaaagagg	gcgccacggc	cagcgagcag	cgcgcgctga	tgtcggagct	caagatcctc	2700
	attcacatcg	gcaaccacct	caacgtggtc	aacctcctcg	gggcgtgcac	caagcccgag	2760
	ggccccctca	tgggtgatcgt	ggagttctgc	aagtacggca	acctctccaa	cttcctgcgc	2820
40	gccaagcggg	acgccttcag	cccctgcgcg	gagaagtctc	ccgagcagcg	cggacgcttc	2880
	cgcgccatgg	tggagctcgc	caggctggat	cggaggcggc	cggggagcag	cgacaggggtc	2940
	ctcttcgcgc	ggttctcgaa	gaccgagggc	ggagcgagge	gggcttctcc	agaccaagaa	3000
	cgtgaggacc	tgtggctgag	cccgtgacc	atggaagatc	ttgtctgcta	cagcttcag	3060
	gtggccagag	ggatggagtt	cctggcttcc	cgaaagtgc	tccacagaga	cctggctgct	3120
45	cggaacattc	tgtgtcggga	aagcgacgtg	gtgaagatct	gtgactttgg	ccttgcccgg	3180
	gacatctaca	aagaccccca	ctacgtccgc	aagggcagtg	cccggctgcc	cctgaagtgg	3240
	atggccccctg	aaagcatctt	cgacaagggtg	tacaccacgc	agagtgcagt	gtggctcctt	3300
	ggggtgcttc	tctgggagat	cttctctctg	ggggcctccc	cgtaccctgg	ggtgcagatc	3360
	aatgaggagt	tctgccagcg	gctgagagac	gggcacaagga	tgagggcccc	ggagctggcc	3420
50	actcccgcca	tacgcgcgat	catgctgaac	tgttgggtccg	gagaccccaa	ggcgagacct	3480
	gcattctcgg	agctgggtgga	gatcctgggg	gacctgctcc	agggcagggg	cctgcaagag	3540
	gaagaggagg	tctgcatggc	cccgcgcagc	tctcagagct	cagaagaggg	cagcttctcg	3600
	cagggtgtcca	ccatggccct	acacatgcgc	cagctgcagc	ctgaggacag	cccgcgcagc	3660
	ctgcagcgcc	acagcctggc	cgccaggtat	tacaactggg	tgtcctttcc	cggggtgcctg	3720
55	gccagagggg	ctgagacccg	tggttcctcc	aggatgaaga	catttgagga	attcccccag	3780
	accccaacga	cctacaaagg	ctctgtggac	aaccagacag	acagtgggat	ggtgctggcc	3840
	tcggaggaggt	ttgagcagat	agagagcagg	catagacaag	aaagcggcct	caggtag	3897

60 <210> 97
 <211> 4071
 <212> DNA

<213> Homo sapiens

<300>

<302> KDR

5 <310> AF063658

<400> 97

	atggagagca	agggtgctgct	ggccgctgcgc	ctgtggctct	gcgtggagac	ccgggccgcgc	60
	tctgtgggtt	tgccatagtg	ttctcttgat	ctgcccaggc	tcagcataca	aaaagacata	120
10	cttacaatta	aggctaatac	aactcttcaa	attacttgca	ggggacagag	ggacttggac	180
	tggttttggc	ccaataatca	gagtggcagt	gagcaaaggg	tgaggtgac	tgagtgcagc	240
	gatggcctct	tctgtaagac	actcacaatt	ccaaaagtga	tcggaaatga	cactggagcc	300
	tacaagtgtc	tctaccggga	aactgacttg	gcctcgggtca	tttatgtcta	tggtcaagat	360
	tacagatctc	cattttattgc	ttctgttagt	gaccaacatg	gagtcgtgta	cattactgag	420
15	aacaaaaaca	aaactgtggt	gattccatgt	ctcgggtcca	tttcaaactc	caacgtgtca	480
	ctttgtgcaa	gatacccaga	aaagagattt	gttcttgatg	gtaacagaat	ttcctgggac	540
	agcaagaagg	gctttactat	tcccagctac	atgatcagct	atgctggcat	ggtcttctgt	600
	gaagcaaaaa	ttaatgatga	aagttaccag	tctattatgt	acatagttgt	cggtgtaggg	660
	tataggatttt	atgatgtggt	tctgagtcgg	tctcatggaa	ttgaactatc	tggtggagaa	720
20	aagcttgtct	taaattgtac	agcaagaact	gaactaaatg	tggggattga	cttcaactgg	780
	gaataccctt	cttcgaagca	tcagcataag	aaacttgtaa	accgagacct	aaaaaccag	840
	tctgggagtg	agatgaagaa	atttttgagc	accttaacta	tagatggtgt	aacccggagt	900
	gaccaaggat	tgtacacctg	tgcagcatcc	agtgggctga	tgaccaagaa	gaacagcaca	960
	tttgtcaggg	tccatgaaaa	accttttggt	gcttttgtaa	gtggcatgga	atctctggtg	1020
25	gaagccacgg	tgggggagcg	tgtcagaatc	cctgcgaagt	accttggtta	cccaccccc	1080
	gaaataaaat	ggtataaaaa	tggaaatccc	cttgagtcca	atcacacaat	taaagcgggg	1140
	catgtactga	cgattatgga	agtgaagtga	agagacacag	gaaattacac	tgatcatcct	1200
	accaatcccc	tttcaaagga	gaagcagagc	catgtggtct	ctctggttgt	gtatgtccca	1260
	cccagatgtg	gtcgagaatc	tctaactctc	cctgtggatt	cctaccagta	cggcaccact	1320
30	caaacgctga	catgtacggt	ctatgccatt	cctccccgc	atcacatcca	ctggtatttg	1380
	cagttggagg	aagagtgcgc	caacgagccc	agccaagctg	tctcagtgac	aaaccatac	1440
	ccttgtgaag	aatggagaag	tgtggaggac	ttccagggag	gaaataaaat	tgaagttaat	1500
	aaaaatcaat	tgtctcta	tgaaggaaaa	aacaaaactg	taagtaccct	tggtatccaa	1560
	gcggcaaatg	tgtcagcttt	gtacaaatgt	gaagcgggtca	acaaagtcgg	gagaggagag	1620
35	agggtgatct	ccttccacgt	gaccaggggt	cctgaaatta	ctttgcaacc	tgacatgcag	1680
	cccactgagc	aggagagcgt	gtctttgtgg	tgactgcag	acagatctac	gtttgagaac	1740
	ctcacattgt	acaagcttgg	cccacagcct	ctgccaatcc	atgtgggaga	gttggccaca	1800
	cctgtttgca	agaacttgga	tactctttgg	aaattgaatg	ccaccatgtt	ctctaatagc	1860
	acaaattgaca	ttttgatcat	ggagcttaag	aatgcaccc	tgaggagcca	aggagactat	1920
40	gtctgccttg	ctcaagacag	gaagaccaag	aaaagacatt	gcgtgggtcag	gcagctcaca	1980
	gtcctagagc	gtgtggcacc	cacgatcaca	ggaaacctgg	agaatcagac	gacaagtatt	2040
	ggggaaagca	tcgaagtctc	atgcacggca	tctgggaatc	cccctccaca	gatcatgtgg	2100
	tttaaagata	atgagaccct	tgtagaagac	tcaggcattg	tattgaagga	tgggaaaccg	2160
	aacctcacta	tccgcagagt	gaggaaggag	gacgaaggcc	tctacacctg	ccaggcatgc	2220
45	agtgttcttg	gctgtgcaaa	agtggaggca	tttttcataa	tagaagggtgc	ccaggaaaa	2280
	acgaacttgg	aaatcattat	tctagtaggc	acggcgggtg	ttgccatgtt	cttctggcta	2340
	cttcttgtca	tcatcctacg	gaccgttaag	cgggccaatg	gaggggaact	gaagacaggc	2400
	tacttgtcca	tcgtcatgga	tccagatgaa	ctcccattgg	atgaacattg	tgaacgactg	2460
	ccttatgatg	ccagcaaatg	ggaattcccc	agagaccggc	tgaagctagg	taagcctctt	2520
50	ggccgtggtg	cctttggcca	agtgattgaa	gcagatgcct	ttggaattga	caagacagca	2580
	acttgagga	cagtagcagt	caaaatgttg	aaagaaggag	caacacacag	tgagcatcga	2640
	gctctcatgt	ctgaactcaa	gatcctcatt	catattgggt	accatctcaa	tggtgtcaac	2700
	cttctagggt	cctgtaccaa	gccaggaggg	ccactcatgg	tgattgtgga	attctgcaaa	2760
	tttggaaaacc	tgtccactta	cctgaggagc	acagaaaatg	aatttgtccc	ctacaagacc	2820
55	aaagggggcac	gattccgtca	agggaaagac	tacgttgagg	caatccctgt	ggatctgaaa	2880
	cggcgcttgg	acagcatcac	cagtagccag	agctcagcca	gctctggatt	tgtggaggag	2940
	aagtccctca	gtgatgtaga	agaagaggaa	gctcctgaag	atctgtataa	ggacttcctg	3000
	accttggagc	atctcatctg	ttacagcttc	caagtggtca	agggcatgga	gttcttggca	3060
	tcgcgaaaagt	gtatccacag	ggacctggcg	gcacgaaata	tcctcttatc	ggagaagaa	3120
60	gtgggttaaaa	tctgtgactt	tggttggccc	cgggatattt	ataaagatcc	agattatgtc	3180
	agaaaaggag	atgctcgcct	ccctttgaaa	tggatggccc	cagaaacaat	ttttgacaga	3240
	gtgtacacaa	tccagagtga	cgtctggtct	tttggtgttt	tgctgtggga	aatattttcc	3300

5 tttgatgatg atgaaacctg gacaagtagt tccaaaggct acaacttgtt tcttgttgct 660
gcgcatgagt tcggccactc cttaggtctt gaccactcca aggacctgg agcactcatg 720
tttcctatct acacctacac cggcaaaagc cactttatgc ttctgatga cgaagtacaa 780
gggatccagt ctctctatgg tccaggagat gaagacccca accctaaaca tccaaaaacg 840
ccagacaaat gtgaccttc cttatccctt gatgccatta ccagtctccg aggagaaaca 900
atgatcttta aagacagatt cttctggcgc ctgcatcctc agcagggtga tgcggagctg 960
tttttaacga aatcattttg gccagaactt cccaaccgta ttgatgctgc atatgagcac 1020
ccttctcatg acctcatctt catcttcaga ggtagaaaat tttgggctct taatggttat 1080
gacattctgg aaggttatcc caaaaaata tctgaactgg gtcttccaaa agaagttaag 1140
10 aagataagtg cagctgttca ctttgaggat acaggcaaga ctctcctgtt ctgaggaaac 1200
caggtctgga gatatgatga tactaaccat attatggata aagactatcc gagactaata 1260
gaagaagact tcccaggaat tgggtataaa gtagatgctg tctatgagaa aaatggttat 1320
atctattttt tcaacggacc catacagttt gaatacagca tctggagtaa ccgtattgtt 1380
cgcgctcatgc cagcaaatcc cattttgtgg tgttaa 1416
15

<210> 103
<211> 1749
<212> DNA
20 <213> Homo sapiens

<300>
<302> MMP14
<310> NM004995
25

<400> 103
atgtctcccg ccccaagacc ccccgcttgt ctctgctcc ccttgtctac gctcggcacc 60
gcgctcgctt ccctcggttc ggcccaaagc agcagcttca gcccgaagc ctggctacag 120
caatatggct acctgcctcc cggggaccta cgtacccaca cacagcgctc accccagtca 180
30 ctctcagcgg ccctcgctgc catgcagaag ttttacggct tgcaagtaac aggcaaagct 240
gatgcagaca ccatgaaggc catgaggcgc ccccgatgtg gtgttccaga caagtttggg 300
gctgagatca aggccaatgt tcgaaggaag cgctacgcca tccagggtct caaatggcaa 360
cataatgaaa tcactttctg catccagaat tacaccccca aggtgggcga gtatgccaca 420
tacgaggcca ttcgcaaggc gttccgcgtg tgggagagtg ccacaccact gcgcttccgc 480
35 gaggtgacct atgcctacat ccgtgagggc catgagaagc aggcgcacat catgatcttc 540
tttgcgagg gcttccatgg cgacagcacg cccttcgatg gtgagggcgg ctctcctggc 600
catgcctact tcccaggccc caacattgga ggagacaccc actttgactc tgccgagcct 660
tggactgtca ggaatgagga tctgaatgga aatgacatct tcttgggtggc tgtgcacgag 720
ctggggccatg ccctggggct cgagcattcc agtgaccctt cggccatcat ggcaccttt 780
40 taccagtgga tggacacgga gaattttgtg ctgcccgatg atgaccgccg gggcatccag 840
caactttatg ggggtgagtc agggttcccc accaagatgc cccctcaacc caggactacc 900
tcccggcctt ctgttctctga taaacccaaa aacccacact atgggcccga catctgtgac 960
gggaactttg acaccgtggc catgctccga ggggagatgt ttgtcttcaa ggagcgctgg 1020
45 ttctggcggg tgaggaataa ccaagtgatg gatggatacc caatgcccac tggccagttc 1080
tggcggggcc tgctgcgtc catcaacact gctacgaga ggaaggatgg caaattcgtc 1140
ttcttcaaaag gagacaagca ttgggtgttt gatgaggcgt ccctggaaac tggctacccc 1200
aagcacatta aggagctggg ccgagggctg cctaccgaca agattgatgc tgctctcttc 1260
tggatgccca atggaaagac ctacttcttc cgtggaaaca agtactaccg ttccaacgaa 1320
gagctcaggg cagtggatag cgagtacccc aagaacatca aagtctggga agggatccct 1380
50 gagtctccca gaggtcatt catgggcagc gatgaagtct tcaattactt ctacaagggg 1440
aacaataact ggaattcaa caaccagaag ctgaaggtag aaccgggcta cccaagtca 1500
gcctgaggg actggatggg ctgcccacgc ggaggccggc cggatgaggg gactgaggag 1560
gagacggagg tgatcatcat tgagggtggac agggagggcg gcggggcggt gagcgcggt 1620
gccgtggtgc tgcccgtgct gctgctgctc ctgggtgctg cggtgggcct tgcagcttc 1680
55 ttcttcagac gccatgggac cccagggcga ctgctctact gccagcgttc cctgctggac 1740
aaggtctga 1749

<210> 104
60 <211> 2010
<212> DNA
<213> Homo sapiens

<300>
 <302> MMP15
 <310> NM002428

<400> 104
 atgggagcgc acccgagcgc gcccgagcgc ccgggctgga cgggagcct cctcggcgac 60
 cgggaggagg cggcgcgcc gcgactgctg ccgctgctcc tgggtgcttct gggtgacctg 120
 ggccttgagg tagcggccga agacgcggag gtccatgccg agaactggct gcggctttat 180
 ggctacctgc ctcagcccag ccgccatag tccaccatgc gttccgcca gatcttgcc 240
 tcggcccttg cagagatgca gcgcttctac gggatccccg tcaccgggtgt gctcgacgaa 300
 gagaccaagg agtggatgaa gccggcccg tgtggggtgc cagaccagtt cggggtacga 360
 gtgaaagcca acctgcggcg gcgtcggaag cgctacgccc tcaccgggag gaagtggaaac 420
 aaccaccatc tgacctttag catccagaac tacacggaga agttgggctg gtaccactcg 480
 atggaggcgt tgcgagggcg cttccgcgtg tgggagcagg ccacgccccct ggtcttccag 540
 gaggtgcctt atgaggacat ccgggtgcgg cgacagaagg aggcgacat catgggtactc 600
 tttgcctctg gcttccacgg ccgcttgatg gcaccgggtgg ctttctggcc 660
 cagcctatt tccctggccc cggcctaggc ggggacaccc attttgacgc agatgagccc 720
 tggaccttct ccagcactga cctgcatgga aacaacctct tcttggtggc agtgcattgag 780
 ctggggccacg cgctggggct ggagcactcc agcaaccca atgccatcat ggcccggttc 840
 taccagtgga aggacgttga caacttcaag ctgcccagg acgatctccg tggcatccag 900
 cagctctacg gtacccccga cggtcagcca cagcctacc agcctctccc cactgtgacg 960
 ccacggcggc caggccggcc tgaccaccgg ccgcccggc ctcaccagcc accaccccca 1020
 ggtgggaagg cagagcggcc cccaaagccg ggccccccag tccagccccg agccacagag 1080
 cggcccgacc agtatggccc caacatctgc gacggggact ttgacacagt ggcatgctt 1140
 cgcggggaga tgttctgtt caaggccgc tggttctggc gagtccggca caaccgcgtc 1200
 ctggacaact atccccgct catcgggcac ttctggcggt gtctgcccg tgacatcagt 1260
 gctgcctacg agcgccaaga cggctgtttt gtctttttca aaggtagccg ctactggctc 1320
 tttcgagaag cgaacctgga gcccggtac ccacagccgc tgaccagcta tggcctgggc 1380
 atccccatg accgcattga cagggccatc tgggtgggag ccacaggcca caccttcttc 1440
 ttccaagagg acaggtactg gcgcttcaac gaggagacac agcgtggaga ccctgggtac 1500
 cccaagccca tcagtgtctg gcaggggatc cctgcctccc ctaaaggggc ctctctgagc 1560
 aatgacgcag cctacaccta cttctacaag ggcaccaaact actggaaatt cgacaatgag 1620
 cgcctgcgga tggagcccg ctacccaag tccatcctgc gggacttcat gggctgccag 1680
 gagcacgtgg agccaggccc ccgatggccc gacgtggccc ggccgcccct caacccccac 1740
 ggggggtgcag agcccggggc ggacagcgca gaggggcagc tgggggatgg ggaatgggac 1800
 tttggggccg gggtaacaa ggacgggggc agccgcgtgg tgggtcagat tggagggtg 1860
 gcacggacgg tgaacgtggt gatggtgctg gtgccactgc tgctgctgct ctgcgtctg 1920
 ggcctcacct acgcgctggt gcagatgcag cgcaagggtg cgccacgtgt cctgctttac 1980
 tgcaagcgct cgctgcagga gtgggtctga 2010

<210> 105
 <211> 1824
 <212> DNA
 <213> Homo sapiens

<300>
 <302> MMP16
 <310> NM005941

<400> 105
 atgatcttac tcacattcag cactggaaga cggttggatt tctgcatca ttcgggggtg 60
 tttttcttgc aaaccttgct ttggatttta tgtgctacag tctgcggaac ggagcagtat 120
 ttcaatgtg aggttttggtt acaaaagtac ggctaccttc caccgactga cccagaaatg 180
 tcagtctgc gcttcgcaga gacctgcag agtgagcaga actggatgaa gaagccccga 240
 ggcattaaac tgacagggaaa aagaggtagc tccaaatttc atattcgtcg aaagcgatat 360
 tgcggtgtac ctgaccagac aagaggtagc tccaaatttc atattcgtcg aaagcgatat 360
 gcattgacag gacagaaatg gcagcacaag cacatcactt acagtataaa gaacgtaact 420
 ccaaaagtga gagaccctga gactcgtaaa gctattcgcc gtgcctttga tgtgtggcag 480
 aatgtaactc ctctgacatt tgaagaagtt cctacagtg aattagaaaa tggcaaacgt 540
 gatgtggata taaccattat ttttgcattc ggtttccatg gggacagctc tccctttgat 600

```

5  ggagagggag gatttttggc acatgcctac ttccctggac caggaattgg aggagatacc 660
   cattttgact cagatgagcc atggacacta ggaaatccta atcatgatgg aaatgactta 720
   tttcttgtag cagtccatga actgggacat gctctgggat tggagcattc caatgacccc 780
   actgccatca tggctccatt ttaccagtac atggaaacag acaacttcaa actacctaata 840
   gatgatattac agggcatcca gaaaatatat ggtccacctg acaagattcc tccacctaca 900
   agacctctac cgacagtgcc cccacaccgc tctattcctc cggctgaccc aagggaaaaat 960
   gacaggccaa aacctcctcg gccccaacc ggcagacctt cctatcccgg agccaaaccc 1020
   aacatctgtg atgggaactt taacactcta gctattcttc gtcgtgagat gtttgttttc 1080
   aaggaccagt ggttttggcg agtgagaaac aacaggggtg tggatggata cccaatgcaa 1140
10  attacttact tctggcgggg cttgcctcct agtatcgatg cagtttatga aaatagcgac 1200
   gggaattttg tgttctttta agtaacaaa tattgggtgt tcaaggatac aactcttcaa 1260
   cctggttacc ctcatgactt gataaccctt ggaagtggaa ttccccctca tgggtattgat 1320
   tcagccattt ggtgggagga cgtcgggaaa acctatttct tcaagggaga cagatattgg 1380
   agatatagtg aagaaatgaa aacaatggac cctggctatc ccaagccaat cacagtctgg 1440
15  aaagggatcc ctgaatctcc tcagggagca tttgtacaca aagaaaatgg ctttacgtat 1500
   ttctacaaag gaaaggagta ttggaaatcc aacaaccaga tactcaaggt agaacctgga 1560
   catccaagat ccatcctcaa ggattttatg ggtgtgatg gaccaacaga cagagttaaa 1620
   gaaggacaca gccaccaga tgatgtagac attgtcatca aactggacaa cacagccagc 1680
   actgtgaaag ccatagctat tgtcattccc tgcattctgg ccttatgcct ccttgatttg 1740
20  gtttacactg tgtccagtt caagaggaaa ggaacacccc gccacatact gtactgtaaa 1800
   cgctctatgc aagagtgggt gtga 1824

```

```

25  <210> 106
     <211> 1560
     <212> DNA
     <213> Homo sapiens

```

```

30  <300>
     <302> MMP17
     <310> NM004141

```

```

35  <400> 106
   atgcagcagt ttggtggcct ggaggccacc ggcacacttg acgaggccac cctggccctg 60
   atgaaaaccc cagctgctc cctgccagac ctccctgtcc tgaccaggcc tcgcaggaga 120
   cgccaggctc cagccccac caagtggaaac aagaggaaac tgcctgtggg ggtccggacg 180
   ttcccacggg actcaccact ggggcacgac acggtgcgtg cactcatgta ctacgccctc 240
   aaggtctgga gcgacattgc gccctgaac ttccacgagg tggcgggcag caccgcgac 300
   atccagatcg acttctccaa ggccgacctt aacgacggct accccttcga cggccccggc 360
   ggcaccgtgg ccacgcctt cttcccggc caccaccaca ccgcccggga caccacttt 420
   gacgatgacg aggcctggac cttccgctcc tcggatgccc acgggatgga cctgtttgca 480
   gtggctgtcc acgagtttgg ccacgccatt ggttaagcc atgtggccgc tgcacactcc 540
   atcatgcggc cgtactacca gggccgggtg ggtgacccgc tgcgctacgg gctcccctac 600
   gaggacaagg tgcgctctg gcagctgtac ggtgtgctgg agtctgtgtc tcccacggcg 660
   cagcccagg agcctccctt gctgccggag ccccagaca accggtccag cgccccgcc 720
   aggaaggacg tgccccacag atgcagcact cactttgacg cgggtggccc gatccggggt 780
   gaagctttct tcttcaaagg caagtacttc tggcggctga cgccggaccg gcacctggtg 840
   tcctgcagc cggcacagat gcaccgcttc tggcggggcc tgcgctgca cctggacagc 900
   gtggacgccc tgtacgagcg caccagcgac cacaagatcg tcttctttaa aggagacagg 960
50  tactgggtgt tcaaggacaa taacgtagag gaaggatacc cgcgccccgt ctccgacttc 1020
   agcctcccgc ctggcggcat cgacgctgcc tctcctctgg cccacaatga caggacttat 1080
   ttctttaagg accagctgta ctggcgctac gatgaccaca cgaggcacat ggaccccgcc 1140
   taccocgcc agagccccct gtggagggtg gtccccagca cgctggacga cgccatgcgc 1200
   tggccgacg gtgcctccta cttcttccgt ggccaggagt actggaaagt gctggatggc 1260
55  gagctggagg tggcaccggg gtaccacag tccacggccc gggactggct ggtgtgtgga 1320
   gactcacagg ccgatggatc tgtggctgcg ggcgtggacg cggcagaggg gcccccgcgc 1380
   cctccaggac aacatgacca gagccgctcg gaggacggtt acgaggtctg ctcatgcacc 1440
   tctggggcat cctcctccc aggggccccca ggccactgg tggctgccac catgctgctg 1500
60  ctgctgccgc cactgtcacc aggcgccttg tggacagcgg cccaggccct gacgctatga 1560

```

```

<210> 107

```


<211> 1983
<212> DNA
<213> Homo sapiens

5 <300>
<302> MMP2
<310> NM004530

<400> 107
10 atggaggcgc taatggcccg gggcgcgctc acgggtcccc tgagggcgct ctgtctcctg 60
ggctgcctgc tgagccacgc cgccgcgcgc cgcgcgcccc tcatcaagtt ccccggcgat 120
gtcgcgccca aaacggacaa agagttggca gtgcaatacc tgaacacctt ctatggctgc 180
cccaaggaga gctgcaacct gttgtgctg aaggacacac taaagaagat gcagaagttc 240
tttggactgc cccagacagg tgatcttgac cagaatacca tcgagaccat gcggaagcca 300
15 cgctgcggca acccagatgt ggccaactac aacttcttcc ctgcgaagcc caagtgggac 360
aagaaccaga tcacatacag gatcattggc tacacacctg atctggaccc agagacagtg 420
gatgatgcct ttgctcgtgc cttccaagtc tggagcgatg tgacccact gcggttttct 480
cgaatccatg atggagaggc agacatcatg atcaactttg gccgctggga gcatggcgat 540
ggataccctt ttgacggtaa ggacggactc ctggctcatg ccttcgcccc aggcactggt 600
20 gttgggggag actcccattt tgatgacgat gagctatgga ccttgggaga aggccaagtg 660
gtccgtgtga agtatggcaa cgccgatggg gactactgca agtccccctt ctgtttcaat 720
ggcaaggagt acaacagctg cactgatact ggccgcagcg atggcttctt ctgggtgctc 780
accacctaca actttgagaa ggatggcaag tacggcttct gtccccatga agccctgttc 840
accatgggcg gcaacgctga aggacagccc tgcaagtttc cattccgctt ccagggcaca 900
25 tcctatgaca gctgcaccac tgagggccgc acggatggct accgctggtg cggcaccact 960
gaggactacg accgcgacaa gaagtatggc ttctgccttg agaccgccat gtccactggt 1020
ggtgggaact cagaaggctg ccctgtgttc ttcccttca ctttctctgg caacaaatat 1080
gagagctgca ccagcgccgg ccgcagtgc ggaagatgt ggtgtgcgac cacagccaac 1140
tacgatgacg accgcaagtg gggcttctgc cctgaccaag ggtacagcct gttcctctgt 1200
30 gcagcccacg agtttgccca cgccatgggg ctggagcact cccaagaccc tggggccctg 1260
atggcaccca ttacacctc caccaagaac ttccgtctgt cccaggatga catcaagggc 1320
attcaggagc tctatggggc ctctcctgac attgaccttg gcaccggccc cccccccaca 1380
ctgggccctg tcactcctga gatctgcaaa caggacattg tatttgatgg catcgctcag 1440
atccgtgggt agatcttctt cttcaaggac cggttcattt ggcggactgt gacgccacgt 1500
35 gacaagccca tggggccctt gctggtggcc acattctggc ctgagctccc ggaaaagatt 1560
gatgcggtat acgaggcccc acaggaggag aaggctgtgt tctttgcagg gaatgaatac 1620
tggatctact cagccagcac cctggagcga gggtaaccca agccactgac cagcctggga 1680
ctgccccctg atgtccagcg agtggatgcc gcctttaact ggagcaaaaa caagaagaca 1740
tacatctttg ctggagacaa attctggaga tacaatgagg tgaagaagaa aatggatcct 1800
40 ggctttccca agctcatgc agatgcctgg aatgccatcc ccgataacct ggatgccgtc 1860
gtggacctgc agggcggcgg tcacagctac ttcttcaagg gtgcctatta cctgaagctg 1920
gagaacaaaa gtctgaagag cgtgaagttt ggaagcatca aatccgactg gctaggctgc 1980
tga 1983

45 <210> 108
<211> 1434
<212> DNA
<213> Homo sapiens

50 <300>
<302> MMP2
<310> XM006271

55 <300>
<302> MMP3
<310> XM006271

<400> 108
60 atgaagagtc ttccaatcct actgttgctg tgcgtggcag tttgctcagc ctatccattg 60
gatggagctg caagggtgta ggacaccagc atgaaccttg ttcagaaaata tctagaaaac 120
tactacgacc tcgaaaaaga tgtgaaacag tttgttagga gaaaggacag tggctcctgt 180

<213> Homo sapiens

<300>

<302> PKC eta

5 <310> NM006255

<400> 114

atgtcgtctg gcaccatgaa gttcaatggc tatttgaggg tccgcacg tggaggcagt 60
gggctgcagc ccacccgctg gtccctgcgc cactcgctct tcaagaaggg ccaccagctg 120
10 ctggacccct atctgacggg gagcgtggac cagggtgcgc tgggccagac cagcaccaag 180
cagaagacca acaaacccac gtacaacgag gagttttgcg ctaacgtcac cgacggcggc 240
cacctcgagt tggcgtctt ccacgagacc cccctgggct acgacttcgt ggccaactgc 300
accctgcagt tccaggagct cgtcggcagc accggcgcc cggacacctt cgagggttgg 360
gtggatctcg agccagaggg gaaagtattt gtgtaataa cccttaccgg gaggttcact 420
15 gaagctactc tccagagaga ccggatcttc aaacatttta ccaggaagcg ccaaagggct 480
atgcgaaggc gaggccacca gatcaatgga cacaagttca tggccacgta tctgaggcag 540
cccacctact gctctcactg caggaggttt atctggggag tgtttgggaa acagggttat 600
cagtgccaaag tgtgcacctg tgcgtccat aaacgctgcc atcatctaata tgttacagcc 660
tgtacttgcc aaaaacaatat taacaaagtg gattcaaaga ttgcagaaca gaggttcggg 720
20 atcaacatcc cacacaagtt cagcatccac aactacaaag tgccaacatt ctgcgatcac 780
tgtggctcac tgctctgggg aataatgcga caaggacttc agtgtaaaat atgtaaaatg 840
aatgtgcata ttcgatgtca agcgaacgtg gcccttaact gtggggtaaa tgcgggtggaa 900
cttgccaaga ccttggcagg gatgggtctc caacccgaa atatttctcc aacctcgaaa 960
ctcgtttcca gatcgacct aagacgacag ggaaaggaga gcagcaaaga aggaaatggg 1020
25 attgggggta attcttccaa ccgacttggg atcgacaact ttgagttcat ccgagtgttg 1080
gggaaggggg gttttgggaa ggtgatgctt gcaagagtaa aagaaacagg agacctctat 1140
gctgtgaagg tgctgaagaa ggacgtgatt ctgctgggat atgatgtgga atgcaccatg 1200
accgagaaaa ggtcctctgc tctggcccg aatcacccct tcctcactca gttgttctgc 1260
tgctttcaga ccccgatcg tctgtttttt gtgatggagt ttgtgaatgg gggtagcttg 1320
30 atgttccaca ttcagaagtc tctcgtttt gatgaagcac gagctcgctt ctatgctgca 1380
gaaatcattt cggctctcat gttcctccat gataaaggaa tcacttatag agatctgaaa 1440
ctggacaatg tctgttgga ccacgagggg cactgtaaac tggcagactt cggaatgtgc 1500
aaggagggga tttgcaatgg tgcaccacg gccacattct gtggcacgcc agactatata 1560
gtccagaga tcctccagga aatgctgtac gggcctgcag tagactggtg ggcaatgggc 1620
35 gtgttgctct atgagatgct ctgtggtcac gcgccttttg aggcagagaa tgaagatgac 1680
ctctttgagg ccatactgaa tgatgaggtg gtctacccta cctggctcca tgaagatgcc 1740
acagggatcc taaaatcttt catgaccaag aacccacca tgcgcttggg cagcctgact 1800
cagggaggcg agcacgccat cttgagacat ccttttttta aggaaatcga ctggggccag 1860
ctgaaccatc gccaaataga accgcctttc agaccagaa tcaaataccg agaagatgtc 1920
40 agtaattttg accctgactt cataaaggaa gagccagttt taactccaat tgatgagggg 1980
catcttccaa tgattaacca ggatgagttt agaaactttt cctatgtgtc tccagaattg 2040
caaccatag 2049

45 <210> 115

<211> 948

<212> DNA

<213> Homo sapiens

50 <300>

<302> PKC epsilon

<310> XM002370

<400> 115

atgttggcag aactcaaggg caaagatgaa gtatatgctg tgaaggtctt aaagaaggac 60
gtcatccttc aggatgatga cgtggactgc acaatgacag agaagaggat tttggctctg 120
gcacggaaac acccgtacct tacccaactc tactgctgct tccagaccaa ggaccgcctc 180
tttttctgca tggaaatagt aaatgggtgga gacctcatgt ttcagattca gcgctcccga 240
aaattcgacg agcctcgttc acggttctat gctgcagagg tcacatcggc cctcatgttc 300
60 ctccaccagc atggagtcat ctacagggat ttgaaactgg acaacatcct tctggatgca 360
gaaggtoact gcaagctggc tgacttcggg atgtgcaagg aagggttctt gaatgggtgtg 420
acgaccacca cgttctgtgg gactcctgac tacatagctc ctgagatcct gcaggagtgtg 480

gagtatggcc cctccgtgga ctggtggggc ctgggggtgc tgatgtacga gatgatggct 540
 ggacagcctc cctttgaggg cgacaatgag gacgacctat ttgagtccat cctccatgac 600
 gacgtgctgt acccagtcctg gctcagcaag gaggtctgca gcatcttgaa agctttcatg 660
 5 acgaagaatc cccacaagcg cctgggctgt gtggcatcgc agaattggcg ggacgccatc 720
 aagcagcacc cattcttcaa agagattgac tgggtgctcc tggagcagaa gaagatcaag 780
 ccacccttca aaccacgcat taaaaccaa agagacgtca ataattttga ccaagacttt 840
 acccgggaag agccggtact cacccttggt gacgaagcaa ttgtaaagca gatcaaccag 900
 gaggaattca aagggtttctc ctactttggt gaagacctga tgccctga 948

10 <210> 116
 <211> 1764
 <212> DNA
 <213> Homo sapiens

15 <300>
 <302> PKC iota
 <310> NM002740

20 <400> 116
 atgtcccaca cggtcgcagg cggcggcagc ggggaccatt cccaccaggt ccgggtgaaa 60
 gcctactacc gcggggatat catgataaca cattttgaac cttccatctc ctttgagggc 120
 ctttgcaatg aggttcgaga catgtgttct tttgacaacg aacagctctt caccatgaaa 180
 25 tggatagatg aggaaggaga cccgtgtaca gtatcatctc agttggagtt agaagaagcc 240
 tttagacttt atgagctaaa caaggattct gaactcttga ttcattgtgtt cccttggtga 300
 ccagaacgtc ctgggatgcc ttgtccagga gaagataaat ccatctaccg tagaggtgca 360
 cgccgctgga gaaagcttta ttgtgccaat ggccacactt tccaagccaa gcgtttcaac 420
 aggcgtgctc actgtgccat ctgcacagac cgaatatggg gacttggacg ccaaggatat 480
 aagtgcacat actgcaaaact cttggttcat aagaagtgcc ataaactcgt cacaattgaa 540
 30 tgtggggggc attctttgcc acaggaacca gtgatgccca tggatcagtc atccatgcat 600
 tctgaccatg cacagacagt aattccatat aatccttcaa gtcatgagag tttggatcaa 660
 gttggtgaag aaaaagaggg aatgaacacc agggaaagtg gcaaagcttc atccagtcta 720
 ggtcttcagg attttgattt gctccgggta ataggaagag gaagtatatc caaagtactg 780
 35 ttggttcgat taaaaaaaac agatcgatatt tatgcaatga aagttgtgaa aaaagagctt 840
 gttaaatgatg atgaggatat tgattgggta cagacagaga agcatgtgtt tgagcaggca 900
 tccaatcatc ctttccttgt tgggctgcat tcttgctttc agacagaaag cagattgttc 960
 tttgttatag agtatgtaaa tggaggagac ctaatgtttc atatgcagcg acaaagaaaa 1020
 cttcctgaag aacatgccag attttactct gcagaaatca gtctagcatt aaattatctt 1080
 40 catgagcagag ggataattta tagagatttg aaactggaca atgtattact ggactctgaa 1140
 ggccacatta aactcactga ctacggcatg tgtaagggaag gattacggcc aggagataca 1200
 accagcactt tctgtggtac tcctaattac attgctcctg aaatttttaag aggagaagat 1260
 tatggtttca gtgttgactg gtgggctcct ggagtgtcga tgtttgagat gatggcagga 1320
 aggtctccat ttgatattgt tgggagctcc gataaccctg accagaacac agaggattat 1380
 45 ctcttccaag ttattttgga aaaacaaatt cgcataccac gttctctgtc tgtaaaagct 1440
 gcaagtgttc tgaagagttt tcttaataag gaccctaagg aacgattggg ttgtcatcct 1500
 caaacaggat ttgctgatat tcagggacac ccgttcttcc gaaatgttga ttgggatatg 1560
 atggagcaaaa aacagggtgtt acctcccttt aaaccaaata tttctgggga atttgggttg 1620
 gacaactttg attctcagtt tactaatgaa cctgtccagc tcaactccaga tgacgatgac 1680
 50 attgtgagga agattgatca gtctgaattt gaaggttttg agtatatcaa tcctcttttg 1740
 atgtctgcag aagaatgtgt ctga 1764

55 <210> 117
 <211> 2451
 <212> DNA
 <213> Homo sapiens

60 <300>
 <302> PKC mu
 <310> XM007234

<400> 117

5 atgtatgata agatcctgct ttttcgccat gaccctacct ctgaaaacat ccttcagctg 60
 gtgaaagcgg ccagtgatat ccaggaaggc gatccttattg aagtggctctt gtcagcttcc 120
 gccacctttg aagactttca gattcgtccc cagctctctt ttgttcattc atacagagct 180
 ccagctttct gtgatcactg tggagaaatg ctgtgggggc tggtagctca aggtctttaa 240
 tgtgaagggt gtggtctgaa ttaccataag agatgtgcat ttaaaatacc caacaattgc 300
 agcgggtgtga ggcggagaag gctctcaaac gtttccctca ctgggggtcag caccatccgc 360
 acatcatctg ctgaactctc tacaagtgcc cctgatgagc cccttctgca aaaatcacca 420
 tcagagtcgt ttattggctg agagaagagg tcaaattctc aatcatacat tggacgacca 480
 attcaccttg acaagatttt gatgtctaaa gttaaagtgc cgcacacatt tgtcatccac 540
 10 tcctacaccc ggcccacagt gtgccagtac tgcaagaagc ttctgaaggg gcttttcagg 600
 cagggcttgc agtgcaaga ttgcagattc aactgccata aacgttgtgc accgaaagta 660
 ccaaacaact gccttggcga agtgaccatt aatggagatt tgcttagccc tggggcagag 720
 tctgatgtgg tcatggaaga agggagtgtat gacaatgata gtgaaaggaa cagtgggctc 780
 atggatgata tggaaagaagc aatgggtccaa gatgcagaga tggcaatggc agagtggcag 840
 15 aacgacagtg gcgagatgca agatccagac ccagaccagc aggcagccaa cagaaccatc 900
 agtccatcaa caagcaacaa tatcccactc atgagggtag tgcagtctgt caaacacacg 960
 aagaggaaaa gcagcacagt catgaaagaa ggatggatgg tccactacac cagcaaggac 1020
 acgctgcgga aacggcacta ttggagattg gatagcaaat gtattaccct ctttcagaat 1080
 gacacaggaa ccaggtacta caaggaaatt cctttatctg aaattttgtc tctggaacca 1140
 20 gtaaaaactt cagctttaat tcctaattggg gccaatcctc attgtttcga aatcactacg 1200
 gcaaatgtag tgtattatgt gggagaaaat gtggtcaatc cttccagccc atcaccaaat 1260
 aacagtgttc tcaccagtgg cgttgggtgca gatgtggcca ggatgtggga gatagccatc 1320
 cagcatgccc ttatgcccgt cattcccaag ggctcctcgc tgggtacagg aaccaacttg 1380
 cacagagata tctctgtgag tatttcagta tcaaattgcc agattcaaga aaatgtggac 1440
 25 atcagcacag tatatcagat ttttctgat gaagtactgg gttctggaca gtttggaaat 1500
 gtttatggag gaaaacatcg taaaacagga agagatgtag ctattaaaat cattgacaaa 1560
 ttacgatttc caacaaaaca agaaagccag cttcgtaatg aggttgcaat tctacagaac 1620
 cttcatcacc ctggtgttgt aaatttggag tgtatgtttg agacgcctga aagagtgttt 1680
 gttgttatgg aaaaactcca tggagacatg ctggaaatga tcttgtcaag tgaaaagggc 1740
 30 aggttggccag agcacataac gaagttttta attactcaga tactcgtggc tttgcggcac 1800
 cttcatttta aaaatatcgt tcactgtgac ctcaaaccag aaaatgtgtt gctagcctca 1860
 gctgatcctt ttctcaggt gaaactttgt gattttgggt ttgcccggat cattggagag 1920
 aagtctttcc ggaggtcagt ggtgggtacc ccgcttacc tggctcctga ggtcctaagg 1980
 aacaagggct acaatcgctc tctagacatg tggctgtgtg ggtcatcat ctatgtaaag 2040
 35 ctaagcggca cattcccatt taatgaagat gaagacatac acgaccaaat tcagaatgca 2100
 gctttcatgt atccaccaaa tccctggaag gaaatatctc atgaagccat tgatcttatc 2160
 aacaatttgc tgcaagtaaa aatgagaaag cgctacagtg tggataagac cttgagccac 2220
 ccttggtcac agactatca gacctgtgta gatttgcgag agctggaatg caaaatcggg 2280
 gagcgtcaca taccatga aagtgtgac ctgaggtggg agaagtatgc aggcgagcag 2340
 40 gggctgcagt accccacaca cctgatcaat ccaagtgtca gccacagtga cactcctgag 2400
 actgaagaaa cagaaatgaa agccctcggt gagcgtgtca gcacccatg a 2451

45 <210> 118
 <211> 2673
 <212> DNA
 <213> Homo sapiens

50 <300>
 <302> PKC nu
 <310> NM005813

55 <400> 118
 atgtctgcaa ataattcccc tccatcagcc cagaagtctg tattaccac agctattcct 60
 gctgtgcttc cagctgcttc tccgtgttca agtcctaaga cgggactctc tgcccgactc 120
 tctaattggaa gcttcagtgc accatcactc accaactcca gaggtcagc gcatacagtt 180
 tcattttctac tgcaaatggg cctcacacgg gagagtgtta ccattgaagc ccaggaactg 240
 tctttatctg ctgtcaagga tcttgtgtgc tccatagttt atcaaaagt tccagagtgt 300
 ggattctttg gcattgtatga caaaattcct ccttttgcgc atgacatgaa ctcagaaaac 360
 60 attttgcagc tgattacctc agcagatgaa atacatgaag gagacctagt ggaagtgggt 420
 ctttcagctt tagccacagt agaagacttc cagattcgtc cacatactct ctatgtacat 480
 tcttacaaag ctctacttt ctgtgattac tgtgtgaga tgctgtgggg attggtacgt 540

	caaggactga	aatgtgaagg	ctgtggatta	aattaccata	aacgatgtgc	cttcaagatt	600
	ccaaataact	gtagtggagt	aagaaagaga	cgtctgtcaa	atgtatcttt	accaggaccc	660
	ggcctctcag	ttccaagacc	cctacagcct	gaatatgtag	cccttcccag	tgaagagtca	720
	catgtccacc	aggaaccaag	taagagaatt	ccttcttgga	gtggctgccc	aatctggatg	780
5	gaaaagatgg	taatgtgcag	agtgaaggtt	ccacacacat	ttgctgttca	ctcttacacc	840
	cgtcccacga	tatgtcagta	ctgcaagcgg	ttactgaaag	gcctctttcg	ccaaggaatg	900
	cagtgtaaag	attgcaaatt	caactgccat	aaacgctgtg	catcaaaaagt	accaagagac	960
	tgccttgagg	aggttacttt	caatggagaa	ccttccagtc	tgggaacaga	tacagatata	1020
	ccaatggata	ttgacaataa	tgacataaat	agtgatagta	gtcgggggtt	ggatgacaca	1080
10	gaagagccat	cacccccaga	agataagatg	ttcttcttgg	atccatctga	tctcgatgtg	1140
	gaaagagatg	aagaagccgt	taaaacaatc	agtcctatcaa	caagcaataa	tattccgcga	1200
	atgaggggtg	tacaatccat	caagcacaca	aagaggaaga	gcagcacaat	ggtgaaggaa	1260
	gggtggatgg	tccattacac	cagcagggat	aaactgagaa	agaggcatta	ttgggagactt	1320
	gacagcaaat	gtctaacatt	atttcagaat	gaatctggat	caaagtatta	taaggaaatt	1380
15	ccactttcag	aaattctccg	catatcttca	ccacgagatt	tcacaaacat	ttcacaaggc	1440
	agcaatccac	actgttttga	aatcattact	gatactatgg	tatacttcgt	tggtgagaac	1500
	aatggggaca	gctctcataa	tcctgttctt	gctgccactg	gagttggact	tgatgtagca	1560
	cagagctggg	aaaaagcaat	tcgccaagcc	ctcatgcctg	ttactcctca	agcaagtgtt	1620
	tgcacttctc	cagggcaagg	gaaagatcac	aaagatttgt	ctacaagtat	ctctgtatct	1680
20	aattgtcaga	ttcaggagaa	tgtggatatc	agtactgttt	accagatctt	tgcagatgag	1740
	gtgcttggtt	caggccagtt	tggcatcggt	tatggaggaa	aacatagaaa	gactgggagg	1800
	gatgtggcta	ttaaagtaat	tgataagatg	agattcccca	caaaacaaga	aagtcaactc	1860
	cgtaatgaag	tggctatttt	acagaatttg	caccatcctg	ggattgtaaa	cctggaatgt	1920
	atgtttgaaa	cccagaacg	agtctttgta	gtaatggaaa	agctgcatgg	agatatgttg	1980
25	gaaatgattc	tatccagtga	gaaaagtcgg	cttcagaaac	gaattactaa	attcatggtc	2040
	acacagatac	ttgttgcttt	gaggaatctg	catttttaaga	atattgtgca	ctgtgattta	2100
	aagccagaaa	atgtgctgct	tgcatacaga	gagccatttc	ctcaggtgaa	gctgtgtgac	2160
	tttggaattg	cacgcatcat	tggtgaaaag	tcattcagga	gatctgtggt	aggaactcca	2220
	gcatacttag	cccctgaagt	tctccggagc	aaagggttaca	accgttccct	agatatgtgg	2280
30	tcagtgggag	ttatcatcta	tgtgagcctc	agtggcacat	ttccttttaa	tgaggatgaa	2340
	gatataaatg	accaaatacca	aaatgctgca	tttatgtacc	caccaaatcc	atggagagaa	2400
	atttctgggtg	aagcaattga	tctgataaac	aatctgcttc	aagtgaagat	gagaaaaacgt	2460
	tacagtgttg	acaaatctct	tagtcatccc	tggctacagg	actatcagac	ttggcttgac	2520
	cttagagaat	ttgaaactcg	cattggagaa	cgttacatta	cacatgaaag	tgatgatgct	2580
35	cgctgggaaa	tacatgcata	cacacataac	cttgtatacc	caaagcactt	cattatggct	2640
	cctaataccag	atgatatgga	agaagatcct	taa			2673
40	<210> 119						
	<211> 2121						
	<212> DNA						
	<213> Homo sapiens						
45	<300>						
	<302> PKC tau						
	<310> NM006257						
	<400> 119						
50	atgtcgccat	ttcttcggat	tggcttgtcc	aactttgact	gcgggtcctg	ccagtcttgt	60
	cagggcgagg	ctgttaaccc	ttactgtgct	gtgctcgta	aagagtatgt	cgaatcagag	120
	aacgggcaga	tgtatatcca	gaaaaagcct	accatgtacc	caccctggga	cagcactttt	180
	gatgcccata	tcaacaaggg	aagagtcatg	cagatcattg	tgaaggcaaa	aaacgtggac	240
	ctcatctctg	aaaccacgt	ggagctctac	tcgctggctg	agaggtgcag	gaagaacaa	300
	gggaagacag	aaatatgggt	agagctgaaa	cctcaaggcc	gaatgcta	gaatgcaaga	360
55	tactttctgg	aaatgagtga	cacaaaggac	atgaatgaat	ttgagacgga	aggcttcttt	420
	gctttgcata	agcgccgggg	tgccatcaag	caggcaagg	tccaccacgt	caagtgccac	480
	gagttcactg	ccaccttctt	cccacagccc	acattttgct	ctgtctgcca	cgagtttgtc	540
	tggggcctga	acaaacaggg	ctaccagtgc	cgacaatgca	atgcagcaat	tcacaagaag	600
	tgtattgata	aagttatagc	aaagtgcaca	ggatcagcta	tcaatagccg	agaaaccatg	660
60	ttccacaagg	agagattcaa	aattgacatg	ccacacagat	ttaaagtcta	caattacaag	720
	agcccagcct	tctgtgaaca	ctgtgggacc	ctgctgtggg	gactggcacg	gcaaggactc	780
	aagtgtgatg	catgtggcat	gaatgtgcat	catagatgcc	agacaaaggt	ggccaacctt	840

	tgtggcataa	accagaagct	aatggctgaa	gcgctggcca	tgattgagag	caactcaacag	900
	gctcgctgct	taagagatac	tgaacagatc	ttcagagaag	gtccgggttga	aattgggtctc	960
	ccatgctcca	tcaaaaatga	agcaaggccg	ccatgtttac	cgacaccggg	aaaaagagag	1020
	cctcagggca	tttcctggga	gtctccgttg	gatgaggtgg	ataaaatgtg	ccatcttcca	1080
5	gaacctgaac	tgaacaaaga	aagaccatct	ctgcagatta	aactaaaaat	tgaggatttt	1140
	atcttgacac	aaatgttggg	gaaaggaagt	tttggcaagg	tcttcctggc	agaattcaag	1200
	aaaaccaatc	aatttttctg	aataaaggcc	ttaaagaaag	atgtgggtctt	gatggacgat	1260
	gatgttgagt	gcacgatggt	agagaagaga	gttctttcct	tggcctggga	gcatccggtt	1320
	ctgacgcaca	tgttttgtag	attccagacc	aaggaaaacc	tcttttttgt	gatggagtac	1380
10	ctcaacggag	gggacttaat	gtaccacatc	caaagctgcc	acaagttcga	cctttccaga	1440
	gcgacgtttt	atgctgctga	aatcattctt	ggtctgcagt	tccttcattc	caaaggaata	1500
	gtctacaggg	acctgaagct	agataacatc	ctgttagaca	aagatggaca	tatcaagatc	1560
	gcggattttg	gaatgtgcaa	ggagaacatg	ttaggagatg	ccaagacgaa	taccttctgt	1620
	gggacacctg	actacatcgc	cccagagatc	ttgctgggtc	agaaatacaa	ccactctgtg	1680
15	gactgggtggt	ccttcggggg	tctcctttat	gaaatgctga	ttggtcagtc	gcctttccac	1740
	gggcaggatg	aggaggagct	cttccactcc	atccgcattg	acaatccctt	ttaccacagg	1800
	tggctggaga	aggaagcaaa	ggaccttctg	gtgaagctct	tcgtgcgaga	acctgagaag	1860
	aggctgggag	tgaggggaga	catccgccag	caccctttgt	ttcgggagat	caactgggag	1920
	gaacttgaac	ggaaggagat	tgaccacagg	ttcgggccga	aagtgaatac	accatttgac	1980
20	tgacagcaat	tcgacaaaga	attcttaaac	gagaagcccc	ggctgtcatt	tgccgacaga	2040
	gcactgatca	acagcatgga	ccagaatatg	ttcaggaact	tttcccttcat	gaacccccgg	2100
	atggagcggc	tgatatcctg	a				2121
25	<210> 120						
	<211> 1779						
	<212> DNA						
	<213> Homo sapiens						
30	<300>						
	<302> PKC zeta						
	<310> NM2744						
	<400> 120						
35	atgcccagca	ggaccgaccc	caagatggaa	gggagcggcg	gccgcgtccg	cctcaaggcg	60
	cattacgggg	gggacatctt	catcaccagc	gtggacgccc	ccacgacctt	cgaggagctc	120
	tgtgaggaag	tgagagacat	gtgtcgtctg	caccagcagc	acccgctcac	cctcaagtgg	180
	ttggacagcg	aaggtgaccc	ttgcacgggt	tcctcccaga	tgagagctga	agaggctttc	240
	cgctcgccc	gtcagtgacg	ggatgaaggc	ctcatcattc	atgttttccc	gagcacccct	300
40	gagcagcctg	gcctgccatg	tccgggagaa	gacaaatcta	tctaccgccg	gggagccaga	360
	agatggagga	agctgtaccg	tgccaacggc	cacctcttcc	aagccaagcg	ctttaacagg	420
	agagcgtact	gcggtcagtg	cagcgagagg	atatggggcc	tcgcgaggga	aggctacagg	480
	tgcatacaat	gcaaaactgt	ggtccataag	cgctgccacg	gcctcgtccc	gctgacctgc	540
	aggaagcata	tggattctgt	catgccttcc	caagagcctc	cagtagacga	caagaacgag	600
45	gacgccgacc	ttccttccga	ggagacagat	ggaattgctt	acatttcttc	atccccgaag	660
	catgacagca	ttaaagacga	ctcggaggac	cttaagccag	ttatcgatgg	gatggatgga	720
	atcaaaaatct	ctcaggggct	tgggtgagcg	gactttgacc	taatcagagt	catcgggcgc	780
	gggagctacg	ccaaggttct	cctgggtgag	ttgaagaaga	atgaccaaat	ttacgccatg	840
	aaagtgggtga	agaaagagct	ggtgcatgat	gacgaggata	ttgactgggt	acagacagag	900
50	aagcacgtgt	ttgagcaggc	atccagcaac	cccttctctg	tcggattaca	ctcctgcttc	960
	cagacgacaa	gtcgggtgtt	cctgggtcatt	gagtacgtca	acggcgggga	cctgatgttc	1020
	cacatgcaga	ggcagaggaa	gctccctgag	gagcacgcca	ggtttctacg	ggccgagatc	1080
	tgcatacgcc	tcaacttctc	gcacgagagg	gggatcatct	acagggacct	gaagctggac	1140
	aacgtctctc	tggatgcgga	cgggcacatc	aagctcacag	actacggcat	gtgcaaggaa	1200
55	ggcctggggc	ctggtgacac	aacgagcact	ttctgcggaa	ccccgaatta	catcgcccc	1260
	gaaatcctgc	ggggagagga	gtacgggttc	agcgtggact	ggtgggcgct	gggagtcctc	1320
	atgtttgaga	tgatggccgg	gcgctccccg	ttcgacatca	tcaccgacaa	cccgagacatg	1380
	aacacagcag	actacctttt	ccaagtgtat	ctggagaagc	ccatccggat	ccccgggttc	1440
	ctgtccgtca	aagcctccca	tgttttaaaa	ggatttttaa	ataaggacct	caaagagagg	1500
60	ctcggctgcc	ggccacagac	tggattttct	gacatcaagt	cccacgcgtt	cttccgcagc	1560
	atagactggg	acttgctgga	gaagaagcag	gcgctccctc	cattccagcc	acagatcaca	1620
	gacgactacg	gtctggacaa	ctttgacaca	cagttcacca	gcgagcccg	gcagctgacc	1680

```

    atggaccggg agatggcagc atcgtgcgga ggcgcgggtt tcgtaggtct gatactcttg 60
    acctgtgcac cgcactataa gctgttcctc gctagggtca tatggtgggt acaatatttt 120
    atcaccaggg ccgaggcaca cttgcaagtg tggatcccc ccctcaacgt tcgggggggc 180
    cgcgatgccg tcatacctcct cacgtgcgcg atccaccag agctaattctt taccatcacc 240
5   aaaatcttgc tcgccatact cggtcactc atggtgctcc aggctgggtat aaccaaagtg 300
    ccgtacttcg tcgcgcgaca cgggctcatt cgtgcatgca tgctgggtgcg gaagggtgct 360
    gggggtcatt atgtccaaat ggctctcatg aagttggccg cactgacagg tacgtacgtt 420
    tatgaccatc tcacccact gcgggactgg gccacgcgg gcctacgaga ccttgcggtg 480
    gcagttgagc ccgtcgtctt ctctgatatg gagaccaagg ttatcacctg gggggcagac 540
10  accgcggcgt gtggggacat catcttgggc ctgcccgtct ccgccgcag ggggaggag 600
    atacatctgg gaccggcaga cagccttgaa gggcaggggt ggcgactcct c 651

    <210> 129
15  <211> 161
    <212> DNA
    <213> Hepatitis C virus

    <300>
20  <302> NS4A
    <310> AJ238799

    <400> 129
25  gcacctgggt gctggtaggc ggagtcctag cagctctggc cgcgatttgc ctgacaacag 60
    gcagcgtggg cattgtgggc aggatcatct tgtccggaaa gccggccatc attcccgaca 120
    gggaaagtcct ttaccgggag ttcgatgaga tggaagagtg c 161

    <210> 130
30  <211> 783
    <212> DNA
    <213> Hepatitis C virus

    <300>
35  <302> NS4B
    <310> AJ238799

    <400> 130
40  gcctcacacc tcccttacat cgaacaggga atgcagctcg ccgaacaatt caaacagaag 60
    gcaatcgggt tgctgcaaac agccaccaag caagcggagg ctgctgctcc cgtgggtggaa 120
    tccaagtggc ggaccctcga agccttcttg gcgaagcata tgtggaattt catcagcggg 180
    atacaatatt tagcaggctt gtccactctg cctggcaacc ccgcgatagc atcactgatg 240
    gcattcacag cctctatcac cagcccgtc accacccaac ataccctcct gtttaacatc 300
    ctgggggggat ggggtggcgc ccaacttgct cctcccagcg ctgcttctgc tttcgtaggc 360
45  gccggcatcg ctggagcggc tgttggcagc ataggccttg ggaagggtgct tgtggatatt 420
    ttggcagggt atggagcagg ggtggcaggc gcgctcgtgg cctttaaggt catgagcggc 480
    gagatgccct ccaccgagga cctgggtaac ctactccctg ctatcctctc ccctggcgcc 540
    ctagtcgtcg gggtcgtgtg cgcagcgata ctgcgtcggc acgtgggcc aggggagggg 600
    gctgtgcagt ggatgaaccg gctgatagcg ttcgcttcgc ggggtaacca cgtctcccc 660
50  acgcactatg tgcttgagag cgacgctgca gcacgtgtca ctcagatcct ctctagtctt 720
    accatcactc agctgctgaa gaggcttcac cagtggatca acgaggactg ctccacgcca 780
    tgc 783

    <210> 131
55  <211> 1341
    <212> DNA
    <213> Hepatitis C virus

    <300>
60  <302> NS5A
    <310> AJ238799

```


<400> 131
 tccggctcgt ggctaagaga tgtttgggat tggatatgca cgggtgttgac tgatttcaag 60
 acctgggctcc agtccaagct cctgccgcga ttgccgggag tcccccttctt ctcatgtcaa 120
 5 cgtgggtaca agggagtctg gcggggcgac ggcacatgc aaaccacctg cccatgtgga 180
 gcacagatca ccggacatgt gaaaaacggt tccatgagga tcgtggggcc taggacctgt 240
 agtaacacgt ggcattggaac attccccatt aacgcgtaca ccacgggccc ctgcacgccc 300
 tccccggcgc caaattattc tagggcgctg tggcgggtgg ctgctgagga gtacgtggag 360
 gttacgcggg tgggggattt ccactacgtg acgggcatga ccactgacaa cgtaaagtgc 420
 10 ccgtgtcagg ttccggcccc cgaattcttc acagaagtgg atggggtgcg gttgcacagg 480
 tacgtccag cgtgcaaacc cctcctacgg gaggaggtca cattcctggt cgggctcaat 540
 caatacctgg ttgggtcaca gctcccatgc gagcccgaa cggacgtagc agtgctcact 600
 tccatgctca ccgacccctc ccacattacg gcggagacgg ctaagcgtag gctggccagg 660
 ggatctcccc cctccttggc cagctcatca gctagccagc tgtctgcgcc ttccctgaag 720
 15 gcaacatgca ctaccctgca tgactccccg gacgtgacc tcacgaggg caacctcctg 780
 tggcggcagg agatgggcgg gaacatcacc cgcgtggagt cagaaaataa ggtagtaatt 840
 ttggactctt tcgagccgct ccaagcggag gaggatgaga gggaaagtatc cgttccggcg 900
 gagatcctgc ggaggtccag gaaattccct cgagcgatgc ccatatgggc acgcccggat 960
 tacaacccctc cactgttaga gtccctggaag gacccggact acgtccctcc agtgggtacac 1020
 20 ggggtgtccat tggccgctgc caaggccctt ccgataccac ctccacggag gaagaggacg 1080
 gttgtcctgt cagaatctac cgtgtcttct gccttggcgg agctcgccac aaagaccttc 1140
 ggcagctccg aatcgctggc cgtcgacagc ggcacggcaa cggcctctcc tgaccagccc 1200
 tccgacgacg gcgacgcggg atccgacgtt gagtgtact cctccatgcc ccccccttag 1260
 ggggagccgg gggatcccg tctcagcgac ggggtcttgggt ctaccgtaag cgaggaggct 1320
 25 agtgaggacg tcgtctgctg c 1341

<210> 132
 <211> 1772
 30 <212> DNA
 <213> Hepatitis C virus

<300>
 <302> NS5B
 35 <310> AJ238799

<400> 132
 tcgatgtcct acacatggac aggcgcctct atcacgccat gcgctgcgga ggaaaccaag 60
 ctgcccatac atgcaactgag caactctttt ctccgtcacc acaacttgggt ctatgctaca 120
 40 acatctcgca gcgcaagcct gcggcagaag aaggctcacct ttgacagact gcaggctcctg 180
 gacgaccact accgggacgt gctcaaggag atgaaggcga aggcgtccac agttaaggct 240
 aaacttctat ccgtggagga agcctgtaag ctgacgcccc cacattcggc cagatctaaa 300
 tttggctatg gggcaaaagga cgtccggaac ctatccagca aggcggttaa ccacatccgc 360
 tccgtgtgga aggacttgct ggaagacact gagacaccaa ttgacaccac catcatggca 420
 45 aaaaatgagg ttttctgctt ccaaccagag aagggggggc gcaagccagc tcgccttacc 480
 gtattcccag atttgggggt tcgtgtgtgc gagaaaatgg cccctttacc tggtggtctcc 540
 accctccctc aggcctgtat gggctcttca tacggattcc aatactctcc tggacagcgg 600
 gtcgagttcc tggatgaatgc ctggaaaagc aagaaaatgcc ctatgggctt cgcatatgac 660
 acccgctggt ttgactcaac ggtcactgag aatgacatcc gtgttgagga gtcaatctac 720
 50 caatgttgtg acttggcccc cgaagccaga caggccataa ggtcgctcac agagcggctt 780
 tacatcgggg gccccctgac taattctaaa gggcagaact gcggctatcg ccgggtgccg 840
 gcgagcgggt tactgacgac cagctgcggt aataccctca catgttactt gaaggccgct 900
 gcggcctgtc gagctgcgaa gctccaggac tgcacgatgc tcgtatgcgg agacgacatt 960
 ctggttatct gtgaaaagcgc ggggacccaa gaggacgagg cgagcctacg ggccttaccg 1020
 55 gaggctatga ctagatactc tgccccccct ggggacccgc ccaaaccaga atacgacttg 1080
 gagttgataa catcatgctc ctccaatgtg tcagtcgcgc acgatgcac tcggcaaaagg 1140
 gtgtactatc tcacccgtga cccaccacc ccccttgccg gggctgctgt ggagacagct 1200
 agacacactc cagtoaatc ctggctagc aacatcatca tgatatgcgc cacctgtggt 1260
 gcaaggatga tccatgatgc tcatttcttc tccatccttc tagctcagga acaacttgaa 1320
 60 aaagccctag attgtcagat ctacggggcc tggttactcca ttgagccact tgacctacct 1380
 cagatcattc aacgactcca tggccttagc gcattttcac tccatagtta ctctccaggt 1440
 gagatcaata ggggtggcttc atgcctcagg aaacttgggg taccgcctct gcgagctctg 1500

```

agacatcggg ccagaagtgt ccgcgctagg ctactgtccc aggggggggag ggctgccact 1560
tgtggcaagt acctcttcaa ctgggcagta aggaccaagc tcaaactcac tccaatcccc 1620
gctgcgtccc agttggattt atccagctgg ttcgttgctg gttacagcgg gggagacata 1680
tatcacagcc tgtctcgtgc ccgacccgcg tggttcatgt ggtgcctact cctactttct 1740
5 gtaggggtag gcatctatct actccccaac cg                                     1772

<210> 133
<211> 1892
10 <212> DNA
    <213> Hepatitis C virus

<300>
<302> NS3
15 <310> AJ238799

<400> 133
cgcctattac ggccctactcc caacagacgc gaggcctact tggttgcctc atcactagcc 60
tcacaggccg ggacaggaac caggtcgagg gggagggtcca agtgggtctcc accgcaacac 120
20 aatcttttct ggcgacctgc gtcaatggcg tgtgttggac tgtctatcat ggtgccggct 180
caaagaccct tgccggccca aagggcccaa tcacccaaat gtacaccaat gtggaccagg 240
acctcgctcg ctggcaagcg ccccccgggg cgcgttcctt gacaccatgc acctgcggca 300
gctcggacct ttacttggtc acgaggcatg ccgatgtcat tccggtgcgc cggcggggcg 360
acagcagggg gagcctactc tccccaggc ccgtctccta cttgaagggc tcttcggggc 420
25 gtccactgct ctgccccctg gggcacgctg tgggcatctt tcgggctgcc gtgtgcaccc 480
gaggggttgc gaaggcgggt gactttgtac ccgtcgagtc tatggaaacc actatgcggt 540
ccccggctct cacggacaac tcgtccccctc cggccgtacc gcagacattc caggtggccc 600
atctacacgc ccctactggg agcggcaaga gactaagggt gccggctgcg tatgcagccc 660
aaggggtataa ggtgcttgtc ctgaacccgt ccgtcgccgc caccctaggt ttcggggcgt 720
30 atatgtctaa ggcacatggt atcgacccta acatcagaac cggggtaagg accatcacca 780
cgggtgcccc catcacgtac tccacctatg gcaagtttct tgccgacggt ggttgctctg 840
ggggcgcccta tgacatcata atatgtgatg agtgccactc aactgactcg accactatcc 900
tgggcactcg cacagtcctg gaccaagcgg agacggctgg agcgcgactc gtcgtgctcg 960
ccaccgctac gcctccggga tcgggtcaccg tgccacatcc aaacatcgag gaggtggctc 1020
35 tgtccagcac tggagaaatc cccttttatg gcaaagccat ccccatcgag accatcaagg 1080
gggggaggca cctcatthtc tgccattcca agaagaaatg tgatgagctc gcccggaagc 1140
tgtccggcct cggactcaat gctgtagcat attaccgggg ccttgatgta tccgtcatac 1200
caactagcgg agacgtcatt gtcgtagcaa cggacgctct aatgacgggc tttaccggcg 1260
atttcgactc agtgatcgac tgcaatacat gtgtcaccca gacagtcgac ttcagcctgg 1320
40 acccgacctt caccattgag acgacgaccg tgccacaaga cgcgggtgtca cgctcgcagc 1380
ggcgaggcag gactggttagg ggcaggatgg gcatthacag gtttgtgact ccaggagaac 1440
ggccctcggg catgttcgat tcctcgggtc tgtgcgagtg ctatgacgcg ggctgtgctt 1500
'ggtacgagct cagccccgcc gagacctcag ttaggttgcg ggcttaccta aacacaccag 1560
ggttgcccggt ctgccaggac catctggagt tctgggagag cgtctttaca ggccctcacc 1620
45 acatagacgc ccatttcttg tcccagacta agcaggcagg agacaacttc ccctacctgg 1680
tagcatacca ggctacgggt tgccgccagg ctcaggctcc acctccatcg tgggacccaa 1740
tgtggaagtg tctcatacgg ctaaagccta cgctgcacgg gccaacgccc ctgctgtata 1800
ggctgggagc cgttcaaaac gaggttacta ccacacaccc cataacccaa tacatcatgg 1860
catgcatgtc ggctgacctg gaggtcgtca cg                                     1892

<210> 134
<211> 822
<212> DNA
55 <213> Homo sapiens

<300>
<302> stmn cell factor
<310> M59964
60 <400> 134
atgaagaaga cacaaacttg gattctcact tgcatttata ttcagctgct cctatttaat 60

```

5 cctctcgtca aaactgaagg gatctgcagg aatcgtgtga ctaataatgt aaaagacgtc 120
 actaaattgg tggcaaatct tccaaaagac tacatgataa ccctcaaata tgtccccggg 180
 atggatgttt tgccaagtca ttgttggata agcgagatgg tagtacaatt gtcagacagc 240
 ttgactgata ttctggacaa gttttcaaat atttctgaag gcttgagtaa ttattccatc 300
 atagacaaac ttgtgaatat agtcgatgac cttgtggagt gcgtcaaaga aaactcatct 360
 aaggatctaa aaaaatcatt caagagccca gaaccagggc tctttactcc tgaagaattc 420
 tttagaattt ttaatagatc cattgatgcc ttcaaggact ttgtagtggc atctgaaact 480
 agtgattgtg tggtttcttc aacattaagt cctgagaaag attccagagt cagtgtcaca 540
 aaaccattta tgttaccccc tgttcagacc agctccctta ggaatgacag cagtagcagt 600
 10 aataggaagg ccaaaaatcc cctggagac tccagcctac actgggcagc catggcattg 660
 ccagcattgt tttctcttat aattggcttt gcttttggag ccttatactg gaagaagaga 720
 cagccaagtc ttacaagggc agttgaaaat atacaaatta atgaagagga taatgagata 780
 agtatgttgc aagagaaaga gagagagttt caagaagtgt aa 822

15 <210> 135
 <211> 483
 <212> DNA
 <213> Homo sapiens

20 <300>
 <302> TGFalpha
 <310> AF123238

25 <400> 135
 atgggtccct cggctggaca gctcgccctg ttcgctctgg gtattgtgtt ggctgcgtgc 60
 caggccttgg agaacagcac gtccccgctg agtgacagac cgcccggtggc tgcagcagtg 120
 gtgtccattt ttaatgactg ccagatttcc cacactcagt tctgcttcca tggaaacctgc 180
 aggttttttg tgcaggagga caagccagca tgtgtctgcc attctgggta cgttgggtgca 240
 30 cgctgtgagc atgcggaccc cctggccgtg gtggctgccca gccagaagaa gcaggccatc 300
 accgccttgg tgggtgtctc catcgtggcc ctggctgtcc ttatcatcac atgtgtgctg 360
 atacactgct gccagggtccg aaaacactgt gagtgggtgcc gggccctcat ctgccggcac 420
 gagaagccca gcgcccctcc gaaggggaaga accgcttgct gccactcaga aacagtggtc 480
 tga 483

35 <210> 136
 <211> 1071
 <212> DNA
 <213> Homo sapiens

40 <300>
 <302> GD3 synthase
 <310> NM003034

45 <400> 136
 atgagccctt gcgggcccgc ccggcgacaa acgtccagag gggccatggc tgtactggcg 60
 tggaaagtcc cgcggaccgc gctgcccatt ggagccagtg ccctctgtgt cgtgggtcctc 120
 50 tgttggtctt acatcttccc cgtctaccgg ctgcccacgc agaaagagat cgtgcagggg 180
 gtgctgcaac agggcacggc gtggaggagg aaccagaccg cggccagagc gttcaggaaa 240
 caaatggaag actgctgcga ccctgcccatt ctctttgcta tgactaaaat gaattcccct 300
 atgggggaaga gcatgtggta tgacggggag tttttatact cattcaccat tgacaattca 360
 acttactctc tcttcccaca ggcaacccca ttccagctgc cattgaagaa atgcgcgggtg 420
 gtgggaaatg gtgggattct gaagaagagt ggctgtggcc gtcaaataga tgaagcaaat 480
 55 ttgtgcatgc gatgcaatct ccctcctttg tcaagtgaat acactaagga tgttggtatcc 540
 aaaagtccag tagtgacagc taatcccagc ataattcggc aaagggtttca gaaccttctg 600
 tgggtccagaa agacatttgt ggacaacatg aaaatctata accacagtta catctacatg 660
 cctgcctttt ctatgaagac aggaacagag ccactcttga ggggtttatta tacactgtca 720
 gatgttggtg ccaatcaaac agtgcgtgtt gccaacccca actttctgct tagcattgga 780
 60 aagttctgga aaagtagagg aatccatgcc aagcgctgt ccacaggact ttttctgggt 840
 agcgcagctc tgggtctctg tgaagaggtg gccatctatg gcttctggcc cttctctgtg 900
 aatatgcatg agcagcccat cagccaccac tactatgaca acgtcttacc cttttctggc 960

	ttccatgcc	tgcccagga	atttctccaa	ctctgggtatc	ttcataaaaat	cggtgcactg	1020
	agaatgcagc	tggacccatg	tgaagatacc	tcactccagc	ccacttccta	g	1071
5	<210>	137					
	<211>	744					
	<212>	DNA					
	<213>	Homo sapiens					
10	<300>						
	<302>	FGF14					
	<310>	NM004115					
	<400>	137					
15	atggccgcgg	ccatcgctag	cggcttgatc	cgccagaagc	ggcagggcgg	ggagcagcac	60
	tgggaccggc	cgtctgccag	caggaggcgg	agcagcccca	gcaagaaccg	cgggctctgc	120
	aacggcaacc	tgggtggatat	cttctccaaa	gtgcgcactc	tcggcctcaa	gaagcgcagg	180
	ttgcggcgcc	aagatcccca	gctcaagggg	atagtgacca	ggttatattg	caggcaaggc	240
	tactacttgc	aaatgcaccc	cgatggagct	ctcgatggaa	ccaaggatga	cagcactaat	300
20	tctacactct	tcaacctcat	accagtggga	ctacgtgttg	ttgccatcca	gggagtga	360
	acaggggtgt	atatagccat	gaatggagaa	ggttaacctc	acccatcaga	actttttacc	420
	cctgaatgca	agtttaaaga	atctgttttt	gaaaattatt	atgtaatcta	ctcatccatg	480
	ttgtacagac	aacaggaatc	tggtagagcc	tggtttttgg	gattaaataa	ggaagggcaa	540
	gctatgaaag	ggaacagagt	aaagaaaacc	aaaccagcag	ctcattttct	acccaagcca	600
25	ttggaagtgt	ccatgtaccg	agaacctatc	ttgcatgatg	ttggggaaac	ggtcccgaag	660
	cctgggggtga	cgccaagtaa	aagcacaagt	gcgtctgcaa	taatgaatgg	aggcaaacca	720
	gtcaacaaga	gtaagacaac	atag				744
30	<210>	138					
	<211>	1503					
	<212>	DNA					
	<213>	Human immunodeficiency virus					
35	<300>						
	<302>	gag (HIV)					
	<310>	NC001802					
	<400>	138					
40	atgggtgcga	gagcgtcagt	attaagcggg	ggagaattag	atcgatggga	aaaaattcgg	60
	ttaaggccag	ggggaaagaa	aaaatataaa	ttaaaacata	tagtatgggc	aagcagggag	120
	ctagaacgat	tcgcagttaa	tcctggcctg	ttagaaacat	cagaaggctg	tagacaaata	180
	ctggggacagc	tacaaccatc	ccttcagaca	ggatcagaag	aacttagatc	attatataat	240
	acagtagcaa	ccctctattg	tgtgcatcaa	aggatagaga	taaaagacac	caaggaagct	300
45	ttagacaaga	tagaggaaga	gcaaaacaaa	agtaagaaaa	aagcacagca	agcagcagct	360
	gacacaggac	acagcaatca	ggtcagccaa	aattacccta	tagtgcgaga	catccagggg	420
	caaattggtac	atcaggccat	atcacctaga	actttaaatg	catgggtaaa	agtagtagaa	480
	gagaaggctt	tcagcccaga	agtgataccc	atgttttcag	cattatcaga	aggagccacc	540
	ccacaagatt	taaacacccat	gctaaacaca	gtggggggac	atcaagcagc	catgcaaatg	600
50	ttaaaagaga	ccatcaatga	ggaagctgca	gaatgggata	gagtgcattc	agtgcattga	660
	gggcctattg	caccaggcca	gatgagagaa	ccaaggggaa	gtgacatagc	aggaactact	720
	agtacccttc	aggaacaaat	aggatggatg	acaaataatc	cacctatccc	agtagggaga	780
	atttataaaa	gatggataat	cctggggatta	aataaaaatag	taagaatgta	tagccctacc	840
	agcattctgg	acataagaca	aggaccaaag	gaacccttta	gagactatgt	agaccggttc	900
55	tataaaactc	ttagagccga	gcaagcttca	caggaggtaa	aaaattggat	gacagaaacc	960
	ttgttgggtcc	aaaatgcgaa	cccagattgt	aagactatct	taaaagcatt	gggaccagcg	1020
	gctacactag	aagaaatgat	gacagcatgt	cagggagtag	gaggaccggg	ccataaggca	1080
	agagtttttg	ctgaagcaat	gagccaagta	acaaattcag	ctaccataat	gatgcagaga	1140
	ggcaattttta	ggaaccaaag	aaagattggt	aagtgtttca	attgtggcaa	agaagggcac	1200
60	acagccagaa	attgcagggc	ccctagggaa	aagggctggt	ggaaatgtgg	aaaggaagga	1260
	caccaaataga	aagattgtac	tgagagacag	gctaattttt	tagggaagat	ctggccttcc	1320
	tacaagggaa	ggccagggaa	ttttcttcag	agcagaccag	agccaacagc	cccaccagaa	1380

5 <210> 155
<211> 21
<212> RNA
<213> Künstliche Sequenz

10 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(K3A) einer dsRNA, die homolog zur 5'-UTR der
Neomycin-Sequenz ist

15 <400> 155
gaugaggauc guuucgcaug a 21

20 <210> 156
<211> 21
<212> RNA
<213> Künstliche Sequenz

25 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (K3B) einer dsRNA, die
komplementär zur 5'-UTR der Neomycin-Sequenz ist

30 <400> 156
augcgaaacg uuccucaucc u 21

35 <210> 157
<211> 24
<212> RNA
<213> Künstliche Sequenz

40 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(K2A) einer dsRNA, die homolog zur 5'-UTR der
Neomycin-Sequenz ist

45 <400> 157
acaggagag gaucguuucg caug 24

50 <210> 158
<211> 24
<212> RNA
<213> Künstliche Sequenz

55 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (K2B) einer dsRNA, die
komplementär zur 5'-UTR der Neomycin-Sequenz ist

60 <400> 158
ugcgaaacga uccucauccu gucu 24

<210> 159
<211> 24
<212> RNA
<213> Künstliche Sequenz

<220>

<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S4B) einer dsRNA, die
komplementär zur YFP-bzw. GFP-Sequenz ist

5 <400> 159
gaaagucgugc ugcuucaugc ggcgc 24

```

10      <210> 160
        <211> 24
        <212> RNA
        <213> Künstliche Sequenz

```

15 <223> Beschreibung der künstlichen Sequenz: sense-Strang
(PKC1 A) einer dsRNA, die homolog zur
Proteinkinase C-Sequenz ist

20 <400> 160
cuucucgcgcc ucacaccgcg gcaa 24

```

25      <210> 161
        <211> 22
        <212> RNA
        <213> Künstliche Sequenz

```

30 <220>
 <223> Beschreibung der künstlichen Sequenz:
 antisense-Strang (PKC2 B) einer dsRNA, die
 komplementär zur Proteinkinase C-Sequenz ist

<400> 161
gcagcggugu gaggcggaga ag 22

35

40 <210> 162
 <211> 21
 <212> RNA
 <213> Künstliche Sequenz

45 <223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S12B) einer dsRNA, die
komplementär zur YFP- bzw. GFP-Sequenz ist

<400> 162
aagucgugcu gcuucaugug g 21

```
50      <210> 163
      <211> 23
      <212> RNA
      <213> Künstliche Sequenz
```

```
<220>
<223> Beschreibung der künstlichen Sequenz:
        antisense-Strang (S11B) einer dsRNA, die
        komplementär zur YFP- bzw. GFP-Sequenz ist
```

<400> 163
aaqucgugcu gcuucaugug guc 23

5 <210> 164
<211> 20
<212> RNA
<213> Künstliche Sequenz

10 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(S13A) einer dsRNA, die homolog zur YFP- bzw.
GFP-Sequenz ist

15 <400> 164
ccacaugaag cagcacgacu 20

20 <210> 165
<211> 22
<212> RNA
<213> Künstliche Sequenz

25 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S13B) einer dsRNA, die
komplementär zur YFP- bzw. GFP-Sequenz ist

30 <400> 165
agucgugcug cuucaugugg uc 22

35 <210> 166
<211> 20
<212> RNA
<213> Künstliche Sequenz

40 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (S14B) einer dsRNA, die
komplementär zur YFP- bzw. GFP-Sequenz ist

45 <400> 166
agucgugcug cuucaugugg 20

50 <210> 167
<211> 24
<212> RNA
<213> Künstliche Sequenz

55 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(S4A) einer dsRNA, die homolog zur YFP- bzw.
GFP-Sequenz ist

60 <400> 167
ccacaugaag cagcacgacu ucuu 24

<210> 168
<211> 21
<212> RNA
<213> Künstliche Sequenz

<220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-7A) einer dsRNA, die homolog zur humanen
5 EGFR-Sequenz ist

<400> 168
aacaccgcag caugucaaga u 21

10 <210> 169
<211> 21
<212> RNA
<213> Künstliche Sequenz

15 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-7B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

20 <400> 169
cuugacaugc ugcgguguuu u 21

25 <210> 170
<211> 22
<212> RNA
<213> Künstliche Sequenz

30 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-8A) einer dsRNA, die homolog zur humanen
EGFR-Sequenz ist

35 <400> 170
aaguuaaaau ucccguccgu au 22

40 <210> 171
<211> 22
<212> RNA
<213> Künstliche Sequenz

45 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-8B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

50 <400> 171
ugauagcgac gggaaauuuu ac 22

55 <210> 172
<211> 22
<212> RNA
<213> Künstliche Sequenz

60 <220>
<223> Beschreibung der künstlichen Sequenz: sense-Strang
(ES-2A) einer dsRNA, die homolog zur humanen
EGFR-Sequenz ist

<400> 172
agugugaucc aagcuguccc aa 22

5 <210> 173
<211> 24
<212> RNA
<213> Künstliche Sequenz

10 <220>
<223> Beschreibung der künstlichen Sequenz:
antisense-Strang (ES-5B) einer dsRNA, die
komplementär zur humanen EGFR-Sequenz ist

15 <400> 173
uugggacagc uuggaucaca cuuu 24

TRANSLATION FROM GERMAN

(12) WORLD ORGANIZATION OF INTELLECTUAL PROPERTY INTERNATIONAL APPLICATION PUBLISHED PURSUANT TO THE PATENT COOPERATION TREATY (PCT)

(19) World Organization for Intellectual Property International Office		
(43) International Publication Date: 18 July 2002	PCT	(10) International Publication Number: WO 02/055693 A2
(51) International Patent Classification: C12N 15/11	LIMMER,	Stephan
(21) International Application Number: PCT/EP02/00152	[GERMANY/GERMANY];	
(22) International filing date: 9 January 2002	Universitätsstrasse 30, 95447 Bayreuth	
(25) Submission language: German	(GERMANY). ROST, Sylvia	
(26) Publication language: German	[GERMANY/GERMANY];	
(30) Priority data:	Universitätsstrasse 30, 95447 Bayreuth	
101 00 586.5 9 January 2001 GERMANY	(GERMANY). HADWIGER, Philipp	
101 55 280.7 26 October 2001 GERMANY	[GERMANY/GERMANY; Universitätsstrasse	
101 58 411.3 29 November 2001 GERMANY	30, 95447 Bayreuth (GERMANY).	
101 60 151.4 7 December 2001 GERMANY	(74) Attorneys: GASSNER, Rolfgang;	
(71) Applicant: (for all designated states, except US):	Nägelsbachstrasse 49a, 91052 Erlangen	
RIBOPHARMA AG	(GERMANY).	
[GERMANY/GERMANY]; Universitätsstrasse	(81) Designated states (national): AE, AG,	
30, 95447 Bayreuth (GERMANY).	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY,	
	BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK,	
	DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,	
	GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP,	
	KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA,	
	MD, MG, MK, MN, MW, MX, MZ, NO, NZ,	
	OM, PH, PL, PT, RO, RU, SD, SE, SG, SI,	
	SK, SL, TJ, TM, TRADENAME, TR, TT, TZ,	
	UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.	
(72) Inventor and		
(75) Inventor/Applicant (for US only): KREUTZER,		
Roland [GERMANY/GERMANY];		
Universitätsstrasse 30, 95447 Bayreuth		
(GERMANY).		

(84) Regional states (*regional*): ARIPO Patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian Patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European Patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR). OAPI Patent (BR, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published:


– without International Search Report and republished on receipt of the report

Refer to the "Guidance Notes on Codes and Abbreviations" at the beginning of each regular issue of the PCT Gazette for explanation of the two-letter codes and other abbreviations..

(54) Title: **METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE**

(57) Abstract

The invention relates to a method for inhibiting the expression of a target gene in a cell, comprising the following steps: introduction of an amount of at least one dual-stranded ribonucleic acid (dsRNA I) which is sufficient to inhibit the expression of the target gene. The dsRNA I has a dual-stranded structure formed by a maximum of 49 successive nucleotide pairs. One strand (as1) or at least one section of the one strand (as1) of the dual-stranded structure is complementary to the sense strand of the target gene. The dsRNA has an overhang on the end (E1) of dsRNA I formed by 1 – 4 nucleotides.



Variant 1

Variant 2

METHOD FOR INHIBITING THE EXPRESSION OF A TARGET GENE

The invention concerns a method, an application and a medicament for inhibition of expression of a target gene.

Methods to inhibit expression of genes of medical or biotechnological interest by means of a double-strand ribonucleic acid (dsRNA) are known from WO 99/32619 and WO 00/44895. The known methods are highly effective. But there is also a requirement to further increase their efficiency.

The task of the present invention is to eliminate the shortcomings according to the prior art. In particular, a method, an application and a medicament are to be offered, with which even more efficient inhibition of expression of the target gene is attainable.

This task is solved by the features of Claims 1, 41 and 81. Advantageous embodiments are apparent from the features of Claims 2 to 40, 42 to 80 and 82 to 120.

With the features claimed according to the invention, a drastic increase in the effectiveness of inhibition of expression of the target gene in vitro and in vivo is surprisingly achieved. By the special design of the ends of the dsRNA, both their efficiency in mediating the inhibiting effect on expression of the target gene and their stability can be deliberately influenced. By increasing the stability, the effective concentration in the cell is increased.

Target gene according to the invention is understood to mean the DNA strand of the double-strand DNA in the cell that is complementary to a DNA strand, including all transcribed regions that serve for transcription as matrix. The target gene is therefore generally the “sense” strand. The one strand or anti-sense strand (as1) can be complementary to an RNA transcript formed during expression of the target gene or its processing product, for example, an mRNA. Insertion is understood to mean uptake in the cell. Uptake can occur by the cell itself; it also can be mediated by auxiliaries or aids. “Overhang” is understood to mean a terminal single-strand overhang that does not have paired nucleotides, according to Watson and Crick. “Double-strand

structure” is understood to mean a structure, in which the nucleotides of the individual strands are essentially paired according to Watson and Crick. A double-strand structure in the context of the present invention can also have individual mismatches.

According to a particularly advantageous embodiment, the dsRNA I has the overhang on the 3' end of one strand or the anti-sense strand as1 and/or on the 3' end of the other end or sense strand ss1. The dsRNA I can also be formed smoothly on one end. In this case, the smooth end is advantageously situated on the side of dsRNA I that has the 5' end of one strand (anti-sense strand; as1). In this form, the dsRNA I, on the one hand, has very good efficiency and, on the other hand, high stability in a living organism. The overall in vivo efficiency is excellent. The overhang is expediently formed from 1 to 4 nucleotides, preferably from 1 or 2 nucleotides.

According to another embodying feature, the efficiency of the method can be further increased if at least one additional dsRNA II, formed according to the dsRNA I according to the invention, is inserted into the cell, in which the one strand or at least a section of one strand of the double-strand structure of dsRNA I is complementary to a first region of the sense strand of the target gene, and in which an additional strand or at least a section of the additional strand of the double-strand structure of the additional dsRNA II is complementary to a second region of sense strand of the target gene. Inhibition of expression of the target gene is significantly increased in this case. The first and second region can overlap in sections, abut each other, or also be spaced from each other.

It has also proven advantageous if the dsRNA I and/or the additional dsRNA II have a length of less than 25 consecutive nucleotide pairs. A length in the range between 19 and 23 nucleotide pairs has proven to be particularly effective. The efficiency can be further increased if single-strand overhangs of 1 to 4 nucleotides are present on the double strands preferably formed from 19 to 23 nucleotide pairs.

The target gene, according to an additional embodying feature, can have the sequences SQ001 to SQ140, given in the enclosed sequence protocol. It can also be chosen from the following groups: oncogene, cytokine gene, id-protein gene, prion gene, genes for expression of

angiogenesis-inducing molecules, adhesion molecules and cell surface receptors. genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules, as well as genes for expression of the EGF receptors. The target gene can be the MDR1 gene, in particular. In this context, one of the existing sequences SQ141-173 or a combined dsRNA I/II from antisense (as) and sense sequences (ss) that go together can be used.

According to an additional advantageous embodying feature, expression is inhibited according to the principle of RNA interference.

The target gene is expediently expressed in pathogenic organisms, preferably in plasmodia. It can be a component of a virus or viroid, especially a human pathogenic virus or viroid. The virus or viroid can also be an animal or plant pathogenic virus or viroid.

According to another embodying feature, it is prescribed that the unpaired nucleotides be substituted by nucleoside thiophosphates.

At least one end of the dsRNA I/II can be modified, in order to counteract degradation in the cell or dissociation in the individual strand. Advantageously, cohesion caused by the complementary nucleotide pairs of the double-strand structure is increased by at least one chemical length. The chemical length can be formed by a covalent or ionic bond, a hydrogen bridge bond, hydrophobic interactions, preferably van-der-Waals or stacking interactions, or by metal ion coordination. It has also proven expedient and to increase stability if the chemical link is formed in the vicinity of one end. Additional advantageous embodiments with respect to chemical linking can be deduced from the features of Claims 24 to 30, without requiring a further explanation for this.

The dsRNA I/II can be incorporated particularly easily in the cell if it is enclosed in micellar structures, advantageously in liposomes. It has also proven advantageous for transport of dsRNA I/II into the cell that it is bonded to at least a viral sheath protein, originating from a virus, derived from a virus or synthetically produced, associated with the sheath protein or

enclosed by it. The sheath protein can be derived from polyoma virus. The sheath protein can contain, in particular, the virus protein 1 and/or the virus protein 2 of polyoma virus. According to another embodiment, it is prescribed that, during formation of a capsid or capsid-like structure from the sheath protein, one side face the interior of the capsid or capsid-like structure. It is also advantageous that the one strand of dsRNA I/II (as1/2) is complementary to the primary or processed RNA transcript of the target gene. The cell can be a vertebrate cell or a human cell.

It has also been found that the dsRNA I/II can advantageously be administered already in an amount of, at most, 5 mg/kg of body weight per day to a mammal, preferably a human. Even in this low dose, an excellent efficiency is achieved.

It has surprisingly been found that the dsRNA I/II can be taken up in a buffer solution for administration and then administered orally or by injection or infusion intravenously, intratumorally, by inhalation or intraperitoneally.

The use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in the cell is also proposed according to the invention, in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (anti-sense strand; as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of the target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

According to an additional stipulation of the invention, a medicament for inhibiting the expression of a target gene in a cell is proposed, containing a double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of a target gene, in which the dsRNA I has a double-strand structure from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the sense strand of target gene, and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides on at least one end.

The preceding comments are referred to for the further advantageous embodiment of dsRNA I/II.

The invention is further explained on an example below, with reference to the drawings and practical examples. In the drawings:

- Fig. 1a, b schematically depicts a first and second double-strand RNA and
- Fig. 2 schematically depicts a target gene,
- Fig. 3 depicts relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (first experiment),
- Fig. 4 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (second experiment),
- Fig. 5 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (third experiment),
- Fig. 6 shows relative YFP fluorescence after application of different dsRNA in NIH/3T3 cells (fourth experiment),
- Fig. 7 shows relative YFP fluorescence after application of different dsRNA in HeLa-S3 cells (fifth experiment),
- Fig. 8 shows fluorescence micrographs of NIH/3T3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 9 shows fluorescence micrographs of HeLa-S3 cells after transfection with pcDNA-YFP and after cotransfection with pcDNA-YFP and different dsRNAs,
- Fig. 10 shows gel electrophoretic separation of S1 after incubation in mouse serum,

- Fig. 11 shows gel electrophoretic separation of S1 after incubation in human serum,
- Fig. 12 shows gel electrophoretic separation of S7 after incubation in mouse serum,
- Fig. 13 shows gel electrophoretic separation of S7 after incubation in human serum,
- Fig. 14 shows gel electrophoretic separation of K3 after incubation in mouse serum,
- Fig. 15 shows gel electrophoretic separation of PKC1/2 after incubation in mouse serum,
- Fig. 16 shows gel electrophoretic separation of S1A/S4B after incubation in human serum,
- Fig. 17 shows gel electrophoretic separation of K2 after incubation in human serum and
- Fig. 18 shows GFP-specific immunoperoxidase staining on kidney paraffin sections of transgenic GFP mice,
- Fig. 19 shows GFP-specific immunoperoxidase staining on heart paraffin sections of transgenic GFP mice,
- Fig. 20 shows GFP-specific immunoperoxidase staining on pancreas paraffin sections transgenic GFP mice,
- Fig. 21 shows Western blot analysis of GFP expression in plasma,
- Fig. 22 shows Western blot analysis of GFP expression in the kidneys,
- Fig. 23 shows Western blot analysis of GFP expression in the heart,
- Fig. 24 shows Western blot analysis of EGFR expression in U-87 MG glioblastoma cells,

- Fig. 25a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 74 hours,
- Fig. 25b shows quantification of the band according to Fig. 25a, in which the averages from two values are shown,
- Fig. 26a shows Northern blot analysis of the MDRI mRNA levels in colon carcinoma cell line LS174T, in which the cells were harvested after 48 hours,
- Fig. 26b shows quantification of the band according to Fig. 26a, in which the average values from the two values are shown,
- Fig. 27 shows a comparative depiction of a transmitted light and fluorescence photomicrograph of a transfection with 175 nM dsRNA (sequence R1 in Table 4).

The double-strand ribonucleic acids dsRNA I and dsRNA II, depicted schematically in Figures 1a and 1b, each have a first end E1 and a second end E2. The first and second ribonucleic acids dsRNA I/dsRNA II have single-strand sections formed from about 1 to 4 unpaired nucleotides on their two ends E1 and E2. Two possible variants are shown (variants 1 and 2), in which variant 2 has a smooth end (E2). The smooth ends, however, can also lie on the other end (E1) in another variant.

A target gene situated on DNA is schematically shown in Fig. 2. The target gene is made recognizable by a black bar. It has a first region B1 and a second region B2.

Each strand of the first dsRNA I (as1) and the second dsRNA II (as2) is complementary to the corresponding region B1 or B2 on the target gene.

Expression of the target gene is then inhibited with particular efficiency, if the dsRNA I/dsRNA II has single strand sections on its ends E1, E2. The single-strand sections can be formed both on

strand as1 or as2 and on the counterstrand (ss1 or ss2) or on strand as1, as2 and on the counterstrand.

The regions B1 and B2, as shown in Fig. 2, can be spaced from each other. However, they can also be adjacent to each other or overlap.

I. Inhibition of Expression of the YFP Gene in Fibroblasts:

Double-strand RNAs (dRNAs) were prepared from sequences of the yellow fluorescent protein (YFP), a variant of the GFP (green-fluorescent protein) of the alga *Aequoria victoria* and microinjected into fibroblasts, together with a YFP-coding plasmid. Fluorescence reduction was then evaluated relative to cells without dsRNA.

Experimental Protocol:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and ordinary chemical methods, the RNA single strands apparent from the sequence protocols SQ148, 149 and SQ159 and the single strands complementary to them were synthesized. Purification then occurred by HPLC. Hybridization of the single strands to a double-strand occurred by heating the stoichiometric mixture of single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 90°C and subsequent cooling over 6 hours to room temperature. The dsRNAs so obtained were microinjected into the test cell.

The murine fibroblast cell line NIH/3T3, ECACC no. 930615624 (European Collection of Animal Cell Cultures) served as test system for these cell culture experiments. The plasmid pcDNA-YFP was used for microinjections, which contained an 800 bp large Bam HI/Eco RI-YFP fragment in the corresponding restriction cleavage sites of the vector pcDNA3. Expression of YFP was investigated under the influence of simultaneously cotransfected sequence-homologous dsRNA. Evaluation occurred under the fluorescence microscope, at the earliest, 3 hours after injection, with reference to green fluorescence.

Preparation of the Cell Cultures:

Cultivation of the cells occurred in DMEM with 4.5 g/L glucose, 10% fetal calf serum (FCS), 2 mM L-glutamine, penicillin/streptomycin (100 IU/100 µg/mL, Biochrom) in an incubator under a 5% CO₂ atmosphere at 37°C. The cells underwent passage every 3 days, in order to keep them in the exponential growth phase. A day before performance of transfection, the cells were trypsinized (10 × trypsin/TEDTA, Biochrom) and inoculated with a cell density of 0.73×10^5 cells into coated petri dishes (CORNING® Cell Culture Dish, 35 mM, Corning Inc., Corning, USA). The petri dishes were incubated with 0.2% gelatin (Biochrom) for at least 30 minutes at 37°C, washed once with PBS and immediately used for seeding of the cells. To permit recovery of individual cells, CELLocate coverslips from the Eppendorf company were used (square size 55 µm).

Microinjection:

To perform microinjection, the petri dishes were removed from the incubator for about 10 minutes. About 50 cells were microinjected per dish and batch (FemtoJet; Mikromanipulator 5171, Eppendorf). Glass capillaries (FemtoTip) from the Eppendorf company with a tip inside diameter of 0.5 µm were used for microinjection. The injection time was 0.8 seconds and the pressure 30 hPa. The microinjections were conducted on an Olympus IX50 microscope with a fluorescence device. 14 mM NaCl, 3 mM KCl, 10 mM KH₂PO₄, pH 7.0, was used as injection buffer, which contains 0.01 µg/mL pcDNA-YFP. To check successful microinjection, 0.08% (w/v) Dextran-70000 coupled Texas-Red (Molecular Probes, Leiden, Netherlands) was added to the injection solution. To investigate inhibition of the YFP expression with specific dsRNA, dsRNAs were added to the injection solution: batch 1: 0.1 µM dsRNA (sequence protocol SQ148/149); batch 2: 0.1 µM dsRNA (sequence protocol SQ148/159); batch 3: without RNA. After microinjection, the cells were incubated for at least three more hours in the incubator. The intracellular YFP fluorescence was then evaluated on the microscope: simultaneously red and green-fluorescent cells: microinjection was successful, no inhibition of YFP expression by dsRNA was observed; or control cells were involved, in which no dsRNA were injected; only red fluorescent cells: microinjection was successful, the dsRNA inhibits YFP expression.

Results:

At a dsRNA concentration of 0.1 μM , a significantly increased inhibition or expression of the YFP gene in fibroblasts could be observed during use of dsRNA with the protruding single-strand regions (sequence protocol SQ148/159) on both 3' ends by two nucleotides each, in comparison with dsRNA without protruding single-strand ends (Table 1).

The use of short dsRNA molecules, containing 19-25 base pairs with overhangs of a few, preferably 1 to 3, non-base-paired, single-strand nucleotides, therefore permits comparatively stronger inhibition of gene expression in mammal cells than the use of dsRNAs with the same number of base pairs without the corresponding single-strand overhangs at the same RNA concentration.

Batch	Name	Sequence protocol number	0.1 μM
1	S1A/ S1B	SQ148 SQ149	+
2	S1A/ S4B	SQ148 (protruding end) SQ159	+++
3		without RNA	–

Table 1: The symbols show the relative percentage of non-fluorescent or weakly green fluorescent cells (+++ > 90%; ++ 60-90%; + 30-60%; - < 10%).

II. Inhibition of Gene Expression with Target Gene in Cultivated HELA-S3 Cells and Mouse Fibroblasts by dsRNA:

The efficiency of inhibition of YFP expression after transient transfection of a YFP-coding plasmid based on RNA interference with dsRNAs can be modulated by the configuration of the 3' ends in the length of the base-paired regions.

Practical Example:

To detect the efficiency of dsRNA during specific inhibition of gene expression, transiently transfected NIH/3T3 cells (fibroblasts from NIH Swiss mouse embryo, ECCAC (European Collection of Animal Cell Cultures) no. 93061524) and HELA-S3 (human cervical carcinoma cells, DSMZ (German Collection of Microorganisms and Cell Cultures) no. ACC 161) were used. The plasmid pcDNA-YFP was used for transfection, which contains an 800 bp Bam HI/Eco RI-YFP fragment in the corresponding cleavage sites of the vector pcDNA3. Double-strand RNAs derived from the sequence of the yellow fluorescent protein (YFP) were produced and transiently transfected with the plasmid pcDNA-YFP in the fibroblasts (the employed specific dsRNAs are complementary in their anti-sense strands to the corresponding sections of the gene sequences above YFP and GFP). After 48 hours, the fluorescence reduction was quantified. Cells that were transfected either only with pcDNA-YFP or with pcDNA-YFP and a controlled dsRNA (not derived from the YFP sequence) functioned as controls.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA individual strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred by means of HPLC. The column NucleoPac PA-100, 9 × 250 mM, from the Dionex company was used; 20 mM tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions in a corresponding work bench (HS18, Hera Safe, Kendro, Heraeus). Cultivation of NIH/3T3 cells and HELA-S3 occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's Modified Eagle Medium, Biochrom), for the mouse fibroblasts, and Ham's F12 for the HELA cells with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells underwent passage every 3 days. 24 hours before the forming transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 1.0×10^4 cells/recess into a 96-well plate (Multiwell dishes 96-well flat bottom, Labor Schubert & Weiss GmbH) in 150 µL growth medium.

Performance of Transient Transfection:

Transfection was conducted with Lipofectamine PlusTM reagent (Life Technologies) according to the information of the manufacturer. 0.15 µg pcDNA-YFP plasmid was introduced per well. The total transfection volume was 60 µL. 3-fold samples were used in each case. Plasmid DNA was first complexed, together with dsRNA. For this purpose, the plasmid DNA and the dsRNA were diluted in a serum-free medium and 1 µL PLUS reagent was used per 0.1 µg plasmid DNA (in a volume of 10 µL) and, after mixing for 15 minutes at room temperature, they were incubated. During incubation, 0.5 µL Lipofectamine was diluted in a total of 10 µL serum-free medium per 0.1 µg plasmid DNA, thoroughly mixed, added to the plasmid/dsRNA/PLUS mixture and incubated for another 15 minutes. During incubation, a medium change was conducted. For this purpose, the cells were washed once with 200 µL serum-free medium and then with 40 µL serum-free medium and then incubated further in the incubator, up to addition of DNA/dsRNA/PLUS/Lipofectamine. After addition of 20 µL DNA/dsRNA/PLUS/Lipofectamine per well, the cells were incubated for 2.5 hours in the incubator. After incubation, the cells were then washed once with 200 µL growth medium and incubated for 24 hours until detection of the fluorescence in 200 µL growth medium in the incubator.

Detection of Fluorescence:

24 hours after the last medium change, the fluorescence of the cells was photographed on the fluorescence microscope (IX50-S8F2, fluorescence unit U-ULS100Hg, burner U-RFL-T200, Olympus) with a USH-I02D mercury lamp (USHIO Inc., Tokyo, Japan), equipped with a WIB fluorescence cube and a digital CCD camera (Orca IIIIm, Hamamatsu and C4742-95 camera controller). Evaluation of the fluorescence recording occurred with the analysis software 3.1 (Soft Imaging System GmbH, Germany). In order to relate the YFP fluorescence to cell density, a cell nucleus staining was carried out (Hoechst staining). For this purpose, the cells were first fixed for 5 in 100 μ L methylcarnoy (75% methanol, 25% glacial acetic acid) and then again for 10 minutes in methylcarnoy. After air drying, the fixed cells were incubated for 30 minutes in the dark with 100 μ L per well of Hoechst die (75 ng/mL). After washing twice with PBS (PBS Dulbecco w/o Ca^{2+} , M^{2+} , Biochrom), the Hoechst-stained cells were photographed under the fluorescence microscope (Olympus, WU fluorescence cube for Hoechst).

Figures 3 to 9 show the results on inhibition of YFP expression by dsRNA in the cultivated cells:

The effects of YFP-specific dsRNAs and control dsRNAs on YFP expression in NIH/3T3 mouse fibroblasts after transient transfection are summarized in Figures 3, 4, 5 and 6. The experiments were run as described in the experimental protocol. The concentration of dsRNA refers to the concentration in the medium during the transfection reaction. The designations for the dsRNAs can be gathered from Table 2. The relative fluorescence per image section in area percent is shown. 3 different image sections were evaluated per well. The averages are obtained from the 3-fold batches.

The specific inhibition of YFP gene expression by dsRNAs in HELA-S3 cells is shown in Figures 7 and 9. The inhibiting effect of differently configured dsRNA constructs (Table 2) in different concentrations on expression of YFP in HELA cells is shown in Fig. 7. Fig. 8 shows representative fluorescence microscope recordings of NIH/3T3 mouse fibroblasts transiently transfected with YFP without dsRNA and with dsRNA specifically directed against YFP ($\times 100$ magnification).

8A: YFP controls

8B: S1, 10 nM

8C: S4, 10 nM
8D:S7, 10 nM
8E: S7/S11, 1 nM
8F: S7/S12, 1 nM

Fig. 9 shows representative fluorescence microscope recordings of HELA-3S cells transiently transfected with YFP without dsRNA and with dsRNAs specifically directed against YFP ($\times 100$ magnification).

9A:K2-controls, 10 nM
9B: S1, 10 nM
9C: S4, 10 nM
9D:S7, 10 nM
9E: S7/11, 1 nM
9F: S7/12, 1 nM
9G:S1A/S4B, 10 nM
9H: YFP controls

Results:

Fig. 3 shows that YFP expression after transient cotransfection of mouse fibroblasts with the YFP plasmid and dsRNAs specifically directed against the YFP sequence is inhibited with particular efficiency when the 3' ends of the regions containing 22 and 19 base pairs of the dsRNAs have single-strand sections of two nucleotides (nt). Whereas the dsRNA S1 with smooth 3' ends at a concentration of 1 nM (referred to the concentration in the cell culture medium during performance and transfection) exhibits no inhibiting effect on YFP expression, the dsRNAs S7 (19 nucleotide pairs) and S4 (24 nucleotide pairs), each with 2 nt overhangs on both 3' ends, inhibit the YFP expression by 50 or by 70% in comparison with the corresponding control dsRNAs K3 and K2. At a concentration of 10 nM, the dsRNA denoted S1 with smooth ends inhibits YFP expression by about 65%, whereas inhibition of YFP expression by the dsRNA S4 is about 94% (Fig. 4). The inhibiting effects of the dsRNAs denoted S4 and S7 is concentration-dependent (Figures 3 and 4, see also Fig. 7).

Fig. 4 shows that, for efficient suppression of YFP gene expression, the single-strand structure is not necessary on both 3' ends (on the sense and anti-sense strand). To achieve the most effective possible inhibition of YFP expression, only the 2 nt overhang on the 3' end is necessary on the anti-sense strand. Inhibition of YFP expression at a concentration of 1 nM in the two dsRNAs S4 (with 2 nt overhangs on both 3' ends) and S1A/S4B (with the 2 nt overhang on the 3' end of the anti-sense strand) lies at about 70%. On the other hand, if the 2 nt overhang is situated on the 3' end of the sense strand (and the 3' end of the anti-sense strand carries no single-strand region), inhibition of YFP gene expression is only 50%. Similarly, inhibition at higher concentrations is much better, if at least the 3' end of the anti-sense strand carries a 2 nt overhang.

A more distinct inhibition of YFP expression is achieved, if the base-paired region has 21 nucleotide pairs instead of 22 (S1 and S4), 20 (S13 and S13/14) or 19 (S7) (Figures 5, 6 and 7). Inhibition of YFP expression by S1 (22 base pairs with smooth ends) in a concentration of 5 nM is about 40%, whereas inhibition by S7/S12 (21 base pairs with smooth ends), also with 5 nM, lies at about 92%. If the dsRNA with 21 base pairs also has a 2 nt overhang on the anti-sense strand 3' end (S7/S11), inhibition lies at ~ 97% (compared with ~ 73% inhibition with S4 and ~ 70% inhibition with S7).

III. Investigation of Serum Stability of Double-Strand RNA (dsRNA):

The objective is to increase the effectiveness found the cell cultures of inhibition of gene expression of target genes mediated by dsRNA for use in vivo. This is achieved by improved stability of the dsRNAs in serum and by an extended residence time of the molecule in the circulation and the increased effective concentration of the functional molecules related to this, resulting from improved stability.

Practical Example:

The serum stability of dsRNAs that inhibit GFP expression was tested in vivo in murine and human serum.

Experimental Protocol:

Incubation with human or murine serum with the corresponding dsRNA occurred at 37°C. 85 µL serum was incubated with 15 µL 100 µM dsRNA. After specified incubation times (30 minutes, 1 h, 2 h, 4 h, 8 h, 12 h, 24 h), the samples were frozen at -80°C. dsRNA without serum (+ 85 µL ddH₂O) and dsRNA at time 0 were used as control.

For isolation of the dsRNA from the incubation charge, which occurred on ice, 400 µL with 0.1% SDS was added to the charges and these are subjected to phenol extraction: 500 µL phenol:chloroform:isoamyl alcohol (IAA, 25:24:1, Roti[®]-Phenol, Roth, Karlsruhe) was added per charge and vortexed for 30 seconds at the highest stage (Vortex Genie-2; Scientific Industries). After 10 minutes of incubation on ice, phase separation occurred by centrifuging at 12,000 × g, 4°C for 10 minutes (Sigma 3K30, Rotor 12131-H). The upper aqueous phase (about 200 µL) was taken off and subjected first to DNase I and the proteinase K digestion: addition of 20 µL 10-fold DNase I buffer (100 mM Tris, pH 7.5, 25 mM MgCl₂, 1 mM CaCl₂) and 10 U DNase I (D7291, Sigma-Aldrich), 30 minutes incubation at 37°C, addition of 6 U DNase I again and incubation for another 20 minutes at 37°C, addition of 5 µL proteinase K (20 mg/mL, 04-1075, Peqlab, Germany) and 30 minutes incubation at 37°C. Phenol extraction was then conducted. For this purpose, 500 µL phenol:chloroform:IAA (25:24:1) was added, vortexed at the highest stage for 30 seconds, 10 minutes for 12000 × g, 4°C, centrifuged, the supernatant taken off and mixed in succession with 40 µL 3M Na-Ac (sodium acetate), pH 5.2, and 1 mL 100% EtOH, mixed thoroughly in the meantime and precipitated for at least 1 hour at -80°C. The precipitate was pelletized by centrifuging at 12000 × g for 30 minutes and 4°C, washed with 70% EtOH and recentrifuged (10 minutes, 12000 × g, 4°C). The air dried pellet was taken up in 30 µL RNA gel application buffer (7 M urea, 1 × TBE (0.09 M tris-borate, 0.002 M EDTA

(ethylenediaminetetraacetate), 0.02% (w/v) bromophenol blue, 0.02% (w/v) xylene cyanol) and stored at -20°C until gel application.

For characterization of the dsRNA, an analytical, denaturing polyacrylamide gel electrophoresis (analytical PAGE) was conducted. The urea gels were prepared right before the run: 7 M urea (21 g) was dissolved during agitation in 25 mL 40% aqueous acrylamide/bisacrylamide stock solution (Rotiphoresis gel, A515.1, Roth) and 5 μ L 10 \times TBE (100 g Tris, 55 g boric acid, 9.3 g EDTA per L distilled water) and made up to 50 μ L with distilled water. Right before pouring, 50 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and 500 μ L 10% APS (ammonium peroxodisulfate) were added. After polymerization, the gel was introduced to a vertical electrophoresis apparatus (Merck, Darmstadt) and a prerun was conducted for 30 minutes at a constant 40 mA current intensity. As run buffer, 1 \times TBE buffer was used. Before application onto the gel, the RNA samples were heated for 5 minutes at 100°C, cooled on ice and centrifuged for 20 seconds in a table-top centrifuge (Eppendorf, minispin). 15 μ L was applied to the gel. The run occurred for about 2 hours at a constant current of 40 mA. After the run, the gel was stained for 30 minutes at RT (room temperature) with Stains all stain solution (20 mL Stains all stock solution dissolved in 200 mL formamide) mixed with 200 mL distilled water and 180 mL formamide) and the background staining eliminated after rinsing in distilled water for 45 minutes. The gels were photographed with the photo documentation system Image Master VDS from Pharmacia.

Figures 10 to 17 show the serum stability of dsRNA after incubation with human and murine serum and subsequent electrophoretic separation in 20% 7 M urea gel.

Fig. 10: Incubation of S2 (0-22-0) in mouse serum

1. at time 0 (without serum)
2. at time 0
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours

7. for 12 hours
8. 2 μL 100 μM S1 without incubation
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 11: Incubation of S1 (0-22-0) in human serum

1. 2 μL 100 μM S1 untreated (without incubation)
2. for 30 minutes
3. for 2 hours
4. for 4 hours
5. for 6 hours
6. for 8 hours
7. for 12 hours
8. for 24 hours
- S1A) Sense strand S1 (10 μL 20 μM S1A)
- S1B) Anti-sense strand S1 (10 μL 20 μM S1B)

Fig. 12: Incubation at S7 (2-19-20) in mouse serum

1. at time 0 (without serum)
2. for 30 minutes
3. for 4 hours
4. for 12 hours

Fig. 13: Incubation of S7 (2-19-2) in human serum

1. Sense strand S7 (10 μL 20 μM S7A)
2. Anti-sense strand S7 (10 μL 20 μM S7B)
3. for 30 minutes
4. for 1 hour
5. for 2 hours
6. for 4 hours
7. for 6 hours

8. for 12 hours
9. for 24 hours
10. at time 0 (without serum)

Fig. 14: Incubation of K3 (2-19-20) in mouse serum

1. Sense strand K3 (10 μ L 20 μ M K3A)
2. Anti-sense strand K3 (10 L 20 μ M K3B)
3. at time 0 (without serum)
4. at time 0 (with serum)
5. for 30 minutes
6. for 1 hour
7. for 2 hours
8. for 4 hours
9. for 12 hours

Fig. 15: Incubation of PKC1/2 (0-22-2) in mouse serum

1. for 30 minutes
2. for 1 hour
3. for 2 hours
4. for 4 hours
5. for 12 hours
6. 2 μ L 100 μ M PKC1/2 (untreated)

Fig. 16: Incubation of S1A/S4B (0-22-2) in human serum

1. at time 0 (without serum)
2. for 24 hours
3. for 12 hours
4. for 8 hours
5. for 6 hours
6. for 4 hours
7. for 2 hours

8. for 30 minutes
9. Sense strand S1A (10 μ L 20 μ M S1A)
10. Anti-sense strand S4B (10 μ L 20 μ M S4B)

Fig. 17: Incubation of K2 (2-22-2) in human serum

1. Sense strand K2 (10 μ L 20 μ M K2A)
2. Anti-sense strand K2 (10 μ L 20 μ M K2B)
3. at point 0 (without serum)
4. for 30 minutes
5. for 2 hours
6. for 4 hours
7. for 6 hours
8. for 8 hours
9. for 12 hours
10. for 24 hours

Results:

dsRNAs without single-strand regions on the 3' ends are much more stable in both human and murine serum than dsRNAs with single-strand 2nt overhangs on the 3' ends (Figures 10 to 14 and 17). After 12 and 24 hours incubation at S1 in murine or human serum, bands in the original size are almost fully retained. On the other hand, in dsRNAs with 2nt overhangs on both 3' ends, the stability in human and murine serum diminishes significantly. After only 4 hours of incubation of S7 (Figures 12 and 13) or K3 (Fig. 14), no bands can be detected in the original size.

In order to increase the stability of dsRNA in serum, it is sufficient if the dsRNA has a smooth end. In mouse serum after 4 hours incubation (Fig. 15, track 4), the bands in the original size are scarcely broken down in comparison with S7 (after 4 hours complete degradation; Fig. 12, track 3).

As an optimal compromise with respect to biological efficacy of dsRNA, the use of dsRNA with a smooth end and a single-strand region of 2 nucleotides can be considered, in which the single-strand overhang should be situated on the 3' end of the anti-sense strand.

The sequences used here are apparent from the following Table 2 and the sequence protocols SQ148-151 and 153-167.

Name	Sequenz- proto- koll-Nr.	dsRNA-Sequenz	
S1	SQ148 SQ149	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - GGUGUACUUCGUCGUGCUGAAG -5'	0-22-0
S7	SQ150 SQ151	(A) 5' - CCACAUGAAGCAGCAGACUU -3' (B) 3' - CUGGUGUACUUCGUCGUGCUG -5'	2-19-2
K1	SQ153 SQ154	(A) 5' - ACAGGAUGAGGAUCGUUUCGCA -3' (B) 3' - UGUCCUACUCCUAGCAAAGCGU -5'	0-22-0
K3	SQ155 SQ156	(A) 5' -GAUGAGGAUCGUUUCGCAUGA-3' (B) 3' -UCCUACUCCUAGCAAAGCGUA-5'	2-19-2
K2	SQ157 SQ158	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3' (B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	2-22-2
S1A/ S4B	SQ148 SQ159	(A) 5' - CCACAUGAAGCAGCAGACUUC -3' (B) 3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	0-22-2

PKC 1/2	SQ160	(A)	5' - CUUCUCCGCCUCACACCGCUGCAA -3'	2-22-0
	SQ161	(B)	3' - GAAGAGGCGGAGUGUGGCGACG -5'	
S7/S12	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-0
	SQ162	(B)	3' - GGUGUACUUCGUCGUGCUGAA -5'	
S7/S11	SQ150	(A)	5' - CCACAUGAAGCAGCACGACUU -3'	0-21-2
	SQ163	(B)	3' - CUGGUGUACUUCGUCGUGCUGAA -5'	
S13	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-2
	SQ165	(B)	3' - CUGGUGUACUUCGUCGUGCUGA -5'	
S13/14	SQ164	(A)	5' - CCACAUGAAGCAGCACGACU -3'	0-20-0
	SQ166	(B)	3' - GGUGUACUUCGUCGUGCUGA -5'	
S4	SQ167	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-2
	SQ159	(B)	3' - CUGGUGUACUUCGUCGUGCUGAAG -5'	
K1A/ K2B	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA -3'	0-22-2
	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	
K1B/ K2A	SQ154	(A)	5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-0
	SQ157	(B)	3' - UGUCCUACUCCUAGCAAAGCGU -5'	
S1B/ S4A	SQ149	(A)	5' - CCACAUGAAGCAGCACGACUUCUU -3'	2-22-0
	SQ167	(B)	3' - GGUGUACUUCGUCGUGCUGAAG -5'	

Key to figure: (Headings)

Name

Sequence protocol no.

dsRNA sequence

Table 2

IV. In Vivo Study:

Double-strand RNA (dsRNA) that was derived from the GFP sequence where unspecific dsRNA was injected intravenously into the caudal vein of “GFP laboratory mice” that express the green fluorescent protein (GFP) in all cells that conduct protein biosynthesis. At the end of the experiment, the animals were killed and the GFP expression analyzed in tissue sections and in plasma.

Experimental Protocol:

Synthesis of dsRNA:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany), and ordinary chemical methods, the RNA single strands apparent from the sequence protocols and the single strand complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. As columns, NucleoPac PA-100, 9 × 250 mm from the Dionex company were used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Experimental Animal Keeping and Performance of the Experiment

The transgenic laboratory mouse strain TgN (GFPU) 5Nagy (Jackson Laboratory, Bar Harbor, Maine, USA) was used, which expresses GFP (with a beta-actin promoter and a CMV intermediate early enhancer) in all previously investigated cells (Hadjantonakis AK et al. 1993, Mech. Dev. 76: 79-90; Hadjantonakis AK et al., 1998 Nature Genetics 19: 220-222). GFP-transgenic mice can be clearly distinguished from the corresponding wild types (WT) by means of fluorescence (with a UV hand lamp). For breeding, the corresponding WT was paired with a heterozygous GFP type.

The experiment was performed according to the German Animal Protection Regulations. The animals were kept under controlled environmental conditions in groups of 3-5 animals in type III Makrolon cages from the Ehret company, Emmendingen, at a constant temperature of 22°C and a light-dark rhythm of 12 h. Softwood granulate 8/15 from the Altromin company, Lage, was used as sawdust litter. The animals received tap water and standard feed Altromin 1324 pelletized (Altromin) ad libitum.

To perform the experiment, the heterozygous GFP animals were kept in groups of 3 animals each in cages, as described above. Injections of the dsRNA solution occurred intravenously (IV) into the caudal vein in 12-hour cycles (between 5:30 and 7:00 a.m. and between 5:30 and 7:00 p.m.) over 5 days. The injection volumes were 60 μ L for per 10 g of body weight and the dose was 2.5 mg dsRNA and 50 μ g per kg of body weight. Division into groups was as follows:

- Group A: PBS (phosphate buffered saline) 60 μ L per 10 kg of body weight,
- Group B: 2.5 mg per kg of body weight of a nonspecific control dsRNA (K1 control with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group C: 2.5 mg per kg of body weight of another unspecific control dsRNA (K3 control with 2nt overhangs on both 3' ends and a double-strand region of 19 nucleotide pairs),
- Group D: 2.5 mg per kg of body weight dsRNA (specific against GFP, subsequently referred to as S1, with smooth ends and a double-strand region of 22 nucleotide pairs),
- Group E: 2.5 mg dsRNA per kg of body weight (specific against GFP, subsequently referred to as S7, with 2nt overhangs on the 3' ends of both strands and a double-strand region of 19 nucleotide pairs)
- Group F: 50 μ g S1-dsRNA per kg of body weight (i.e., 1/50 of the dose of group D).

After the last injection of a total of 10 injections, the animals were killed after 14-20 h and the organs and blood taken as described.

Organ Removal:

Immediately after killing the animals by CO₂ inhalation, blood and different organs were taken (thymus, lungs, heart, spleen, stomach, intestines, pancreas, brain, kidneys and liver). The organs were rinsed briefly in cold sterile PBS and divided with a sterile scalpel. One part was fixed for immunohistochemical staining in methylcarnoys (MC, 60% methanol, 30% chloroform, 10% glacial acetic acid) for 24 hours, one part was shock frozen for frozen sections and for protein isolation immediately in liquid nitrogen and stored at -80°C, and another smaller part was frozen for RNA isolation in RNeasy-Protect (Qiagen) at -80°C. The blood was immediately held for 30 minutes on ice after sampling, mixed, centrifuged for 5 minutes at 2000 rpm (Mini spin, Eppendorf), the supernatant removed and stored at -80°C (here referred to as plasma).

Processing of the Biopsies:

After 24 h of fixation of the tissue in MC, the tissue pieces were dehydrated in an increasing alcohol series at RT (room temperature): every 40 minutes 70% methanol, 80% methanol, 2 × 96% methanol and 3 × 100% isopropanol. The tissue was then heated in 100% isopropanol to 60°C in an incubator, then incubated for 1 hour in an isopropanol/paraffin mixture at 60°C and 3 × for 2 hours in paraffin and then imbedded in paraffin. For immunoperoxidase staining, tissue sections with 3 µm section thickness were prepared with a rotary microtome (Leica), mounted on slides (Superfrost, Vogel) and incubated for 30 minutes at 60°C in an incubator.

Immunoperoxidase Staining versus GFP:

The sections were deparaffinized 3 × 5 minutes in xylene, rehydrated in an increasing alcohol series (3 × 3 min 100% ethanol, 2 × 2 min 95% ethanol) and then incubated for 20 minutes in 3% H₂O₂/methanol to block endogenous peroxidases. All incubation steps were conducted subsequently in a moist chamber. After 3 × 3 minutes of washing with PBS, they were incubated

with the first antibody (goat anti-GFP, sc-5384, Santa Cruz, Biotechnology) 1:500 in 1% BSA/PBS overnight at 4°C. Incubation with the biotinylated secondary antibody (donkey anti-goat; Santa Cruz Biotechnology; 1:2000 dilution) occurred for 30 minutes at RT, whereupon they were incubated for 30 minutes with Avidin D Peroxidase (1:2000 dilution, Vector Laboratories). After each antibody incubation, the sections were washed 3 × 3 min in PBS and the buffer residues removed from the sections with wadding. All antibodies were diluted in 1% bovine serum albumin (BSA)/PBS. Staining with 3,3'-diaminobenzidine (DAB) was conducted with the DAB substrate kit (Vector Laboratories) according to the manufacturer's data. As nuclear counterstain, hematoxylin III according to Gill (Merck) was used. After dehydration in a rising alcohol series at 3 × 5 minutes xylene, the sections were covered with Entellan (Merck). Microscopic evaluation of staining occurred with the IX50 microscope from Olympus, equipped with a CCD camera (Hamamatsu).

Protein Isolation from Tissue Pieces:

800 µL isolation buffer (50 mM HEPES, pH 7.5, 150 mM NaCl; 1 mM EDTA; 2.5 mM EGTA; 10% glycerol; 0.1% Tween; 1 mM DTT, 10 mM β-glycerol phosphate; 1 mM NaF; 0.1 mM Na₃VO₄ with a protease inhibitor tablet "Complete" from Roche) were added to the still frozen tissue pieces and homogenized 2 × 30 seconds with an Ultraturrax (DIAX 900, dispersal die 6 G, Heidolph), and cooled in between on ice. After 30 minutes of incubation on ice, they were mixed and centrifuged for 20 minutes at 1000 × g, 4°C (3K30, Sigma). The supernatant was incubated for another 10 minutes on ice, mixed and centrifuged for 20 minutes to 15000 × g, 4°C. A protein determination according to Bradford, 1976, modified after Zor & Selinger, 1996, was conducted with the supernatant with the Roti-Nanoquant system of Roth according to the data of the manufacturer. BSA (bovine serum albumin) in concentrations from 10 to 100 µg/mL was used for the protein calibration line.

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multigel long electrophoresis chamber from Biometra with a denaturing, discontinuous 15% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 1970). For this purpose, a

separation gel 1.5 mm thick was initially poured: 7.5 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1.5 M Tris/HCl, pH 8.4, 150 μ L 10% SDS, 3.3 mL doubly distilled water, 250 μ L ammonium persulfate (10%), 9 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated up to polymerization with 0.1% SDS. The collected gel was then poured: 0.83 μ L acrylamide/bisacrylamide (30%/0.9%), 630 μ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 μ L 10% SDS, 50 μ L 10% ammonium persulfate, 5 μ L TEMED.

Before application of the gel, the proteins were mixed with a corresponding amount of 4-fold sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiothreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes in a heating unit at 100°C, briefly centrifuged after cooling on ice and applied to the gel. The same plasma or protein amounts were used per track (3 μ L plasma and 25 μ g total protein each). Electrophoresis occurred water-cooled at RT and a constant 50 V. The protein gel marker from Bio-Rad (kaleidoscope prestained standard) was used as length standard.

Western Blot and Immune Detection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.8 mA/cm² for 1.5 h. A Tris/glycine buffer was used as transfer buffer (39 mM glycine, 465 mM Tris, 0.1% SDS and 20% methanol). To check the electrophoretic transfer, both the gels after blotting and the blot membranes after immune detection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid). For saturation of nonspecific bonds, the blot membrane after transfer was incubated in 1% skim milk powder/PBS for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (goat anti-GFP, sc 5384, Santa Cruz Biotechnology) occurred in a dilution of 1:1000 for 1 h at RT. It was then washed 3 \times 5 min and incubated for 1 hour at RT with a secondary antibody (donkey anti-goat IgG horseradish peroxidase labeled, Santa Cruz Biotechnology) in a dilution of 1:1000. Detection occurred with the ECL system from Amersham according to the data of the manufacturer.

Figures 18 to 20 show inhibition of GFP expression after intravenous injection of dsRNA specifically directed against GFP with immunoperoxidase staining relative to GFP on 3 μ m paraffin sections. During the experiment, dsRNA directed against GFP with a double-strand region of 22 nucleotide (nt) pairs without overhangs on the 3' ends (D) and the corresponding unspecific control dsRNA (B), as well as dsRNA directed specifically against GFP with a double-strand region containing 19 nucleotide pairs with 2 nt overhangs on the 3' ends (E) and the corresponding nonspecific control dsRNA (C) were applied in 12-hour cycles over 5 days. (F) received 1/50 of the dose of group D. Animals without dsRNA administration (A) and WT animals were investigated as additional controls. Fig. 18 shows inhibition of GFP expression in kidney sections, Fig. 19 in heart tissue and Fig. 20 in pancreas tissue. Figures 21 to 23 show Western blot analyses of GFP expression in plasma and tissues. Inhibition of GFP expression in plasma is shown in Fig. 21, in the kidneys in Fig. 22 and in the heart in Fig. 23. Total protein isolates from different animals are shown in Fig. 23. The same total protein amounts per track were applied. In the animals, to which unspecific control dsRNA was administered (animals of groups B and C), the GFP expression relative to animals that received no dsRNA is not reduced. Animals that received dsRNA specifically directed against GFP with 2 nt overhangs on the 3' ends of both strands and a double-strand region containing 19 nucleotide pairs exhibited a significantly inhibited GFP expression in the investigated tissues (heart, kidneys, pancreas and blood), compared with the untreated animals (Figures 18 to 23). In the animals of groups D and F, in which dsRNA directed specifically against GFP with smooth ends and double-strand region containing 22 nucleotide pairs was administered, only those animals that received dsRNA in a dose of 50 μ g/kg of body weight per day exhibited a specific inhibition of GFP expression, which, however, was much less pronounced than that of the animals in group E. The summarizing evaluation of GFP inhibition in the tissue sections and in Western blot shows that inhibition of GFP expression in blood and the kidneys is strongest (Figures 18, 21 and 22).

V. Inhibition of Gene Expression of EGF Receptor with dsRNA as a Therapeutic Approach in Forms of Cancer with EGFR Overexpression or EGFR-induced Proliferation:

The epidermal growth factor (EGF) receptor (EGFR) belongs to the receptor tyrosine kinases, transmembrane proteins with an intrinsic tyrosine kinase activity, which participate in the control

of a series of cellular processes, like cell growth, cell differentiation, migratory processes or cell vitality (review in: Van der Geer et al. 1994). The EGFR family consists of 4 members, EGFR (ErbB1), HER2 (ErbB2), HER3 (ErbB3) and HER4 (ErbB4) with a transmembrane domain, a cysteine-rich extracellular domain and an intracellular catalytic domain. The sequence of EGFR, a 170 kDa protein, has been known since 1984 (Ullrich et al., 1984).

EGFR is activated by peptide growth factors, like EGF, TGF α (transforming growth factor), amphiregulin, beta-cellulin, HB-EGF (heparin-binding EGF-like growth factor) and neuregulin. Ligand bonding induces formation of homo- or heterodimers with subsequent autophosphorylation of cytoplasmic tyrosine (Ullrich & Schlessinger, 1990; Alroy & Yarden, 1997). The phosphorylated amino acids form the bonding sites for a number of proteins that participate in the proximal steps of signal conduction in a complex network. EGFR participates in a wide variety of tumor diseases and is therefore a suitable target for therapeutic approaches (Huang & Harari, 1999). The mechanisms that lead to an aberrant EGFR activation can be due to overexpression, amplification, constituted activation of mutant receptor forms or autocrine loops (Voldborg et al., 1997). An overexpression of EGFR was described for a number of tumors, like breast cancer (Walker & Dearing, 1999), non-small lung carcinoma (Fontanini et al., 1998), pancreatic carcinomas, colon carcinoma (Salomon et al., 1995) and glioblastomas (Rieske et al., 1998). No efficient and specific therapeutic agents have thus far been available for malignant glioblastomas, in particular.

Practical Example:

To demonstrate the efficacy of dsRNA during specific inhibition of EGFR gene expression, U-87 MG cells (human glioblastoma cells), ECCAC (European Collection of Animal Cell Cultures) no. 89081402 were used, which were transfected with dsRNA directed specifically against the EGF receptor (sequence protocol SQ 51). After about 72 hours' incubation, the cells were harvested, the protein isolated and the EGFR expression investigated in the Western blot method.

Experimental Protocol:

dsRNA Synthesis:

By means of an RNA synthesizer (type Expedite 8909, Applied Biosystems, Weiterstadt, Germany) and an ordinary chemical method, the RNA single strands apparent from the sequence protocols and the single strands complementary to them were synthesized. Purification of the crude synthesis products then occurred with HPLC. The column NucleoPac PA-100, 9 × 250 mm, from the Dionex company was used; 20 mM Tris, 10 mM NaClO₄, pH 6.8, 10% acetonitrile was used as low salt buffer and 20 mM Tris, 400 mM NaClO₄, pH 6.8, 10% acetonitrile as high salt buffer. The flow rate was 3 mL/minute. Hybridization of the single strands to a double-strand occurred by heating of the stoichiometric mixture of the single strands in 10 mM sodium phosphate buffer, pH 6.8, 100 mM NaCl, to 80-90°C and subsequent slow cooling over 6 hours to room temperature.

Seeding of the Cells:

All cell culture work was conducted under sterile conditions and an appropriate work bench (HS18, Her safe, Kendro, Heraeus). Cultivation of U-87 MG cells occurred in an incubator (CO₂ incubator T20, Hera cell, Kendro, Heraeus) at 37°C, 5% CO₂ and saturated atmospheric humidity in DMEM (Dulbecco's modified eagle medium, Biochrom) with 10% FCS (fetal calf serum, Biochrom), 2 mM L-glutamine (Biochrom), 1 mM sodium pyruvate (Biochrom), 1 × NEAA (nonessential amino acids, Biochrom) and penicillin/streptomycin (100 IU/100 µg/mL, Biochrom). In order to keep the cells in the exponential growth phase, the cells were subjected to passage every 3 days. 24 hours before application of dsRNA by transfection, the cells were trypsinized (10 × trypsin/EDTA, Biochrom, Germany) and seeded with a cell density of 5 × 10⁵ cells/well in a 6-well plate (6-well plates, Labor Schubert & Weiss GmbH) in 1.5 mL growth medium.

Application of dsRNA in Cultivated U-87 MG Cells:

Application of dsRNA occurred by transfection with OLIGOFECTAMINE™ reagent (Life Technologies) according to the information of the manufacturer. The total transfection volume was 1 mL. The dsRNA was first diluted in serum-free medium: for this purpose, 0.5 µL of a 20

μm stock solution of dsRNA specifically directed against EGFR and 9.5 μL of a 20 μm stock solution of unspecific dsRNA (K1A/K2B) with 175 μL serum-free medium were diluted per well (200 nM dsRNA in transfection charge and 10 nM specific EGFR-dsRNA). The OLIGOFECTAMINETM reagent was also diluted in serum-free mediums: 3 μL with 12 μL medium per well and then incubated for 10 minutes at room temperature. The diluted OLIGOFECTAMINETM reagent was then added to the dsRNAs diluted in medium, mixed and incubated for another 20 minutes at RT. During incubation, a medium change was performed. The cells were washed for this purpose once with 1 mL serum-free medium and incubated further in the incubator with 800 μL serum-free medium, up to addition of dsRNA/OLIGOFECTAMINETM reagent. After addition of 200 μL dsRNA/OLIGOFECTAMINETM reagent per well, the cells were further incubated in the incubator to protein isolation.

Protein Isolation:

About 72 hours after transfection, the cells were harvested and protein isolation carried out. For this purpose, the medium was removed and the cell monolayer washed once with PBS. After addition of 200 μL protein isolation buffer (1 \times protease inhibitor “Complete”, Roche, 50 mM HEPES, pH 7.5, 1509 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 10% glycerol, 0.1% Tween-20, 1 mM DTT, 10 mM β -glycerol phosphate, 1 mM NaF, 0.1 mM Na_3VO_4), the cells were separated by means of a cell scraper, incubated for 10 minutes on ice, transferred to an Eppendorf reaction vessel and stored at -80°C for at least 30 minutes. After thawing, the lysate was homogenized on stage 3 for 10 seconds with a disperser (DIAX 900, dispersing die 6G, Heidolph Instruments GmbH & Co KG, Schwabach), incubated on ice for 10 minutes and centrifuged for 15 minutes at $14000 \times g$, 4°C (3K30, Sigma). A protein determination was conducted with the supernatant according to Bradford with the Roti[®] Nanoquant system from Roth (Roth GmbH & Co., Karlsruhe) according to the information of the manufacturer. For this purpose, 200 μL protein solution in appropriate dilution was mixed with 800 μL 1 \times working solution and the extinction measured in semi-microcells at 450 and 590 nm versus distilled water in a Beckman spectrophotometer (DU 250). The corresponding BSA dilutions were used for the calibration line (beaded BSA, Sigma).

SDS Gel Electrophoresis:

Electrophoretic separation of the proteins occurred in a multi-gel long electrophoresis chamber from Biometra with a denaturing, discontinuous 7.5% SDS-PAGE (polyacrylamide gel electrophoresis) according to Lämmli (Nature 277: 680-685, 197). For this purpose, a separation gel was initially poured with 1.5 mm thickness: 3.7 mL acrylamide/bisacrylamide (30%, 0.9%), 3.8 mL 1 M Tris/HCl, pH 8.4, 150 μ L 10% SDS, 7.15 mL doubly distilled water, 150 μ L ammonium persulfate (10%), 9 μ L TEMED (N,N,N',N'-tetramethylethylenediamine) and coated with 0.1% SDS to polymerization. The collection gel was then poured: 0.83 mL acrylamide/bisacrylamide (30%/0.9%), 630 μ L 1 M Tris/HCl, pH 6.8, 3.4 mL doubly distilled water, 50 μ L 10% SDS, 50 μ L 10% ammonium persulfate, 5 μ L TEMED.

For application to the gel, the protein samples were mixed 1:3 with 4 \times sample buffer (200 mM Tris, pH 6.8, 4% SDS, 100 mM DTT (dithiotreitol), 0.02% bromophenol blue, 20% glycerol), denatured for 5 minutes at 100°C, briefly centrifuged after cooling on ice and applied to the gel. 35 μ g total protein was applied per track. The run occurred water cooled at RT and a constant 50 V. The kaleidoscope protein gel marker (BioRad) was used as length standard.

Western Blot and Immunodetection:

Transfer of the proteins from SDS-PAGE to a PVDF (polyvinylidene difluoride) membrane (Hybond-P, Amersham) occurred in the semi-dry method according to Kyhse-Anderson (J. Biochem. Biophys. Methods 10: 203-210, 1984) at RT and a constant current intensity of 0.5 mA/cm² for 1.5 h. The following were used as transfer buffer: cathode buffer (30 mM Tris, 40 mM glycine, 10% methanol, 0.01% SDS; pH 9.4), anode buffer I (300 mM Tris, pH 10.4, 10% methanol) and anode buffer II (30 mM Tris, pH 10.4, 10% methanol). Before combining the blot stack with 3 mm Whatman paper (Schleicher & Schüll), the gel was incubated in the cathode buffer and the PVDF membrane (30 seconds beforehand in 100% methanol) in anode buffer II (5 min): 2 layers 3 mm paper (anode buffer I), 1 layer 3 mm paper (anode buffer II), PVDF membrane, gel, 3 layers 3 mm paper (cathode buffer). To check electrophoretic transfer, both the gels after blotting and the blot membranes after immunodetection were stained with Coomassie (0.1% Coomassie G250, 45% methanol, 10% glacial acetic acid).

The blot membrane was incubated after transfer in 1% skim milk powder/ PBS/0.1% Tween-20 for 1 h at RT. It was then washed three times for 3 minutes with 0.1% Tween-20/PBS. All subsequent antibody incubations and washing steps occurred in 0.1% Tween-20/PBS. Incubation with the primary antibody (human EGFR extracellular domain, specific goat IgG, catalog no. AF231, R&D Systems) occurred on a rocking device for 2 h at RT and a concentration of 1.5 µg/mL. It was then washed 3 × for 6 minutes and incubated for 1 hour at RT with the secondary antibody (donkey anti-goat IgG horseradish peroxidase label, Santa Cruz Biotechnology) (diluted 1:10000). After washing (3 × 3 min in PBS/0.1% Tween-20), detection occurred immediately with ECL reaction (enhanced chemiluminescence): 200 µL solution A (250 mM luminol, Roth, dissolved in DMSO), 89 µL solution B (90 mM p-coumaric acid, Sigma, dissolved in DMSO) and 2 mL 30% H₂O₂ solution were pipetted into 18 mL distilled water. Depending on the membrane size, 4-6 mL was pipetted directly onto the membrane, incubated for 1 minute at RT and then an x-ray film (Biomax MS, Kodak) applied immediately.

The sequences used here are shown in the following Table 3 and in the sequence protocols S!153, 157, 158, 168-173.

ES-7	SQ168	(A) 5' - AACACCGCAGCAUGUCAAGAU -3'	2-19-2
	SQ169	(B) 3' - UUUUGUGGCGUCGUACAGUUC -5'	
ES-8	SQ170	(A) 5' - AAGUUAAAUUCGCGCUAU -3'	2⁵-19-2⁵
	SQ171	(B) 3' - CAAUUUAAGGGCAGCGAUAGU -5'	
ES2A/ ES5B	SQ172	(A) 5' - AGJGUGAUCCAAGCUGUCCCAA -3'	0-22-2
	SQ173	(B) 3' - UUUCACACUAGGUUCGACAGGGUU -5'	
K2	SQ157	(A) 5' - ACAGGAUGAGGAUCGUUUCGCAUG -3'	2-22-2
	SQ158	(B) 3' - UCUGUCCUACUCCUAGCAAAGCGU -5'	

K1A/	SQ153	(A)	5' - ACAGGAUGAGGAUCGUUUCGCA	-3'	0-22-2
K2B	SQ158	(B)	3' - UCUGUCCUACUCCUAGCAAAGCGU	-5'	

Table 3

Inhibition of EGFR Expression in U-87 MG Glioblastoma Cells:

24 hours after seeding of the cells, they were transfected with 10 nM dsRNA as stated (oligofectamine). After 72 hours, the cells were harvested and the protein isolated. Separation of the proteins occurred in 7.5% SDS-PAGE. 35 µg total protein was applied per track. Fig. 4 shows the corresponding Western blot analysis, from which it follows that the EGFR expression after transfection in U-87 MG cells can be significantly inhibited relative to the corresponding controls with the dsRNA specifically directed against the EGFR gene with a 2 nt overhang on the 3' end of the anti-sense strand. This inhibition of expression of an endogenous gene by specific dsRNA therefore confirms the results stated in the practical example II concerning inhibition of expression of an artificial gene introduced to the cell after transient transfection. The inhibition of EGFR expression mediated by ES-7 and ES-8 is much lower. The dsRNAs used in Fig. 24 can be gathered from Table 3.

VI. Inhibition of Expression of the Multidrug Resistance Gene 1 (MDR1):

Experimental Protocol:

In vitro detection for blocking of MDR1 expression was conducted in the colon carcinoma cell line LS174T (ATCC – American Type Culture Collection, Tom et al., 1976). It is known of this cell line that expression of MDR1 can be induced by addition of rifampicin to the culture medium (Geick et al., 2001). Transfections were conducted with different commercial transfection kits (Lipofectamine, Oligofectamine, both Invitrogen; TransMessenger, Qiagen), in which the TransMessenger transfection kit also proved to be best suited for this cell line.

To run the RNA interference experiments, 4 short double-strand ribonucleic acids R1-R4 were used, whose sequences are shown in Table 4. The ribonucleic acids are homologous with sections of the coding sequence of MDR1 (sequence protocol SQ 30). Sequences R1-R3 consists of a 22-mer sense and a 24-mer anti-sense strand, in which the forming double-strand has a two nucleotide overhang on the 3' end of the anti-sense strand (0-22-2). The sequence R4 corresponds to R1, but consists of a 19-mer double strand with 2 nucleotide overhangs on each 3' end (2-19-2).

<u>Name</u>	<u>Sequenz- proto- koll-Nr.</u>	<u>Sequenz</u>	<u>Position in Daten- bank-# AF016535</u>
Seq	SQ141	5' - CCA UCU CGA AAA GAA GUU AAG A-3'	1320-1342
R1	SQ142	3' -UG GGU AGA GCU UUU CUU CAA UUC U-5'	1335-1318
Seq	SQ143	5' - UAU AGG UUC CAG GCU UGC UGU A-3'	2599-2621
R2	SQ152	3' -CG AUA UCC AAG GUC CGA ACG ACA U-5'	2621-2597
Seq	SQ144	5' - CCA GAG AAG GCC GCA CCU GCA U-3'	3778-3799
R3	SQ145	3' -UC GGU CUC UUC CGG CGU GGA CGU A-5'	3799-3776
Seq	SQ146	5' - CCA UCU CGA AAA GAA GUU AAG-3'	1320-1341
R4	SQ147	3' -UG GGU AGA GCU UUU CUU CAA U -5'	1339-1318

			<u>Position in Daten- bank-# AF402779</u>
K1A/	SQ153	5' - ACA GGA UGA GGA UCG UUU CGC A-3'	2829-2808
K2B	SQ158	3' -UC UGU CCU ACU CCU AGC AAA GCG U-5'	2808-2831

Key to figure: (Headings)

Name

Sequence Protocol no.

Sequence

Table 4

The sequences shown in Table 4 are shown again in the sequence protocol as sequences SQ 141-147, 152, 153, 158. The dsRNAs were transfected in a concentration of 175 nM as double charges into the cells, which were seeded the day before in 12-well plates at 3.8×10^5 cells/well. For this purpose, 93.3 μ L EC-R buffer (TransMessenger kit, Qiagen, Hilden) was mixed with 3.2 μ L Enhancer-R per transfection charged, thoroughly mixed and incubated for 5 minutes at room temperature. After addition of 6 μ L TransMessenger transfection reagent, the transfection charges were vigorously mixed for 10 seconds and incubated for 10 minutes at room temperature. In the meantime, the medium was withdrawn from the cells by suction, washed once with PBS (phosphate buffered saline) and 200 μ L fresh medium without FCS per well was added to the cells. After 10 minutes of incubation, 100 μ L FCS-free medium was pipetted into the transfection charged, mixed and the mixture pipetted dropwise into the cells (the dsRNA concentration of 175 μ M refers to 400 μ L of medium total volume). The dsRNA/TransMessenger complexes were incubated for 4 hours at 37°C with the cells in FCS-free medium. A medium change was then conducted, in which the fresh medium contained 10 μ M Rifampicin and 10% FCS. As control, and unspecific dsRNA sequence, having no homology with the MDR1 gene sequence, was used (K) and a MOCK transfection carried out, which contained all reagents, except dsRNA.

The cells were harvested after 24, 48 and 72 hours and a total RNA extracted with the RNeasy-Mini-Kit from Qiagen. 10 μ g total RNA of each sample was separated on a 1% agarose formaldehyde gel electrophoretically, blotted onto a nylon membrane and specific probes, random marked with 5'- α^{32} -P-dCTP, were hybridized exposed first relative to MDR1 and, after stripping of the blot, relative to GAPDH as internal control and exposed on x-ray film.

The x-ray films were digitized (Image Master, VDS Pharmacia) and quantified with the Image-Quant software. Balancing of the MDR1-specific bands with the corresponding GAPDH bands was then carried out.

Results:

Figures 25 and 26 show Northern blots (Figures 25a, 26a) with quantitative evaluation of the MDR1-specific bands after balancing with the corresponding GAPDH values (Figures 25b, 26b). A reduction of MDR1-mRNA by up to 55% could be observed in comparison with MOCK transfection and by up to 45% in comparison with unspecific control transfection. After 48 h, a significant reduction of MDR1-mRNA levels was achieved with the dsRNA constructs designated R1, R2, R3 (Table 4). After 48 hours, no significant reduction relative to the controls was observed with the R4 dsRNA constructs (Figures 26a, 26b). After 72 hours, a much stronger reduction of MDR1-mRNA levels was observed with R1, R2 and R2 relative to the controls, in comparison with the 48-hour values (Figures 25a and 25b).

With R4 at this point a significant reduction of MDR1-mRNA levels could also be achieved. The constructs with a 2 nt overhang on the 3' end of the anti-sense strand and a double-strand region of 22 nucleotide pairs therefore reduced the MDR1-mRNA more efficiently than the constructs of the 2 nt overhangs on the 3' ends of both strands (anti-sense and sense strand) and a double-strand region of 19 nucleotide pairs relatively independently of the sequence region homologous to the MDR1 gene (after 48 hours; Fig. 26b). The results therefore confirm the inhibition of EGFR gene expression described in practical example 4 by specific dsRNAs after transfection in U-87 MG cells.

The transfection efficiency was determined in a separate experiment by means of a Texas-Red-labeled DNA oligonucleotide (TexRed-A (GATC)₅T; also 175 nM transfected) (Figures 27a, 27b; 400-fold magnification, 48 hours after transfection). The amount is about 50% based on the red fluorescent cells, in comparison with the total cell count. If one considers the transfection rate of the cells at about 50%, the observed reduction of MDR1-mRNA level lies at about 45-55% (compared with the controls), with the conclusion that in all cells that could be transfected

successfully with specific dsRNA, the MDR1-mRNA was almost fully broken down and specifically.

Literature:

Altroy I & Yarden Y (1997): The Erb signalling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Letters 410: 83-86.

Bass, B.L., 2000. Double-stranded RNA as a template for gene silencing. Cell 101, 235-238.

Bosher, J.M. and Labouesse, M., 2000. RNA interference: genetic wand and genetic watchdog. Nature Cell Biology 2, E31-E36.

Bradford MM (1976): Rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248-254.

Caplen, N.C., Fleenor, J., Fire, A., and Morgan, R.A., 2000. dsRNA-mediated gene silencing in cultured *Drosophila* cells: a tissue culture model for the analysis of RNA interference. Gene 252, 95-105.

Clemens, J.C., Worby, C.A., Simonson-Leff, N., Muda, M., Maelhama, T., Hemmings, B.A., and Dixon, J.E., 2000. Use of double-stranded RNA interference in *Drosophila* cell lines to dissect signal transduction pathways. Proc. Natl. Acad. Sci. USA 97, 6499-6503.

Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, Fe-hrenbacher L, Wolter JM, Paton V, Shak S, Liebermann G & Slamon DJ (1999): Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that

has progressed after chemotherapy for metastatic disease.
Journal of Clinical Oncology 17: 2639-2648.

Ding, S.W., 2000. RNA silencing. Curr. Opin. Biotechnol. 11, 152-156.

Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., and Mello, C.C., 1998. Potent and specific genetic interference by double-stranded RNA in *Caenorhabditis elegans*. Nature 391, 806-811.

Fire, A., 1999. RNA-triggered gene silencing. Trends Genet. 15, 358-363.

Freier, S.M., Kierzek, R., Jaeger, J.A., Sugimoto, N., Caruthers, M.H., Neilson, T., and Turner, D.H., 1986. Improved free-energy parameters for prediction of RNA duplex stability. Proc. Natl. Acad. Sci. USA 83, 9373-9377 .

Geick, A., Eichelbaum, M., Burk, O. (2001). Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. J. Biol. Chem. 276 (18), 14581-14587.

Fontanini G, De Laurentiis M, Vignati S, Chine S, Lucchi M, Silvestri V, Mussi A, De Placido S, Tortora G, Bianco AR, Gullick W, Angeletti CA, Bevilacqua G & Ciardiello F (1998): Evaluation of epidermal growth factor-related growth factors and receptors and of neoangiogenesis in completely resected stage I-IIIa non-small-cell lung cancer: amphiregulin and microvessel count are independent prognostic factors of survival. Clinical Cancer Research 4: 241-249.

- Hammond, S.M., Bernstein, E., Beach, D., and Hannon, G.J., 2000. An RNA-directed nuclease mediates post-transcriptional gene silencing in *Drosophila* cells. *Nature* 404, 293-296.
- Higgins, C.F. (1995). The ABC of channel regulation. *Cell*, 82, 693-696.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1993): Generating green fluorescent mice by germline transmission of green fluorescent ES cells. *Mech. Dev.* 76: 79-90.
- Hadjantonakis AK, Gertsenstein M, Ikawa M, Okabe M & Nagy A (1998): Non-invasive sexing of preimplantation mammalian embryos. *Nature Genetics* 19: 220-222.
- Kyhse-Anderson J (1984): Electrophoretic transfer of multiple gels: A simple apparatus without buffer tank for rapid transfer of proteins from polyacrylamide to nitrocellulose. *J. Biochem. Biophys. Methods* 10: 203-210.
- Lämmli UK (1970): Cleavage of structural proteins during the assembly of the head of bacteriophage T4. *Nature* 227: 680-685.
- Loc, T.W., and Clarke, D.M. (1999) *Biochem. Cell Biol.* 77, 11-23.
- Huang SM & Harari PM (1999): Epidermal growth factor receptor inhibition in cancer therapy: biology, rationale and preliminary clinical results. *Investigational New Drugs* 17: 259-269.
- Limmer, S., Hofmann, H.-P., Ott, G., and Sprinzl, M., 1993. The 3'-terminal end (NCCA) of tRNA determines the structure and

stability of the aminoacyl acceptor stem. Proc. Natl. Acad. Sci. USA 90 , 6199-6202.

Montgomery, M.K. and Fire, A., 1998. Double-stranded RNA as a mediator in sequence-specific genetic silencing and co-suppression. Trends Genet. 14, 255-258.

Montgomery, M.K., Xu, S., and Fire, A., 1998. RNA as a target of double-stranded RNA-mediated genetic interference in *Caenorhabditis elegans*. Proc. Natl. Acad. Sci. USA 95, 15502-15507.

Rieske P, Kordek R, Bartkowiak J, Debiec-Rychter M, Bienhat W & Liberski PP (1998): A comparative study of epidermal growth factor (EGFR) and mdm2 gene amplification and protein immunoreactivity in human glioblastomas. Polish Journal of Pathology 49: 145-149.

Robert, J. (1999). Multidrug resistance in oncology: diagnostic and therapeutic approaches. Europ J Clin Invest 29, 536-545.

Stavrovskaya, A.A. (2000) Biochemistry (Moscow) 65 (1), 95-106.

Salomon DS, Brandt R, Ciardiello F & Normanno N (1995): Epidermal growth factor related peptides and their receptors in human malignancies: Critical Reviews in Oncology and Haematology 19: 183-232.

Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., Kahan, B.D. (1976), In vitro, 12, 180-191.

- Tsuruo, T., Iida, H., Tsukagoshi, S., Sakurai, Y. (1981). Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil. *Cancer Res*, 41, 1967-72.
- Ui-Tei, K., Zenno, S., Miyata, Y., and Saigo, K., 2000. Sensitive assay of RNA interference in *Drosophila* and Chinese hamster cultured cells using firefly luciferase gene as target. *FEBS Lett.* 479, 79-82.
- Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, Lee J, Yarden Y, Liebermann TA, Schlessinger J et al. (1984): Human epidermal growth factor receptor cDNA sequences and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. *Nature* 309: 418-425.
- Ullrich A & Schlessinger J (1990): Signal transduction by receptors with tyrosine kinase activity. *Cell* 61: 203-212.
- Van der Geer P, Hunter T & Linberg RA (1994): Receptor protein-tyrosine kinases and their signal transduction pathways. *Annual review in Cell Biology* 10: 251-337.
- Voldborg BR, Damstrup L, Spang-Thomsen M & Poulser HS (1997): Epidermal growth factor Receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. *Annals of Oncology* 8: 1197-1206.
- Walker RA & Dearing SJ (1999): Expression of epidermal growth factor receptor mRNA and protein in primary breast carcinomas. *Breast Cancer Research Treatment* 53: 167-176.

Zamore, P.D., Tuschl, T., Sharp, P.A., and Bartel, D.P., 2000.
RNAi: double-stranded RNA directs the ATP-dependent cleavage
of mRNA at 21 to 23 nucleotide intervals. Cell 101 , 25-33.

Zor T & Selinger Z (1996): Linearization of the Bradford protein assay increases its sensitivity: theoretical and experimental studies. Anal. Biochem. 236: 302-308.

Claims

1. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2) of dsRNA I.

2. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

3. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

4. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

5. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

6. Method according to one of the preceding claims, in which at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which

an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

7. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

8. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) overlap or abut each other in sections.

9. Method according to one of the preceding claims, in which the first region (B1) and the second region (B2) are spaced from each other.

10. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

11. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

12. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

13. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a combined dsRNA construct of the sequences SQ141-173 from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

14. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.

15. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
16. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
17. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
18. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
19. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
20. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
21. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
22. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
23. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

24. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
25. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs instead of nucleotides.
26. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.
27. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.
28. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.
29. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
30. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).
31. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
32. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

33. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
34. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
35. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
36. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
37. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
38. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
39. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
40. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
41. Use of a double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

42. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

43. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

44. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

45. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

46. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

47. Use according to one of the Claims 41 to 46, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

48. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

49. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
50. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
51. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
52. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
53. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
54. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
55. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
56. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
57. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

58. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
59. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
60. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
61. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
62. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
63. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).
64. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
65. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
66. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

67. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.
68. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
69. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
70. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).
71. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
72. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
73. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.
74. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
75. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

76. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

77. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

78. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

79. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

80. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

81. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

82. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

83. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).
84. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).
85. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.
86. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.
87. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.
88. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.
89. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.
90. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

91. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
92. Use according to one of the Claims 81 to 91, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
93. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
94. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
95. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
96. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
97. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
98. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
99. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
100. Use according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

101. Use according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
102. Use according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
103. Use according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
104. Use according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
105. Use according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
106. Use according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
107. Use according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
108. Use according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
109. Use according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

110. Use according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
111. Use according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
112. Use according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
113. Use according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
114. Use according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
115. Use according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
116. Use according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
117. Use according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
118. Use according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.
119. Use according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

120. Use according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

121. Method for inhibition of expression of a target gene in a cell, comprising the following steps:

introduction of at least one double-strand ribonucleic acid (dsRNA I) in an amount sufficient to inhibit expression of the target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA has an overhang formed from 1 to 4 nucleotides on at least one end (E1, E2) of dsRNA I.

122. Method according to Claim 1, in which the dsRNA has the overhang on a 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

123. Method according to Claim 1 or 2, in which the dsRNA I is formed smooth on one end (E1, E2).

124. Method according to Claim 3, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

125. Method according to one of the preceding claims, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

126. Method according to one of the preceding claims, in which at least an additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the

preceding claims, is introduced to the cell, in which one strand (as1) or at least a section of one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and which an additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

127. Method according to one of the preceding claims, in which the dsRNA I and/or dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

128. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

129. Method according to one of the preceding claims, in which the first (B1) and the second region (B2) are spaced from each other.

130. Method according to one of the preceding claims, in which the target gene has one of the sequences SQ001 to SQ140.

131. Method according to one of the preceding claims, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

132. Method according to one of the preceding claims, in which the target gene is the MDR1 gene.

133. Method according to one of the preceding claims, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of the sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.

134. Method according to one of the preceding claims, in which expression is inhibited according to the principle of RNA interference.
135. Method according to one of the preceding claims, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
136. Method according to one of the preceding claims, in which the target gene is a component of a virus or a viroid.
137. Method according to Claim 16, in which the virus is a human pathogenic virus or viroid.
138. Method according to one of the Claims 16, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
139. Method according to one of the preceding claims, in which unpaired nucleotides are substituted by nucleoside thiophosphate.
140. Method according to one of the preceding claims, in which at least one end (E1, E2) of dsRNA I/II is modified, in order to counteract degradation in the cell or dissociation into single strands.
141. Method according to one of the preceding claims, in which the cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.
142. Method according to one of the preceding claims, in which the chemical link is formed by a covalent or ionic bond, hydrogen bridge bond, hydrophobic interactions, preferably van der Waals or stacking interactions, or by metal-ion coordination.
143. Method according to one of the preceding claims, in which the chemical link is formed in the vicinity of one end (E1, E2).

144. Method according to one of the preceding claims, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

145. Method according to one of the preceding claims, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

146. Method according to one of the preceding claims, in which the chemical link is formed by purine analogs.

147. Method according to one of the preceding claims, in which the chemical link is formed by azabenzene units.

148. Method according to one of the preceding claims, in which, to produce the chemical link, at least one of the following groups is used: methylene blue; bifunctional groups, preferably bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil, psoralene.

149. Method according to one of the preceding claims, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.

150. Method according to one of the preceding claims, in which the chemical link is produced by triple helix bonds situated in the vicinity of the ends (E1, E2).

151. Method according to one of the preceding claims, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.

152. Method according to one of the preceding claims, in which the dsRNA I/II is bonded to at least one sheath protein originating from the virus, derived from it or synthetically produced, associated with it or enclosed by it.

153. Method according to one of the preceding claims, in which the sheath protein is derived from polyoma virus.
154. Method according to one of the preceding claims, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
155. Method according to one of the preceding claims, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
156. Method according to one of the preceding claims, in which one strand (as1/as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
157. Method according to one of the preceding claims, in which the cell is a vertebrate cell or a human cell.
158. Method according to one of the preceding claims, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.
159. Method according to one of the preceding claims, in which the dsRNA I/II is taken up in a buffer solution for application.
160. Method according to one of the preceding claims, in which the dsRNA I/II is administered orally or by means of injection or infusion, intravenously, intratumorally, by inhalation, intraperitoneally.
161. Use of one of double-strand ribonucleic acid (dsRNA I) to inhibit expression of a target gene in a cell,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs, and in which one strand (as1) or at least a section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed from 1 to 4 nucleotides at least on one end (E1, E2).

162. Use according to Claim 41, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

163. Use according to Claim 41 or 42, in which the dsRNA I is formed smooth on one end (E1, E2).

164. Use according to Claim 43, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

165. Use according to one of the Claims 41 to 44, in which the overhang is formed from 1 to 4 nucleotides, preferably one or two nucleotides.

166. Use according to one of the Claims 41 to 45, in which one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 41 to 45, is introduced to the cell, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the sense strand of the target gene, and in which the other strand (as2) or at least a section of the other strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

167. Use according to one of the Claims 41 to 47, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

168. Use according to one of the Claims 41 to 47, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

169. Use according to one of the Claims 41 to 48, in which the first (B1) and the second region (B2) are spaced from each other.
170. Use according to one of the Claims 41 to 49, in which the target gene has the sequences S1001 to SQ140.
171. Use according to one of the Claims 41 to 50, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.
172. Use according to one of the Claims 41 to 51, in which the target gene is the MDR1 gene.
173. Use according to one of the Claims 41 to 52, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
174. Use according to one of the Claims 41 to 53, in which expression is inhibited according to the principle of RNA interference.
175. Use according to one of the Claims 41 to 54, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
176. Use according to one of the Claims 41 to 55, in which the target gene is a component of a virus or viroid.
177. Use according to Claim 56, in which the virus is a human pathogenic virus or viroid.

178. Use according to Claim 56, in which the virus or viroid is an animal or plant pathogenic virus or viroid.

179. Use according to one of the Claims 41 to 58, in which unpaired nucleotides are substituted by nucleoside thiophosphates.

180. Use according to one of the Claims 41 to 59, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.

181. Use according to one of the Claims 41 to 60, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

182. Use according to one of the Claims 41 to 61, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van-der-Waals or stacking interactions, or by metal ion coordination.

183. Use according to one of the Claims 41 to 62, in which the chemical link is formed in the vicinity of one end (E1, E2).

184. Use according to one of the Claims 41 to 63, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.

185. Use according to one of the Claims 41 to 64, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.

186. Use according to one of the Claims 41 to 65, in which the chemical link is formed by purine analogs.

187. Use according to one of the Claims 41 to 66, in which the chemical link is formed by azabenzene units.

188. Use according to one of the Claims 41 to 67, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.

189. Use according to one of the Claims 41 to 68, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.

190. Use according to one of the Claims 41 to 69, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

191. Use according to one of the Claims 41 to 70, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.

192. Use according to one of the Claims 41 to 71, in which the dsRNA I/II is bonded to at least one sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.

193. Use according to one of the Claims 41 to 72, in which the sheath protein is derived from polyoma virus.

194. Use according to one of the Claims 41 to 73, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.

195. Use according to one of the Claims 41 to 74, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.

196. Use according to one of the Claims 41 to 75, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.

197. Use according to one of the Claims 41 to 76, in which the cell is a vertebrate cell or a human cell.

198. Use according to one of the Claims 41 to 77, in which the dsRNA I/II is administered in an amount of, at most, 5 mg per kilogram of body weight per day to a mammal, preferably a human.

199. Use according to one of the Claims 41 to 78, in which the dsRNA I/II is taken up in a buffer solution for application.

200. Use according to one of the Claims 41 to 79, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

201. Medicament to inhibit expression of a target gene in a cell, containing a double-strand ribonucleic (dsRNA I) in an amount sufficient to inhibit expression of a target gene,

in which the dsRNA I has a double-strand structure formed from, at most, 49 consecutive nucleotide pairs,

and in which one strand (as1) or at least one section of one strand (as1) of the double-strand structure is complementary to the target gene,

and in which the dsRNA I has an overhang formed on at least one end (E1, E2) from 1 to 4 nucleotides.

202. Medicament according to Claim 81, in which the dsRNA I has the overhang on the 3' end of one strand (as1) and/or on the 3' end of the other strand (ss1).

203. Medicament according to Claim 81 or 82, in which the dsRNA I is formed smooth on one end (E1, E2).

204. Medicament according to one of the Claims 83, in which the smooth end (E1, E2) contains the 5' end of one strand (as1).

205. Medicament according to one of the Claims 81 to 84, in which the overhang is formed from 1 to 4 nucleotides, preferably 1 or 2 nucleotides.

206. Use according to one of the Claims 81 to 85, containing at least one additional double-strand ribonucleic acid (dsRNA II), formed according to the dsRNA I according to one of the Claims 81 to 85, in which the one strand (as1) or at least a section of the one strand (as1) of dsRNA I is complementary to a first region (B1) of the target gene, and in which the additional strand (as2) or at least a section of the additional strand (as2) of dsRNA II is complementary to a second region (B2) of the target gene.

207. Use according to one of the Claims 81 to 86, in which the dsRNA I and/or the dsRNA II have a length of less than 25, preferably 19 to 23, consecutive nucleotide pairs.

208. Use according to one of the Claims 81 to 87, in which the first (B1) and the second region (B2) overlap or abut each other in sections.

209. Use according to one of the Claims 81 to 88, in which the target gene has one of the sequences S1001 to SQ140.

210. Use according to one of the Claims 81 to 89, in which the target gene is chosen from the following group: oncogene, cytokine gene, id-protein gene, prion gene, genes of angiogenesis-inducing molecules, of adhesion molecules and of cell-surface receptors, genes of proteins that participate in metastasizing and/or invasive processes, genes of proteinases, as well as apoptosis and cell cycle-regulating molecules.

211. Use according to one of the Claims 81 to 90, in which the target gene is the MDR1 gene.
212. Use according to one of the Claims 81 to 90, in which one of the sequences SQ141-173 is used as dsRNA I/II and a dsRNA construct of sequences SQ141-173 combined from two related anti-sense (as1/2) and sense sequences (ss1/2) is used.
213. Use according to one of the Claims 81 to 92, in which expression is inhibited according to the principle of RNA interference.
214. Use according to one of the Claims 81 to 93, in which the target gene is expressed in pathogenic organisms, preferably in plasmodia.
215. Use according to one of the Claims 81 to 94, in which the target gene is a component of a virus or viroid.
216. Use according to Claim 95, in which the virus is a human pathogenic virus or viroid.
217. Use according to Claim 95, in which the virus or viroid is an animal or plant pathogenic virus or viroid.
218. Use according to one of the Claims 81 to 97, in which unpaired nucleotides are substituted by nucleoside thiophosphates.
219. Use according to one of the Claims 81 to 98, in which at least one end (E1, E2) of dsRNA is modified, in order to counteract degradation in the cell or dissociation into single strands.
220. Medicament according to one of the Claims 81 to 99, in which cohesion of the double-strand structure caused by the complementary nucleotide pairs is increased by at least one chemical link.

221. Medicament according to one of the Claims 81 to 100, in which the chemical link is formed by a covalent or ionic bond, a hydrogen bridge bond, a hydrophobic interaction, preferably van der Waals or stacking interactions, or by metal ion coordination.
222. Medicament according to one of the Claims 81 to 101, in which the chemical link is formed in the vicinity of one end (E1, E2).
223. Medicament according to one of the Claims 81 to 102, in which the chemical link is formed by means of one or more compound groups, in which the compound groups are preferably poly-(oxyphosphinicooxy-1,3-propanediol) and/or oligoethylene glycol chains.
224. Medicament according to one of the Claims 81 to 103, in which the chemical link is formed by branched nucleotide analogs used instead of nucleotides.
225. Medicament according to one of the Claims 81 to 104, in which the chemical link is formed by purine analogs.
226. Medicament according to one of the Claims 81 to 105, in which the chemical link is formed by azabenzene units.
227. Medicament according to one of the Claims 81 to 106, in which at least one of the following groups is used to produce the chemical link: methylene blue; bifunctional groups, preferably (bis-(2-chloroethyl)-amine; N-acetyl-N'-(p-glyoxyl-benzoyl)-cystamine; 4-thiouracil; psoralene.
228. Medicament according to one of the Claims 81 to 107, in which the chemical link is formed by thiophosphoryl groups applied in the vicinity of the ends (E1, E2) of the double-strand region.
229. Medicament according to one of the Claims 81 to 108, in which the chemical link is produced by triple helix bonds situated in the vicinity of ends (E1, E2).

230. Medicament according to one of the Claims 81 to 109, in which the dsRNA I/II is enclosed in micellar structures, advantageously in liposomes.
231. Medicament according to one of the Claims 81 to 110, in which the dsRNA I/II is bonded to at least one viral sheath protein originating from a virus, derived from it or a synthetically produced viral sheath protein, associated with it or enclosed by it.
232. Medicament according to one of the Claims 81 to 111, in which the sheath protein is derived from polyoma virus.
233. Medicament according to one of the Claims 81 to 112, in which the sheath protein contains the virus protein 1 (VP1) and/or the virus protein 2 (VP2) of polyoma virus.
234. Medicament according to one of the Claims 81 to 113, in which, during formation of a capsid or capsid-like structure from the sheath protein, one side faces the interior of the capsid or capsid-like structure.
235. Medicament according to one of the Claims 81 to 114, in which one strand (as1, as2) of dsRNA I/II is complementary to the primary or processed RNA transcript of the target gene.
236. Medicament according to one of the Claims 81 to 114, in which the cell is a vertebrate cell or a human cell.
237. Medicament according to one of the Claims 81 to 116, in which the first (B1) and second region (B2) are spaced from each other.
238. Medicament according to one of the Claims 81 to 117, in which the dsRNA I/II is contained in an amount of, at most, 5 mg per administration unit.

239. Medicament according to one of the Claims 81 to 118, in which the dsRNA I/II is taken up in a buffer solution.

240. Medicament according to one of the Claims 81 to 119, in which the dsRNA I/II is administered orally or by injection or infusion intravenously, intratumorally, by inhalation, intraperitoneally.

//Key to Figures//

Relative Fluoreszenz = Relative fluorescence

Maus = mouse

Mensch = human

MOCK Transfektion = MOCK transfection

Hellfeld = bright field

Variante = variant

Zielgen = target gene

SEQUENZPROTOKOLL = SEQUENCE PROTOCOL

<120> Method for Inhibition of Expression of a Target Gene

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R1A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R1B) of a dsRNA strand, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R2A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R3A) of a dsRNA that is homologous to the MDR1 gene

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R3B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (R4A) of a dsRNA that is homologous to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R4B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S1A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S1B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S7A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S7B) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (R2B) of a dsRNA, complementary to the MDR1 sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K1A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K1B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K3A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K3B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (K2A) of a dsRNA that is homologous to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (K2B) of a dsRNA, complementary to the 5' UTR of the neomycin sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S4B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (PKC1 A) of a dsRNA that is homologous to the protein kinase C sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (PKC2 B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S12B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S11B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S13B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (S14B) of a dsRNA, complementary to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (S13A) of a dsRNA that is homologous to the YFP or GFP sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-7A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-7B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-8A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-8B) of a dsRNA, complementary to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence sense strand (ES-2A) of a dsRNA that is homologous to the human EGFR sequence

<213> Artificial sequence

<223> Description of artificial sequence anti-sense strand (ES-5B) of a dsRNA, complementary to the human EGFR sequence